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Background: Inability to retain participants in a clinical trial poses a threat to clinical 
research as it can lead to a number of issues ultimately affecting generalisability, 
validity and reliability of the study. Patients with schizophrenia have been reported as 
particularly difficult to engage and retain in research and psychiatric treatment. This 
thesis aimed to improve the current understanding of the retention of people with 
schizophrenia in trials evaluating complex interventions.   
Methods: This thesis adopted a mixed method design. Quantitative methodology was 
used to identify the scale of attrition and to explore potential predictors of dropout. 
This included a systematic review and meta-analysis and a separate meta-analysis of 
individual patient data. Qualitative methodology was used in two studies to explore the 
perspectives of both trial staff and former trial participants on the factors important for 
retention and effective practices and strategies.  
Results: The results of the systematic review and meta-analysis demonstrated the rates 
of dropout from studies to be higher than from experimental interventions. Dropout 
from interventions significantly increased as the number of intervention sessions 
increased. The individual patient data meta-analysis found retention to be higher at the 
final follow-up assessment than at the penultimate one. The effect of arm allocation 
almost reached statistical significance pointing to the possibility of participants in the 
active arm having higher odds of completing the final follow-up than those in the 
control arm. Two qualitative studies identified barriers and facilitators to retention 
related to factors related to participant, researcher, study, and wider context. Some of 
the identified barriers were specific to schizophrenia.   
Conclusion: Attrition is a phenomenon that should be anticipated by trialists and 
prevented with the use of multiple strategies. The extent to which dropout can be 
minimised depends on a number of factors associated with the participant, researcher, 
study, and context.  
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 Chapter 1 
Introduction 
1.1 Background and rationale for conducting the research 
Inability to retain participants in a clinical trial poses a threat to clinical research as it 
can reduce statistical study power, compromise the composition of experimental 
groups, and introduce a risk of bias. These issues can in turn affect generalisability, 
validity and reliability of the study (Gul and Ali 2010, Brueton et al. 2013). Despite the 
availability of statistical methods to deal with missing data from the lost participants, 
these are often imperfect and do not eradicate the risks associated with attrition (Hollis 
and Campbell 1999, Xia et al. 2009).  
Most research investigating trial conduct and methodology, however, has focused on 
the recruitment of participants and this has been described as the most important 
aspect of a successful study (Rojavin 2005, Borschmann et al. 2014). While recruitment 
issues apply to a high proportion of studies, virtually all trials experience loss to follow-
up or dropout from treatment. Not all attrition is problematic and there are no clear 
guidelines about what level of dropout is acceptable; however losing 5% of participants 
may already lead to bias and attrition rates exceeding 20% of participants are 
considered threatening to trial validity (Polit and Hungler 1995, Sackett et al. 2000, 
Schulz and Grimes 2002). A number of studies have examined the levels of attrition or 
retention in trials in a single clinical area, for example depression (Warden et al. 2009) 
and chronic pediatric conditions (Karlson and Rapoff 2009). These types of studies have 
reported a range of factors affecting the likelihood of completing follow-up and 
treatment, including patient characteristics and study factors. However there have 
been difficulties with ascribing differences in retention to any particular cause at an 
individual study level (Veldhuizen et al. 2015).  
Existing systematic reviews of retention issues have identified possible ways of 
preventing dropout in health care research (Robinson et al. 2007), community-based 
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trials (Davis et al. 2002), population-based cohort studies (Booker et al. 2011), and 
randomised controlled trials (RCTs) (Brueton et al. 2013). Evidence on the effectiveness 
of specific strategies in particular populations is scarce as this requires explicit 
evaluations and complex study design, for instance nested studies (Graffy et al. 2010, 
Bower et al. 2014).  
A Cochrane review on strategies to improve retention listed mental health as one of the 
most challenging disease areas to promote retention in clinical trials (Brueton et al. 
2013). This is in line with the established patterns of service and treatment utilisation 
in mental health with non-adherence to psychiatric treatment reported to be higher 
than in physical disorders (Cramer and Rosenheck 1998). Additionally, people with 
schizophrenia have been described as particularly difficult to engage in psychiatric 
services and likely to fail to adhere to medication (Lecomte et al. 2008, Lecomte, 
Leclerc, and Wykes 2012). However, while some literature suggests that a diagnosis of 
schizophrenia increases the risk of non-compliance with outpatient psychiatric 
treatment (Kissling 1994, Kemp and David 1996, Bueno Heredia et al. 2001), other 
authors contradict this notion (Berghofer et al. 2000, 2002, Rossi et al. 2002). Some of 
these discrepancies in findings have been ascribed to the differences in the definitions, 
treatment setting, study design and sample composition (Reneses et al. 2009). Low 
engagement in services increases the vulnerability of people with schizophrenia to non-
adherence to treatment, which commonly comprises long-term therapeutic plans and 
regular contact with services aimed to reduce the risk of relapse (Nose et al. 2003). The 
attrition rates in RCTs of antipsychotic drugs in particular have been shown to reach 
levels threatening trial validity (Cramer and Rosenheck 1998, Wahlbeck et al. 2001, 
Nose et al. 2003). The issues experienced in these type of trials have been shown to 
cause relevant stakeholders; including psychiatrists, trial researchers, mental health 
service users and their carers, to mistrust results of the majority of pharmacological 
trials in schizophrenia (Xia et al. 2009). 
The factors affecting non-compliance with medication have been investigated but these 
are likely to be different in studies involving non-pharmacological treatment, given that 
most of the reported factors have been found to be directly relevant to the medication 
received, for instance unwanted side-effects and attitude towards drugs (Kampman and 
Lethinen 1999). To date, there has been only one systematic study identifying factors 
affecting attrition rates in RCTs on psychosocial treatment for people with 
schizophrenia (Villeneuve et al. 2010). The study was limited to psychosocial 
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interventions, which represent only one type of non-pharmacological treatment 
available to people with schizophrenia. In addition, the study was concerned with a 
complete withdrawal from treatment (as opposed to treatment non-compliance) and 
considered dropout both prior to starting treatment and during treatment. 
Nonetheless, the study began to address the gap in research on attrition in RCTs of 
interventions that do not involve taking antipsychotic medication.  
Completion of follow-up assessments has been argued to be specific to both trial and 
disease (Brueton et al. 2014). Moreover, it has been argued that recruitment and 
retention strategies need to be tailored to the target population and the study design 
(Newington and Metcalfe 2014). A better understanding of which individuals have more 
difficulty completing a trial and which studies are more likely to retain participants can 
help in developing effective, evidence-based recruitment and retention strategies to 
engage participants on a more productive level, ultimately resulting in better quality 
research. Thus, the aim of this thesis was to improve the current understanding of the 
retention of people with schizophrenia in trials evaluating complex interventions. The 
specific empirical objectives and research questions this thesis set out to answer will be 
discussed in Chapter 3 following an introduction to the relevant background literature 
in Chapter 2.  
1.2 Research context 
This thesis presents the doctoral research undertaken as part of a Life Sciences Initiative 
studentship awarded in 2014. The studentship involved a multidisciplinary 
collaboration between the Wolfson Institute of Preventive Medicine and the School of 
Geography and aimed to provide the candidate with the opportunity to develop broad 
as well as in-depth understanding of the selected topic area from a multidisciplinary 
viewpoint (Life Sciences Initiative 2014). The candidate undertook the research at the 
Unit for Social and Community Psychiatry, part of the Wolfson Institute of Preventive 
Medicine at Queen Mary University of London (QMUL) comprising approximately 25 
researchers with backgrounds in psychology, psychiatry, and anthropology. The Unit’s 
portfolio of work includes a range of studies, mainly trials on novel complex 
interventions conducted in collaboration with the registered Pragmatic Clinical Trials 
Unit at QMUL. The Unit is jointly operated by QMUL and East London NHS 
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Foundation Trust and has been a World Health Organisation Collaborating Centre for 
Mental Health Service Development since 2012. The work presented in this thesis has 
been presented to the Unit’s research team at regular research seminars, providing the 
opportunity to discuss the process and findings in a multidisciplinary setting.  
1.3 Thesis overview 
This thesis is presented in eight chapters. Chapter 1 has outlined the rationale for this 
doctoral research, its main aim, the context within which it was conducted, and the 
structure of the thesis. Chapter 2 provides a review of the relevant background 
literature, including: introduction to schizophrenia, developing and testing complex 
interventions for schizophrenia, and retention of patients with schizophrenia in clinical 
trials. Chapter 3 is a brief interim chapter, which briefly outlines the specific objectives 
and research questions informed by the literature discussed in the previous chapter and 
discusses the epistemological and methodological approaches taken to address them. 
Chapter 4 deals with the attrition rates reported in publications identified in a 
systematic literature search and identifying factors predicting those rates in a meta-
analysis. Chapter 4 takes a closer look at the factors associated with study retention in 
a meta-analysis of individual patient data from a convenience sample of relevant trials 
and considers the pattern of retention across the duration of a trial. Chapters 6 and 7 
present findings from two qualitative studies. Experiences of trial researchers and their 
practices are discussed in Chapter 6 and the perspectives of former trial participants 
on their participation and retention practices are explored in Chapter 7. Finally, 
Chapter 8 revisits the research aims and summarises study findings before offering 
interpretation and implications for enhancing retention rates in complex intervention 
RCTs involving people with schizophrenia.  
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 Chapter 2 
Background literature: theory and practice 
of participant retention in randomised 
controlled trials of complex interventions 
for schizophrenia 
2.1 Chapter overview 
Participant retention in trial follow-up assessments and completion of complex 
interventions for schizophrenia evaluated in a trial context are the focal themes of this 
thesis. The focus on schizophrenia is deliberate, rather than merely an example of a 
research area, as there is a widely-held concern around the level of engagement of 
patients with a diagnosis of a psychotic disorder in both psychiatric treatment and 
clinical research. 
The following chapter formulates the rationale for this remit by outlining relevant 
methodological and clinical challenges. The nature of schizophrenia and the currently 
available treatments will first be introduced, followed by a discussion of an RCT as a 
method used to develop and evaluate new treatments for schizophrenia. It then focuses 
on what guides the conduct of trials in a methodological and pragmatic sense and 
contrasts studies evaluating pharmacological and non-pharmacological interventions. 
The particular issues surrounding involving and retaining people with schizophrenia in 
trials are discussed. Retention rates and the factors they are affected by are also 
considered in light of the existing evidence. Finally it discusses the strategies used by 
trial researchers to aid retention and examines the perspectives of participants who 




2.2 Introduction to schizophrenia 
2.2.1 Clinical presentation and impact of schizophrenia 
Schizophrenia is a serious psychiatric disorder characterised by disrupted thinking, 
behaviour, communication and emotional responses. The term ‘psychosis’ is used to 
describe a set of conditions, including schizophrenia, schizoaffective disorder, 
schizophreniform disorder, delusional disorder and non-affective psychoses. Some 
literature includes bipolar disorder and unipolar psychotic depression in the group of 
psychotic disorders. This thesis will use the term ‘schizophrenia’ to encompass all 
diagnoses falling under section F2 of the International Classification of Diseases (ICD-
10), namely schizophrenia, schizotypal and delusional disorders (World Health 
Organisation 1992).  
Although each person who develops a psychotic disorder will experience a unique 
combination of symptoms, there are models and guidelines used for assessing and 
understanding cognitive and behavioural factors associated with the diagnosis. Positive 
symptoms include delusions, hallucinations, disorganised speech and/or behaviour, 
and agitation. Negative symptoms include affective flattening (i.e. limited range of 
emotional expression, poor eye contact, and reduced body language), alogia (i.e. 
poverty of speech), and avolition (i.e. inability to initiate and persist in goal-directed 
activities). Cognitive symptoms may include difficulties with verbal fluency, attention, 
and working memory. According to the Diagnostic and Statistical Manual of Mental 
Disorders fifth edition (DSM-5) (American Psychiatric Association 2013) at least two of 
those symptoms need to be present for at least six months and include at least one 
month of experiencing active symptoms before a formal diagnosis can be made. 
Whilst the condition has been shown to affect approximately 1% of the world’s 
population (Freedman 2003, Saha et al. 2005), making it a relatively low incidence, it is 
one of the leading causes of disability and comprises a considerable proportion of the 
global disease burden (Murray and Lopez 1996). In England alone, its annual cost in 
2007 was estimated at £2.2 billion, with a projected increase to £3.7 billion by 2026 
(Mangalore and Knapp 2007). The scale of this burden has been attributed to two 
particular features of schizophrenia: early onset and persistent and fluctuating 
symptoms (Saha et al. 2005). In addition, compared to the general population, people 
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with schizophrenia have been reported to experience shorter life expectancy (Beary et 
al. 2012) and higher rates of mortality and suicide (McGrath et al. 2008, Hor and Taylor 
2010, Reininghaus et al. 2015). Physical and psychiatric co-morbid conditions are 
common within this population, including substance misuse (Buckley 1998), obesity, 
type II diabetes and coronary heart disease (Morgan et al. 2014). Medication typically 
taken by people with schizophrenia to manage psychotic symptoms often introduces 
additional physiological challenges such as impaired movement, cataracts, and sexual 
dysfunction (Marder et al. 2014). Individuals diagnosed with schizophrenia have been 
found to struggle with employment (Morgan et al. 2014), social functioning (Wiersma 
et al. 2000), and self-care (Liddle 1987, Holmberg and Kane 1999). Moreover, the 
condition can often lead to caregiver burden (McDonell et al. 2003), consequently 
adding to the overall burden of the illness. 
Given its substantial impact on individuals, caregivers and society at large, 
schizophrenia presents an important issue requiring further research identifying the 
best treatment for this population. 
2.2.2 The treatment of schizophrenia 
Treatment of schizophrenia most commonly involves a combination of medication, on-
going support and information, and therapies or rehabilitative strategies (Adams et al. 
2000). The currently recommended approach to treatment in the UK combines 
antipsychotic medication with psychological interventions (National Institute for 
Health and Care Excellence 2014). Despite this recommendation, the pervasiveness of 
pharmacotherapy is discernible in the scientific inquiry into new treatments for 
schizophrenia. A great proportion of clinical trials testing treatment for schizophrenia, 
reported to be as high as 86%, have investigated the efficacy of drug treatments 
(Thornley and Adams 1998). One reason for this disproportion between trials 
evaluating pharmacological interventions and those testing non-pharmacological 
treatment could be the need for the pharmaceutical industry to generate efficacy 
evidence in order to obtain a license and introduce the drug into the marketplace 
(Russell 1996). However, given that the recommended approach combines both types 
of treatments, this imbalance points to the need for generating more evidence around 
new non-pharmacological interventions for schizophrenia.  
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Some debate exists with regards to the mechanisms of psychiatric drug actions. The 
‘disease centred model of psychiatric drug action’ developed in the 1950s and 1960s 
focuses on targeting the biochemistry that produces particular symptoms of 
schizophrenia. An alternative, ‘drug centred model of drug action’ emphasises the 
physical and mental states induced by pharmacotherapy (Moncrieff and Cohen 2009). 
In contrast to these models concerned with the impact of psychiatric drugs, a non-
pharmacological approach focuses on enabling patients with psychosis to cope with the 
illness through cognitive, behavioural, vocational, and psychosocial approaches (Eon 
and Durham 2009). Current evidence proposes three strategies for non-
pharmacological treatment: 1) to support or educate (for instance psychoeducational 
programmes or family interventions); 2) to provide specific skills training (for instance 
life skills programmes); and 3) to focus on a problem or symptom (for instance 
cognitive rehabilitation or psychodynamic therapy) (Adams et al. 2000, NHS Centre for 
Reviews and Dissemination 2000). However, this typology is not exhaustive as some 
existing interventions would not fall under any of the above strategies, for example 
solution-focused therapy, which is goal-directed and focuses on solutions rather than 
problems (O’Connel 2005, Priebe et al. 2013, 2015). Interventions can be delivered either 
individually or in a group setting, with the latter offering an attractive option to health 
care providers in light of the increasing demand for inexpensive and accessible forms 
of psychiatric treatment (McCrone et al. 2008, Burlingame 2014).  
Most non-pharmacological interventions have multiple interconnecting components, 
which interact in non-linear causal pathways, making the majority of them fall into the 
category of complex interventions (Grant et al. 2013). Craig and colleagues (2008, p.2) 
list five characteristics of a complex intervention: 1) multiplicity of the interacting 
components; 2) multiplicity and complexity of behaviours required by those delivering 
or receiving the intervention; 3) multiplicity of groups or organisational levels targeted 
by the intervention; 4) multiplicity and variability of outcomes; and 5) permitted degree 
of flexibility of the intervention. 
Complex interventions conform to specific processes but their format depends on the 
context, yielding them non-standard (Hawe et al. 2004, Petticrew 2011). The Medical 
Research Council (2000) distinguishes four types of complex interventions: 1) 
individual patient care, for instance cognitive behavioural therapy; 2) organisational or 
service modification, for instance community treatment order; 3) interventions 
targeting health professionals, for instance educational interventions; and 4) 
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population level interventions, for instance health campaigns. Because of this context-
dependence and multifaceted nature, testing complex interventions in trials can pose 
methodological challenges (Oakley et al. 2006, Grant et al. 2013) and requires sufficient 
preparation and training of staff to ensure consistency of treatment (Medical Research 
Council 2000).  
2.3 Evidence-based medicine: developing and testing complex 
interventions for schizophrenia 
2.3.1 Evidence-based medicine  
The term ‘evidence-based medicine’ (EBM) has been in use since 1990s when it was first 
coined by David Sackett and his colleagues. They defined EBM as: “the conscientious, 
explicit and judicious use of current best evidence in making decisions about the care 
of the individual patient. It means integrating individual clinical expertise with the best 
available external clinical evidence from systematic research.” (Sackett et al. 1996, p.1). 
EBM, also referred to in the literature as ‘evidence-based practice’ (EBP), advocates a 
move in clinical practice from an ‘authoritarian’ attitude based on professional opinions 
to an ‘authoritative’ one drawing on evidence (Gart et al. 1992, Sackett et al. 1996, Straus 
and McAlister 2000, Akobeng 2005, Seshia and Young 2014). This is achieved by helping 
clinicians to identify and apply the best quality information, together with clinical 
expertise and patients’ choice, in clinical decision making (Sackett et al. 1996). The 
principles of EBM have guided medical education and supported clinicians in following 
evidence-based practice. The process of EBM, as described by Dawes et al. (2005) 
involves five steps:  
 Translation of uncertainty to an answerable question. 
 Systematic retrieval of best evidence available. 
 Critical appraisal of evidence for validity, clinical relevance, and applicability. 
 Application of results in practice. 
 Evaluation of performance. 
With the increasing amount of evidence generated in clinical trials, there was a need to 
consolidate the knowledge and incorporate it systematically into medical practice. One 
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of the most significant developments that enabled this need to be met was the creation 
of the Cochrane Collaboration. The group, operating since 1993, facilitates systematic 
reviews of best available trials across different disciplines and provides instrumental 
evidence in medical treatment and health services (Chalmers 1993).  
2.3.2 Methodological and practical fundamentals of a randomised controlled 
trial 
A cornerstone of EBM was establishing a hierarchy of medical literature, which provides 
a system of rating evidence on the effectiveness of interventions (Elamin and Montori 
2012). The hierarchical classification (Figure 2.1) places RCTs near the top due to a low 
risk of bias and systematic errors (Burns et al. 2011).  
 
Figure 2.1 Hierarchy of evidence [adopted from (Akobeng 2005)] 
A randomised controlled trial is referred to as a ‘gold standard’ in EBM as it offers the 
most scientifically rigorous method of evaluating the effectiveness of an intervention 
(Sackett et al. 1996). The need for rigorous evaluation of non-pharmacological 
interventions, especially psychological and behavioural ones, has resulted in the rise of 
trials evaluating complex interventions (Friedli and King 1998, Stephenson and Imrie 












The most commonly applied RCT design is one involving two arms delivered in parallel. 
One group receives a new intervention being tested (‘experimental’ or ‘active group’) 
and the other (‘comparison’ or ‘control group’) is given an active control condition, an 
inactive control (treatment as usual) or a placebo (Figure 2.2). Multiple-armed RCTs 
compare an active treatment with an alternative active treatment (or multiples of it) 
and an inactive control/placebo.  
 
Figure 2.2 The RCT model [adopted from Kendall (2003)] 
 
One of the key features of an RCT is random allocation to the treatment groups. 
Randomisation ensures that participants are assigned to either experimental or control 
group with no selection bias, i.e. certain characteristics affecting which intervention is 
given to an individual. A correctly conducted randomisation should yield treatment 
groups as alike as possible achieved by distributing all characteristics of patients (for 
instance age, sex, illness duration) randomly across the trial arms. All groups are 
followed up for the same period of time and subjected to the same procedures with the 
exception of the treatment. Since the treatment is the only factor setting the groups 
apart, any differences observed in outcomes can be attributed to the treatment under 
evaluation.  
Another procedure employed to minimise bias in RCTs is ‘allocation concealment’. It 
is an essential technique used to prevent selection bias by preventing the researcher or 
clinician responsible for assigning participants to treatment arms from having any 
influence on which patients are given which treatment. This is a different concept to 
‘blinding’ or ‘masking’, which applies after participants have been allocated to 
treatment. The most common application of this procedure is ‘double blinding’, which 













the participant’s arm allocation. This practice eliminates the potential bias in 
measuring the outcomes and prevents the expectations of participants or researchers 
from influencing the possible effect. While double blinding is possible to achieve in 
pharmacological trials, where the study drugs can be made to look alike, it presents 
challenges in trials evaluating complex interventions and often requires nonstandard 
methods (Boutron et al. 2006).  
The process of conducting an RCT is best illustrated by the Consolidated Standards of 
Reporting Trials (CONSORT) flow diagram (see Appendix 1). The diagram depicts the 
passage of participants through the main phases of a clinical trial. Following the 
selection of a representative population sample from which to recruit a required 
number of trial participants, each participant’s eligibility is assessed and those who do 
not meet pre-specified inclusion criteria are excluded. Once eligibility has been 
checked and informed consent obtained, researchers measure relevant baseline 
variables. Patients who complete the baseline assessment continue on to the next stage: 
random allocation to treatment. Subsequently, the intervention is delivered for a 
specified period of time. Participants are followed-up at pre-specified time points to 
record outcome measures needed for the final analysis. Importantly for this thesis, 
given the longitudinal nature of trials and participants’ right to withdraw at any point, 
each stage of the trial process carries the risk of losing participants. One of the ways of 
ensuring the internal and external validity of RCTs is to minimise the loss of 
participants following recruiting the required numbers. 
Despite the considerable development of trial processes over the past 15 years RCTs 
evaluating non-pharmacological interventions frequently suffer from methodological 
shortcomings preventing them from detecting important treatment effects (Adams et 
al. 2000, Campbell et al. 2000). Some of the concerns include insufficient statistical 
power, problems with study design, implementation failure or genuine ineffectiveness 
(Levati et al. 2016). Complex intervention trials have been argued to be particularly 
challenging in terms of controlling the required research conditions and reporting 
them adequately (Stephenson and Imrie 1998, Grant et al. 2013).  
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2.3.3 Reporting trial information 
Judging the validity of trials relies on information about participant flow but the quality 
of reporting the details has been found to be suboptimal (Begg et al. 1996, Thornley and 
Adams 1998, Moher et al. 2001, Dumville et al. 2006). Reporting of trials evaluating 
complex interventions can present particular challenges given the intricacy of 
treatment and has been reported to be problematic (Craig et al. 2008, Glasziou et al. 
2008, Michie et al. 2009, Pino et al. 2012). Problems specific to reports of this type of 
trials include providing incomplete descriptions of the interventions and/or materials 
used and a lack of definitions of intervention completion (Barnicot et al. 2011, Hopewell 
et al. 2011, Sohanpal et al. 2012, Hoffmann et al. 2013). 
The issues with reporting across trial publications have led to the development of 
guidelines for transparent reporting of participant flow information. The CONSORT 
guidelines have been endorsed by many journals (for example British Journal of 
Psychiatry, The Lancet, British Medical Journal) in an attempt to encourage accurate, 
transparent and complete reporting of trials. This endorsement has been shown to be 
associated with better reporting of participant flow in RCTs (Plint et al. 2006, Kane et 
al. 2007, Turner et al. 2012), with some remaining gaps identified in a Cochrane review 
(Turner et al. 2012). Since the introduction of the original CONSORT guidelines, a 
further extension was developed specifically for the reporting of RCTs of Social and 
Psychological Interventions (SPI) and called CONSORT-SPI (Montgomery et al. 2013). 
However, so far, its uptake appears to be limited.  
Other tools have been developed to aid reporting of complex interventions in addition 
to the CONSORT flowchart. These include the PaT plot, a graphical method for 
depicting the different intervention components and their sequencing (Perera et al. 
2007)(see Figure 2.3 below) and, more recently, the cascade diagram showing the 
relationships between the actors delivering those components (Hooper et al. 2013)(see 
Figure 2.4 below). If used together, the three tools have been argued by their authors 
to form a complete description of an intervention including multiple components and 

















Figure 2.4 An example of a cascade diagram [adapted from Hooper et al. (2013)] 
 
2.3.4 Patient with schizophrenia as a trial participant 
In addition to the particular design and reporting standards applying to RCTs, clinical 
studies need to comply with a set of codes of practices and standards. All research 
carried out with human participants in the UK is required to obtain ethical approval of 
a relevant authority. Studies involving participants associated with the National Health 
Service (NHS) (which is the case for all RCTs of complex interventions in the UK) are 
subject to an ethics review by a Health Research Authority’s Research Ethics Committee 
(REC). 
Research involving people with schizophrenia needs to consider ethical concerns 
associated with the potential decision-making deficits experienced by some individuals 
with this diagnosis. A decision about participation in a trial requires every potential 
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understanding of particular trial attributes such as randomisation, blinding, or control 
condition. Trial participants need to agree to being repeatedly exposed to treatment 
and, in most cases, to completing multiple assessments of outcomes.  
One of the most widely cited studies exploring the decision-making capacity of people 
with mental illness has been the MacArthur Treatment Competence Study carried out 
in the United States with 498 individuals with and without a diagnosis of a mental 
illness, including one sub-group including schizophrenia inpatients (Appelbaum and 
Grisso 1995, Grisso and Appelbaum 1995, Grisso et al. 1995). The study concluded that 
psychiatric inpatients had decision-making abilities similar to those without mental 
illness. However, approximately half of inpatients with schizophrenia showed high 
levels of impairment across four types of legal standards essential for decisional 
capacity, including the ability: 1) to understand relevant information; 2) to appreciate 
its implications for one’s own situation; 3) to reason with information; and 4) to express 
a choice (Appelbaum and Grisso 1995). Furthermore, the findings suggested that these 
impairments could be temporary, reflecting the fluctuating nature of the severity of 
schizophrenia symptoms.  
More recent studies present conflicting evidence on whether or not individuals with 
schizophrenia have sufficient capacity to provide informed consent for research 
participation (Carpenter et al. 2000, Roberts et al. 2002). Carpenter and colleagues 
(2000) proposed that impaired capacity to make decisions about taking part in research 
can be remediated by providing sufficient opportunities to learn the necessary 
information, placing emphasis on the routine procedures carried out by researchers. 
Other evidence has highlighted the diversity of factors affecting the ability to engage in 
research, including: the severity of symptoms and cognitive deficiencies (Roberts 1998); 
stability of lifestyle, substance misuse (Lecomte et al., 2012); sensitivity of the research 
subject (Jorm et al. 2007); specific research context, involvement of alternative 
decision-makers, values held by individuals, and the nature and quality of the 
relationship between researcher and participant (Roberts et al. 2000). The diversity of 
these factors highlights the complexity of involving people with schizophrenia in 
research and in psychiatric treatment (Lecomte, Leclerc, and Wykes 2012). 
Although the evidence on the capacity to consent among people with schizophrenia is 
sizeable, it has focused mainly on the informed consent provided at the point of 
recruitment to a research study. Longitudinal studies require multiple assessments, 
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often over an extended period of time, and thus require researchers to continuously 
ensure that participants continue to give voluntary consent. The risk of a participant 
losing capacity to consent prior to the conclusion of a longitudinal study is 
acknowledged in the Mental Capacity Act 2005 for England and Wales (Department of 
Health 2005). Consequently, there is a need to consider fluctuations in mental health 
and their potential impact on a person’s capacity to monitor their willingness to remain 
involved in a study. One such study by Palmer et al. (2013) investigated the changes in 
capacity to consent over time in individuals with schizophrenia and bipolar disorder 
taking part in a longitudinal study of the side-effects of antipsychotic medications. The 
results showed that any improvements in understanding of study information 
dissipated at each subsequent follow-up assessment. This did not affect decisional 
capacity in all participants but worse neuropsychological performance was associated 
with poorer performance. The study suggests that some patients are likely to experience 
fluctuations in their capacity to make decisions about research participation over the 
duration of study.  
2.4  Retention of patients with schizophrenia in clinical trials 
2.4.1 The attrition problem  
Most literature concerned with trial methodology has focused on recruitment issues, 
presenting it as the “single most important aspect of a successful trial” (Borschmann et 
al. 2014, p.2) and the key to achieving a sufficiently powered sample. However, while 
recruitment is the first step towards achieving sufficient power and delivering a 
successful trial, it does not guarantee those two important aspects. In this respect, 
retention is required to achieve these aspects by striving to keep as many people in the 
trial as possible. If a high number of participants are lost following enrolment into a 
trial, the recruitment efforts are wasted. Retention, therefore, has a significant role in 
ensuring the validity and cost-effectiveness of research. 
The introduction of standardised methods for reporting participant flow discussed in 
section 2.3.1. was an important step in enabling comparisons of retention rates across 
different studies as well as identifying factors predicting retention (Karlson and Rapoff 
2009). However, such comparisons require a shared understanding of what retention 
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is and this has been found to vary across studies (Kane et al. 2007). The inconsistency 
in definitions can result in variability in the reported retention rates and may 
consequently complicate further analyses.  
Retention has been defined as the continued involvement of research participants over 
the projected study duration (Davis et al. 2002), involving developing and maintaining 
relationships with participants (Patel et al. 2013). Failure to retain participants in a study 
is commonly referred to as ‘attrition’. However, there is a considerable lack of clarity 
and consistency of terminology in trial publications and the literature discussing the 
different types and levels of attrition. Some of the relevant terms appearing in the 
literature include non-adherence (Christensen et al. 2009, Dodd et al. 2012), premature 
or early termination (Hatchett and Park 2003, Arnow et al. 2007, Ong et al. 2008, Swift 
and Greenberg 2012), non-persistence (Donkin and Glozier 2012), non-usage attrition 
(Eysenbach 2005), non-participation (Toerien et al. 2009), withdrawal (Martin et al. 
2006, Grant et al. 2009, Toerien et al. 2009, Leucht et al. 2013), and discontinuation 
(Eysenbach 2005, Martin et al. 2006, Warden et al. 2009, Swift and Greenberg 2012).   
A comprehensive typology of attrition proposes five variations, each corresponding to 
a different trial process outlined in the CONSORT diagram (see Figure 2.5): 1) 
enrolment refusal, 2) baseline attrition, 3) post-randomisation attrition during 
intervention, 4) post-randomisation attrition during follow-up, and 5) attrition due to 





Figure 2.5 Definitions of attrition [adopted from (Karlson and Rapoff (2009)] 
 
Marcellus (2004) proposes that participants can be considered ‘non-completers’ or 
‘dropouts’ if they fail to complete the treatment protocol or if they are lost to follow-
up. The former term is more commonly associated with retention at the intervention 
level, also referred to as ‘treatment adherence’ or ‘treatment attendance’; the latter 
relates to study retention or failure to complete follow-up assessments. These 
definitions, however, are not consistently applied in the literature.  
Treatment adherence has been defined as “the extent to which a person’s behaviour in 
terms of taking medications, following diets or executing lifestyle changes coincides 
with the medical or health advice” (Haynes & Sackett 1979, p.27) and is a common 
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problem in psychiatry (Nose et al. 2003). In pharmacological trials, adherence generally 
relates to the extent to which patients take prescribed medication being tested. In 
psychiatric trials, it can be further classified into adherence to medication and 
adherence to scheduled appointments (Nose et al. 2003). In the case of trials evaluating 
complex interventions, adherence depends on the treatment and can be considered as 
entry to treatment, the amount of sessions attended, or implementation of instructions 
(Nose et al. 2003). Non-adherence to treatment has a major impact on the effectiveness 
of complex interventions and presents challenges in both clinical and research practice 
(Nose et al. 2003, Haynes et al. 2006). In addition, while in pharmacological treatment 
non-adherence can be an important indicator of dropout caused by problems with 
treatment tolerability or adverse effects (Rabinowitz et al. 2009), in complex 
interventions it may suggest issues with acceptability, willingness of participants to 
engage with treatment, or pragmatic issues to do with attending treatment.  
The concepts of retention and attrition can be considered as two opposing ends of a 
spectrum of research participation. Both terms will be used throughout this thesis when 
referring to the phenomenon of continuous involvement of participants in a research 
study. Distinctions will be made between the different levels and types of retention or 
attrition to describe the extent to which individuals complete research procedures 
and/or interventions.   
While retention is important for any study, it bears particular importance for clinical 
trials where failure to retain sufficient numbers of participants may lead to many issues, 
including limited statistical power, bias, lack of internal and external validity, 
prolonged trial duration or, in extreme cases, its premature closure (Gross and Fogg 
2001, Williams et al. 2007, Marcantonio et al. 2008, Gul and Ali 2010). For example, high 
attrition rates have been identified as a cause of publication bias particularly in trials of 
Internet-based interventions, with difficulties to publish results of studies that 
experience a substantial loss of participants (Eysenbach 2005). Overall attrition 
comprises the total loss of data across all trial groups. Given that the aim of 
randomisation is to ensure that participants share the same characteristics at baseline, 
dropout can create an imbalance between the groups if the participants who have 
provided follow-up data are different to those who have not. In contrast, selective or 
differential attrition occurs when the degree of dropout differs between trial arms, 
resulting in groups that look different from the initial randomised groups. In this case 
any differences in dropout between groups can lead to researchers erroneously 
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attributing any changes in outcomes solely to the treatment being tested. Some 
evidence proposes that differential attrition can be a consequence of perceived efficacy 
or tolerability of treatment (Stein et al. 2006). In addition, Wortman, (1978) suggested 
that participants who receive an active intervention feel obligated to complete follow-
up assessments more than those in the control arm. However, some evidence suggests 
that these differences are more likely to be observed in trials that cannot blind 
participants, thus resulting in perceived differences in treatment (Boutron et al. 2006). 
Although the risk of issues created by attrition have always been concerns for trial 
conduct, Gross & Fogg (2001) argue that improved access to health care information, 
empowerment of patients and lack of trust in research have increased the magnitude 
of threat posed by attrition in RCTs.  
2.4.2 Reported retention and attrition rates 
Attrition rates in studies across different areas of medicine and types of interventions 
range from 5 to 70% (Marcellus 2004), showing large variability. Some variation can be 
expected depending on the type of treatment (i.e. medication or therapy) and the 
clinical population under study. While studies investigating dropout or non-adherence 
in drug trials across different illnesses are abundant (for example Hugtenburg et al., 
2013; Gelaw et al., 2014; Dauw et al., 2016), such investigations in the context of trials of 
complex interventions are scarce and the existing ones focus mainly on mental health. 
This could be due to the influence of the biomedical model of illness in the physical 
health care, although other models that recognise the importance of psychological and 
social factors do exist and are in use (Wade and Halligan 2004). The number of studies 
investigating psychosocial interventions can be expected to directly correspond to the 
number of studies, especially systematic, exploring retention and adherence in this 
context. This in turn limits the evidence available for the purposes of making 
comparisons in the context of the present study to mainly mental health conditions.  
Most systematic studies available on the subject of attrition in non-pharmacological 
interventions for mental health conditions have focused on depression as a disorder 
and treatment adherence as a phenomenon. The available evidence examined a range 
of interventions, including CBT, psychotherapy, and physical activity. For example, a 
meta-analysis of adherence to CBT for depression reported in 24 studies found that 
intervention completion was higher when the therapy was delivered face-to-face 
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(84.7%) than in Internet-based CBT (65.1%) (van Ballegooijen et al. 2014). A similar rate, 
although expressed as attrition, was found in a meta-analysis of 54 RCTs of 
psychotherapy for major depression, showing 17.5% dropout from the intervention and 
19.9% at the study level (Cooper and Conklin 2015). Physical activity interventions for 
depression evaluated in 40 RCTs attracted an average attrition rate of 18.1% (Stubbs et 
al., 2016, p.463). Completion of psychosocial treatment has also been systematically 
studied in the context of borderline personality disorder (Barnicot et al. 2011). While 
the disorder has been associated with low treatment completion rates, a meta-analysis 
of 41 RCTs evaluating psychotherapeutic interventions found that on average 75% of 
patients complete the treatment if it is shorter than 12 months. A lower completion rate 
of 71% was found for treatment duration longer than 12 months. Overall, the available 
evidence has presented adherence to complex interventions for depression and for 
borderline personality disorder as adequate; however, at the same time a considerable 
variability has been found across individual trials.  
Loss of any proportion of participants creates bias, however different attrition levels 
lead to different levels of problems. Losing fewer than 5% of the original sample is likely 
to lead to little bias, however attrition levels exceeding 20% pose a serious a threat to 
validity (Polit and Hungler 1995, Sackett et al. 2000, Schulz and Grimes 2002, Gul and 
Ali 2010). Internal validity may be compromised if the treatment groups are non-
equivalent and random composition of the groups is altered (Kazdin 1999). High 
attrition can also limit the generalisability of the findings to only those who remain in 
the study, thus compromising external validity (Karlson and Rapoff 2009).  
There are multiple statistical methods to deal with missing data resulting from 
attrition, such as intention to treat (ITT) analysis, complete case analysis, simple 
imputation, and last observation carried forward. Although it is beyond the scope of 
this thesis to review all of these approaches, it is important to acknowledge their 
application. The implications of missing data need to be considered at each stage of a 
trial and statistical methods present one option of dealing with missing data in RCTs 
by increasing statistical power and reducing bias. However, a review of RCTs published 
in top medical journals highlighted inconsistencies in the definitions and applications 
of statistical methods and called for an improvement of handling missing data in RCTs 
(Bell et al. 2014). Moreover, the authors have argued that “prevention is the best way to 
handle missing data, so more effort needs to be put into missing data at the design and 
conduct stage” (p.7), underscoring the importance of maximising participant retention.   
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Despite the methodologically acceptable attrition rates at the study level estimated to 
be below 20%, as discussed above, the dropout levels judged as acceptable in published 
systematic reviews of antipsychotic medication were found to vary between 40% and 
50% (Hutton et al. 2012). In addition, a survey carried out by the Cochrane 
Schizophrenia Group with psychiatrists, researchers and carers showed that credibility 
of trials can suffer if attrition exceeds 25% (Xia et al. 2009). 
The rates of dropout from intervention vary between trials evaluating pharmacological 
versus non-pharmacological treatment for schizophrenia. The attrition rates from 
pharmacological interventions have been estimated at 33% (Wahlbeck et al. 2001) and 
48.9% (Kemmler et al. 2005). In contrast, a meta-analysis of dropout from psychosocial 
treatment reported between 1997 and 2007, defined as “the loss of participants either 
prior to treatment (never showed up) or during treatment (stopped treatment before it 
was completed)” (p. 267), has reported the rate of 13% (Villeneuve et al. 2010). The 
authors do not report the difference between the attrition occurring prior to versus 
during treatment; however these two types of dropout can be expected to differ given 
the change of context following receiving treatment. In addition, the attrition rate 
obtained in the meta-analysis is discussed in the context of treatment compliance, 
despite the authors making a clear distinction between a complete withdrawal from 
treatment and a proportion of completed treatment visits. The limitations of this study 
highlight the need for clear definitions of attrition, especially when considering 
compliance with non-pharmacological treatment. Overall, the results of the meta-
analyses discussed above show that compared to drug treatment, non-pharmacological 
interventions attract lower attrition rates, despite the treatment being on average six 
times longer.  
In addition to attrition levels, a systematic review of adherence to either 
pharmacological or non-pharmacological treatment programmes by patients with 
psychosis in studies published since 1980 found that 25% of patients failed to adhere; a 
rate lower compared to previous studies (Nose et al. 2003). There is some evidence 
suggesting that high non-compliance rates in clinical trials of antipsychotic medication 
are not restricted to a clinical trial setting. For example, a study of the Norwegian 
Prescription Database showed that 43% of 9,000 patients failed to return for their 
second antipsychotic prescription (Kjosavik et al. 2011). Thus, exploring attrition in a 
research setting can provide some indication of the potential reasons for non-
adherence to treatment in clinical practice.  
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2.4.3 Factors affecting participant retention in trials 
In addition to estimating the levels of retention in RCTs involving people with 
schizophrenia, it is also important to understand the reasons for and patterns of loss to 
follow-up throughout the duration of a trial (Brueton et al. 2014). This information can 
affect both the interpretation of results and conduct of trials to minimise attrition and 
enhance the level of engagement (Davis et al. 2002, Thompson et al. 2011, Lecomte, 
Leclerc, and Wykes 2012). One of the most common approaches to determining the 
factors affecting retention involves using available data to investigate any effects of 
study and/or participant characteristics on retention (Karlson and Rapoff 2009).  
This approach has yielded a number of studies identifying predictors of retention in 
clinical trials. Early research focused on patient characteristics, reflecting a belief that 
attrition is patient-driven, before starting to consider retention to be influenced by a 
range of factors, including those related to trials and to individuals (Carroll 1997). As a 
result, factors relevant to research staff, therapists and study design started to also be 
taken into account as potential predictors of retention. Studies considering the pattern 
of retention over time have consistently suggested that the highest proportion of 
dropout occurs early in a trial. Carroll (1997) explained this trend by the self-selective 
nature of trials, poor treatment and/or therapist fit, and inappropriate timing of 
treatment. On the other hand, Hewitt et al. (2010) posited that researchers invest more 
resources into retaining trial participants at the final follow-up than at earlier 
assessments. 
There are a number of studies that have retrospectively examined the predictors of 
retention across trials in different disease areas, for example chronic major depression 
(Arnow et al. 2007), human immunodeficiency virus (Villaruel et al. 2006), and lung 
health (Snow et al. 2007). Among the factors shown to be correlated with attrition are: 
age (Moorman et al. 1999, Snow et al. 2007), ethnicity and gender (Senturia et al. 1998, 
Arnow et al. 2007), education (Hill and Humenick 1995), severity of illness (Verheggen 
et al. 1998), psychological distress (Moser et al. 2000), and patterns of health care 
utilisation (Morse et al. 1995). In addition, some studies have attempted to create 
profiles of a stereotypical participant likely to drop out, for instance: “an older, non-
white male with limited education, multiple health problems, increased life stress, and 
a pattern of erratic health utilisation” (Davis et al. 2002, p.47) in community-based trials 
not limited to any specific disease and, in contrast, “young male patients with poor 
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insight of illness, a history of substance abuse, unemployed and with low social 
functioning” in a systematic review of non-adherence rates among patients with 
psychosis (Nosé et al. 2003, p.1155). Creating such profiles has been argued to inform 
judgements about the risk of the participant dropping out (Nose et al. 2003) and to help 
with adoption of appropriate retention strategies (Brueton et al. 2014). However, the 
lack of uniformity in the patient characteristics associated with dropout rates suggests 
that participant retention may be trial, treatment and disease specific (Carroll 1997, 
Brueton et al. 2014). Thus, factors found to be associated with dropout or retention in 
one group of studies cannot be reliably used to inform studies involving different 
populations. 
Compared to other diseases schizophrenia has been argued to be particularly 
appropriate for the analysis of factors affecting dropout given its complexity and range 
of symptoms (Thompson et al. 2011). These types of analyses have been carried out in a 
small number of studies within the context of service use and participation in both 
pharmacological and non-pharmacological trials, with majority focusing on the former 
type. Results of a meta-analysis of trials evaluating antipsychotics showed an 
association between the study duration and higher dropout from treatment (Wahlbeck 
et al. 2001); however, the same effect was not found in trials up to three months long 
(Kemmler et al. 2005). Davis et al. (2002, p.48) argue that studies with high attrition 
rates tend to “have a longitudinal, repeated-measures design, complex interventions 
that include time-consuming contacts with unskilled or poorly trained staff, and non-
relevant incentives for participation”. Moreover, studies involving explicit analyses of 
predictors of dropout from antipsychotic trials have shown attrition to be higher 
amongst participants experiencing negative symptoms of schizophrenia (Thompson et 
al. 2011), those randomised to placebo arms in trials testing second-generation 
antipsychotics (Kemmler et al. 2005), and those experiencing delusions or substance 
abuse (Carroll 1997). Factors that did not show any significant effects on dropout are 
also important for considering what is and what is not associated with retention. These 
included patients’ age, the Brief Psychiatric Rating Scale (BPRS) score at baseline, trial 
duration, publication year, use of multiple-dosage regiments in Kemmler et al.'s (2005) 
study and schizophrenia symptoms including positive, cognitive, excitement, and 
depression/anxiety as shown by Thompson et al. (2011).  
In comparison to the literature concerned with retention in antipsychotic trials, less 
evidence is available on what influences retention in non-pharmacological treatment 
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of schizophrenia. Engagement of people with schizophrenia in services has been shown 
to be affected by factors such as substance abuse, rapport with their therapist, social 
functioning, severity of symptoms, and insight into the illness (Lecomte, Leclerc, and 
Wykes 2012). Similar findings were shown in a literature review of treatment 
compliance components among people with psychosis (Kampman and Lethinen 1999). 
The review included studies published between 1974 and 1997 and was therefore limited 
to mainly neuroleptic treatment; nevertheless the components reducing compliance 
included complex treatment regimens, side-effects, negative attitude towards 
medication, delusions, substance misuse, living alone, poor housing, and being male. 
Better compliance was associated with recognition of medication’s benefits, support 
from family, family’s awareness of the patient’s illness, and social activity. The 
Villeneuve et al.’s (2010) meta-analysis of dropout from psychosocial treatment for 
schizophrenia discussed in the previous section also included an investigation of the 
moderators of treatment dropout. The study found higher treatment withdrawal to be 
associated with male gender, higher age, longer illness duration, longer treatment 
duration, and better study quality. In addition, individuals who received treatment in 
an inpatient setting had higher adherence rates than those in an outpatient setting. 
Two moderator variables that did not have an effect on the dropout rate were treatment 
modality (individual versus group) and severity of illness.   
It has been suggested that retention is a multi-determined phenomenon affected by the 
interaction of sample and study characteristics (Beutler et al. 1997, Fenton et al. 1997, 
Stasiewicz and Stalker 1999). This was illustrated in a study of psychosocial treatment 
showing that providing the same intervention to a heterogeneous sample can increase 
the risk of drop out if participants perceive themselves to be in the wrong setting, 
receiving the wrong treatment from the wrong person (Carroll 1997). The finding 
illustrates the importance of ensuring the right fit between the trial participant and the 
key aspects of a trial, including researcher, intervention and context in maximising 
participant retention. 
2.4.4 Retention from the perspective of the trial participant  
An alternative approach to exploring the factors affecting retention draws on 
qualitative methods exploring the reasons for refusing to participate or to drop out 
(Karlson and Rapoff 2009). The perspectives of trial participants who make decisions 
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about their involvement are an imperative aspect of understanding retention and help 
to address some of the limitations of the analyses discussed in the previous section. 
There are a slowly increasing number of studies exploring the experiences of patients 
who take part in clinical trials but these tend to focus on the initial decision to 
participate during recruitment.  
Research employing hypothetical scenarios to explore attitudes to trial participation 
has generally shown individuals to have a favourable view of research (Cassileth et al. 
1982, Llewellyn-Thomas et al. 1991, Slevin et al. 1995). Similar results were also reported 
among people with schizophrenia (Roberts et al. 2000, 2006, Kim et al. 2009, Sumner 
et al. 2014). However, generalisation of findings from such studies is limited as they 
focus on supposed rather than actual behaviours and experiences of trial participation 
(Featherstone and Donovan 2002). Previous studies showed that it is possible to engage 
trial participants in qualitative research exploring their attitudes towards research 
(Verheggen et al. 1998, Featherstone and Donovan 2002, Hussain-Gambles 2004, 
Canvin and Jacoby 2006, McCann et al. 2010, Reynolds et al. 2011, Freuler et al. 2013, 
Hanley et al. 2013, Simmonds et al. 2013, Morrison et al. 2014), with a small number of 
such studies involving people with schizophrenia (for instance Roberts et al. 2004). 
Moreover, Featherstone & Donovan (2002) argue that non-participants report different 
reasons for their lack of participation than researchers, highlighting the need for 
gathering the views of both groups and, ideally, capturing the experiences of those who 
drop out or decide not to take part in the first place.  
The current understanding of the decision-making process for taking part and 
remaining involved in clinical research is limited (Roberts et al. 2000; Trauth et al. 2000; 
Garety et al. 2008; Brintnall-Karabelas et al. 2011) and most available evidence comes 
from oncological studies. An example of such study is a systematic review and meta-
analysis of patient-reported barriers to participation in trials, which analysed 12 
qualitative and 21 quantitative studies addressing the attitudes and barriers of patients 
considering participation in cancer trials. The findings identified a number of concerns 
related to the trial methods, interruptions to patient lifestyle, and relationship with 
clinicians (Mills et al. 2006). These are similar to the findings of studies including other 
clinical populations, which have highlighted barriers such as: perceived personal 
disadvantage to do with receiving or not receiving treatment (McCann et al. 2010); 
health practitioners acting as gatekeepers to pragmatic RCTs (Patterson et al. 2011), 
depression trials (Mason et al. 2007), psychosis trials (Bucci et al. 2015); and poor 
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understanding of trial design and own participation in research (Featherstone and 
Donovan 2002). In addition, among the suggested reasons for participation in clinical 
trials in general are: altruism (McCann et al., 2010; Grant et al., 2009); willingness to 
contribute towards medical knowledge, an opportunity for learning about the 
condition, access to clinical review or monitoring, potential access to clinical treatment, 
personal benefit (McCann et al. 2010); commitment to the aims of the research, and a 
lack of concern about randomisation to study arms (Grant et al. 2009).  
Attempts to explain recruitment challenges among people with a mental health 
problem have identified misconceptions about clinical trials, lack of equipoise, 
misunderstanding about trial aims, unclear eligibility criteria, and paternalism as 
potential factors (Howard et al. 2009). Brintnall-Karabelas et al. (2011) highlight the 
need for identifying specific factors, such as inconvenience, finances, or protocol issues, 
taken into account in the decision-making process that are modifiable and that could 
help to promote interest in research participation. Patients with schizophrenia have 
been shown to struggle with understanding trial-related concepts but also to be capable 
of improving with appropriate information-giving (Chong et al. 2009). The difficulties 
with decisional capacity of people with schizophrenia have been discussed in Section 
2.3.4. The severity of schizophrenia symptoms has also been shown to affect attitudes 
to trial participation, with those experiencing more symptoms being, albeit modestly, 
less willing, less affirming and generally more negatively-inclined than those less ill 
(Roberts et al. 2006).  
In contrast to recruitment, retention encompasses multiple, repeated decision-making 
about participation. Each time a participant who has been recruited to a study is to 
receive an intervention or to attend a research assessment he or she needs to make an 
active decision about continuing their participation. Given their right to withdraw at 
any point, participants are not obliged to complete their participation, thus the initial 
consent to take part does not guarantee their retention in a study (Harris and Dyson 
2001). This is exemplified in studies showing trial participants’ waning motivation over 
time (Wilson and Rose 1998, Lloyd-Williams et al. 2003, Stanford et al. 2003, Jancey et 
al. 2006).  
There is a clear paucity of studies exploring decision-making and experiences of trial 
participation among people with schizophrenia, especially following enrolment into a 
study. It is possible that such investigations take place as part of an internal process 
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evaluation but their results are not subsequently published. Access to such evidence 
could be useful in understanding what affects the decisions of this population about 
remaining involved in a trial versus dropping out from treatment or study.  
2.4.5 Strategies for maximising retention  
The efforts to understand the patterns and predictors of retention have been made in 
order to develop ways of maximising participation levels, which is a principal condition 
for a successful completion of a trial. The first step toward achieving high levels of 
participation is recruiting a sufficient number of participants, dictated by sample size 
calculations. The subsequent task for trial researchers is to retain as many as possible 
of those patients in the study and treatment. Both processes have been described as key 
to successful trial completion and as major methodological challenges.  
Although often considered together, each process presents a different set of obstacles. 
Recruitment focuses mostly on attracting eligible participants, obtaining informed 
consent and offering attractive and fair incentives. The importance of recruitment is 
normally limited to the early stages of a trial and its success is clearly demarcated by 
definite targets. In contrast, successful retention is not as clearly defined but it plays an 
important role throughout trials, with each application of treatment and follow-up 
assessment. At each of these points trial researchers return to the issues dealt with in 
recruitment, i.e. confirming informed consent and offering incentives.  
Most of the literature dealing with trial methodology has been dedicated to 
recruitment, which can be attributed to a high proportion of studies failing to achieve 
their recruitment targets (Haidich and Ioannidis 2001, McDonald et al. 2006). The 
interest in recruitment has yielded evidence on the effectiveness of different methods 
to enrol patients into trials, which has translated into multiple recruitment strategies 
at trial researchers’ disposal. Some of the strategies shown to be effective in a Cochrane 
Review of 45 trials include: telephone reminders, use of opt-out from being contacted 
about participation opportunities, procedures for contracting potential participants, 
and open trial design (Treweek et al. 2011). Numerous studies have investigated factors 
affecting recruitment of specific populations, disease areas and trial designs (McDonald 
et al. 2006, Howard et al. 2009, Patterson et al. 2010, Borschmann et al. 2014, Newington 
and Metcalfe 2014, Hughes-Morley et al. 2015). Recruitment challenges identified in 
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studies involving patients with schizophrenia have been associated with practical 
barriers, conceptualisation of mental illness, protection from risk, timing of treatment 
and influence of other patients (Roberts et al. 2000, Woodall et al. 2010). In a survey 
carried out in an inpatient setting, patients diagnosed with schizophrenia were 
reported to be more reluctant than patients with other mental health disorders to take 
part in trials (Zullino et al. 2003). Although the study was limited to the views about 
participation in hypothetical studies, the differences reported by Zullino et al., (2003) 
included being less convinced about the benefit of a new treatment (50% of patients 
with schizophrenia vs 71% other patients), refusing double-blind trials (42.9% vs 
18.8%), being less likely to be motivated by altruistic reasons (67.9% vs 94.2%), as well 
as showing less reliance on their clinician to discuss participation (50% vs 71%).   
Retention has received less attention in the trial methodology literature than 
recruitment, although studies often consider the two processes in unison, without a 
clear distinction made between them. The existing evidence on strategies to maximise 
retention comes from four main perspectives: strategies applied at different stages of a 
study; strategies considered in context of different stakeholders; reports of strategies 
utilised in individual studies; and nested trials of retention strategies.  
Considering retention strategies from the perspective of the study cycle and the 
different stakeholders has led to development of a ‘phased approach’ or a ‘process 
model’. This approach regards research participation as a phenomenon observed over 
time and corresponds to the Karlson and Rapoff’s (2009) typology of attrition 
highlighting key trial mileposts where dropout can occur (see Section 2.4.1). 
Considering retention in the context of study processes allows for recognising how the 
phenomenon of retention changes over time and for considering the differences 
between the different types of attrition and their implications. Buben (2013) proposes 
considering three main phases: study design, patient consent, and patient 
participation. The latter can by further broken down into attrition occurring during 
intervention, during follow-up, or occurring due to missing data (Karlson and Rapoff, 
2009).  
Beginning with writing a study protocol, retention needs to be taken into account when 
calculating sample size and, consequently, planning recruitment efforts. This has direct 
cost and other resource implications as the more participants are required to identify 
an appropriate effect size, the more resources are likely to be required to both recruit 
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and retain them in a study. In addition, as argued by Buben (2013) decisions about study 
design should take into account the associated burden for participants. Consulting 
patients with similar lived experience and study site teams offers an effective way of 
identifying both desirable and undesirable aspects perceived as desirable and 
undesirable study aspects (Beresford, 2002; Sweeney and Morgan, 2009).  
Once a trial has commenced participants are presented with a number of opportunities 
to make decisions about their participation, starting with providing consent. Refusing 
to participate when invited to a study can be classified as ‘enrolment refusal’ (Karlson 
and Rapoff, 2009) and is often not taken into account when considering attrition rates 
as it occurs pre-randomisation. Another potential reason for attrition occurring prior 
to randomisation may include not meeting inclusion criteria. Those participants who 
have consented to take part are then invited to complete a baseline assessment. This 
milepost presents another risk of dropout as participants may refuse to complete 
baseline or be unable to do so, consequently preventing them from being randomised 
into a study, and can be categorised as ‘baseline attrition’ (Karlson and Rapoff, 2009). 
Post-randomisation attrition occurring during intervention is associated with the 
definition of completion specified in the trial protocol. Participants may either not 
receive the allocated intervention or discontinue the intervention before completing 
the treatment course. In contrast, dropout observed during follow-up (i.e. study 
dropout or loss to follow-up) occurs when participants fail to complete one or more 
follow-up assessments (Karlson and Rapoff, 2009). In addition, if large amounts of data 
are missing from particular participants, these individuals may be excluded from some 
analyses and attributed to ‘attrition due to missing data’.  
An alternative model of retention is the Ecological Theory of Research Participation 
(also referred to as the Ecological Model of Attrition) proposed by Lenora Marcellus 
(2004). The theory identifies four primary sources of attrition: participant, researcher, 





















Figure 2.6 An ecological model of research participation [adopted from 
Marcellus (2004)] 
 
As can be seen in Figure 2.6, Marcellus’ (2004) model pictures research participation as 
a multi-faceted system of factors affecting attrition built on interplay between all levels: 
“This model consists of a series of nested layers that represent various influences on an 
individual’s ability and desire to participate in a study. The factors within each layer are 
drawn from longitudinal studies of attrition.” (p.87).  
In addition, the model recognises two types of influences are recognised across all 
levels: transactional and participant-centred. The first is concerned with the direct 
influence of adjacent layers, which can be “transactional, reciprocal, and interactive” in 
nature. The second influence emphasises the importance of putting participants at the 
heart of efforts to increase retention, in line with the previous calls for moving away 
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from traditionally paternalistic research relationships (Gross and Fogg 2001). The 
Ecological Theory of Research Participation was developed to provide a guide to 
identifying factors within each level that affect attrition and to “give investigators the 
opportunity to address situation-specific barriers and develop strategies specific to the 
study and the population of interest in order to maximise participation.” (Marcellus, 
2004, p.89).  
Strategies related to the participants focus on their personal characteristics, including 
values, beliefs, motivation, and demographics. Awareness of these factors can be used 
by researchers to develop a participant-centred approach with retention strategies 
tailored to the specific study population and/or an individual. For example, if a 
participant is in full-time employment, they may need to be offered out-of-hours 
appointments in order to enable them to complete follow-up assessments. In addition, 
the onus is on the relationship between participant and researcher. Examples of 
participant-level strategies identified in the Ecological Model of Attrition include: 
forming a participant advisory group, ensuring convenience, timeliness and 
accessibility of research activities, matching incentives with the needs of the population 
(Marcellus 2004). Strategies at the researcher level aim to minimise the logistical and 
personal barriers between researcher and participant, for instance plan for continuity 
of researchers, express appreciation, emphasise collaborative effort. Retention efforts 
related to the study aim “to develop interventions and procedures that take the needs 
and resources of participants into account” (Marcellus 2004, p.93). Marcellus proposes 
this to be achieved by individualising retention strategies to fit the study, tracking 
participants, showing respect for participants’ time, etc. One of the unique 
contributions of the Ecological Theory of Research Participation is the consideration of 
environmental factors in retention related to organisational, funding, practice, 
political, geographical, disciplinary and philosophical issues. In terms of strategies 
these can translate into an assessment of transportation and monitoring organisational 
policies affecting research processes, for example reimbursing individuals for their 
participation.  
Much of the existing evidence on retention strategies comes from retrospective reports 
of lessons learned by study authors (Robinson et al. 2007), with a small number of 
studies investigating specific strategies in a systematic way. A review of 87 community-
based trials published between 1990 and 1999 identified 21 studies that discussed 
retention rates and retention strategies (Davis et al. 2002). The review found that the 
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trials with the highest reported retention rates employed multi-component retention 
strategies, supporting a previous suggestion made in relevance to psychosocial trials 
that a combination of strategies will be more effective than a single retention strategy 
(Carroll 1997). The review identified nine retention strategies utilised in studies across 
different disease areas. These included: 1) generating study publicity, 2) emphasising 
the significance of study for participants, 3) recruiting those who demonstrate 
compliance with key participation activities, 4) using meaningful incentives, 5) offering 
an appealing control group treatment, 6) maintaining contact between follow-ups, 7) 
training staff in interpersonal skills, 8) individualising data collection to participants’ 
needs and preferences, and 9) keeping a database of all available personal details. 
Although none of the community-based trials included in the review applied all nine 
strategies, the studies with high retention rates used a combination of the following 
strategies: establishing a project identity, offering incentives, training staff, and using 
participant databases.  
The need to assess the effectiveness of strategies to improve retention in RCTs has been 
identified as a result of researchers applying strategies lacking evidence supporting 
their use (Brueton et al. 2013). One of the most methodologically sound ways of testing 
retention strategies is embedding retention trials within larger trials evaluating a 
clinical intervention (Bower et al. 2014). This design, referred to in the literature as a 
‘nested trial’, ‘embedded trial’, or ‘trial within a trial’, enables an evaluation of the 
effectiveness of a specific strategy in a sample already involved in an on-going clinical 
trial. Despite its methodological superiority, this type of research has limitations as it 
presents a number of potential challenges, such as increased complexity, 
incompatibility with the host trial, and potential impact on the collaboration between 
researchers (Graffy et al. 2010, Bower et al. 2014). Most of the retention trials identified 
in the small number of the existing systematic reviews focused on studies utilising 
questionnaires as a method of collecting follow-up data and showed monetary 
incentives to be the most effective in achieving retention (Edwards et al. 2009, Brueton 
et al. 2013, Bower et al. 2014). However, findings of these studies are not directly 
applicable to RCTs evaluating complex interventions in which face-to-face assessments 
are a typically utilised method of collecting outcome data.  
There is a dearth of evidence on the effective ways of retaining participants with a 
diagnosis of schizophrenia in clinical trials. The available suggestions come from 
studies investigating patterns of retention in antipsychotic trials with little evidence 
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specific to non-pharmacological trials. For example, Thompson et al. (2011) emphasise 
the need to focus on retaining patients with high levels of negative schizophrenia 
symptoms and suggest achieving this through home visits, engaging caregivers in 
designing trials, and using text message reminders. In a trial evaluating non-
pharmacological interventions for people with psychosis and substance misuse 
researchers attributed the high retention rates to home visits, flexible scheduling of 
appointments, and persistence of researchers (Barrowclough et al. 2010). This however 
was not subjected to a formal evaluation and stemmed from the researchers’ 
observations of their own practice. Studies employing more systematic and in-depth 
approaches, ideally eliciting multiple stakeholders’ perspectives, to identifying 
retention practices and strategies utilised in trials evaluating non-pharmacological 
treatment for schizophrenia are needed in order to improve the current understanding 
of this trial practice context and inform the efforts to make improvements.  
2.5 Summary 
Medical practice informed by evidence relies on RCTs in developing and evaluating new 
treatments. In psychiatry in particular there is a need to develop complex interventions 
for schizophrenia, which could complement or replace the currently offered 
pharmacotherapy.  
The specific context of testing non-pharmacological treatment for schizophrenia 
presents a number of challenges. One of the issues is poor retention of patients with 
schizophrenia as trial participants in terms of treatment adherence and completion of 
follow-up assessments.  
There is a need to understand the scale of this challenge and the factors contributing 
to the retention of this population, taking into account the perspectives of different 
stakeholders. Generating such evidence could help with informing strategies enabling 





 Chapter 3 
Research Questions and Methods 
3.1 Chapter overview 
The previous chapter presented the available theory and research evidence relevant to 
practicing evidence-based medicine informed by well-conducted RCTs. Poor retention 
of participants with schizophrenia from trials evaluating complex interventions was 
introduced as a potential problem requiring more investigation in order to inform 
current trial practices. The currently available evidence and the identified gaps in the 
literature have informed the research questions addressed in this thesis and the 
methods chosen to investigate them. This brief interim chapter lays the foundation for 
the four empirical chapters that follow by first formulating the specific research 
questions and then outlining the methodological approach taken to address them.  
3.2 Research questions and research objectives 
Based on the aim specified in the introduction (Section 1.2, p.15 ) and the literature 
discussed in Chapter 2, this thesis addresses the following four research questions:  
1. What is the degree of attrition occurring in trials evaluating complex 
interventions for schizophrenia?  
2. What is the retention of patients with schizophrenia in RCTs evaluating 
complex interventions influenced by?  
3. How can patients with schizophrenia be retained in trials?  
4. What are the experiences of patients with schizophrenia in the context of 
retention in trials? 
The specific actions taken to answer the above research questions are expressed as the 
following research objectives:  
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Research Objective 1: To estimate the attrition rates in trials of complex 
interventions for schizophrenia. 
Research Objective 2: To determine and explore the factors associated with 
retention of patients with schizophrenia in trials. 
Research Objective 3: To identify and investigate the retention practices used 
in trials of complex interventions for schizophrenia. 
Research Objective 4: To explore how people with schizophrenia experience 
participation in trials and to identify what factors influence their experiences.  
3.3 Methodological considerations 
The choice of the research design and specific research methods was dictated by the 
nature of the research problem expressed in the research questions, the doctoral 
candidate’s background and experience, and resources available (Creswell 2014). 
To address the overall aim and specific research questions this thesis employed a 
concurrent triangulation design comprising two quantitative and two qualitative parts. 
Each part is referred to as a ‘study’ throughout this thesis; however, combined, they 
form a single study investigating the issue of retention of participants with 
schizophrenia in complex intervention trials. Rationale for undertaking each part and 
the relevant approach is provided in corresponding chapters (4, 5, 6 and 7). This section 
focuses on the overall research paradigm, study design and the choice of mixed 
methods approach. 
3.3.1 Pragmatism as a research paradigm  
Research paradigms are “a basic set of beliefs that guide action” (Guba, 1990, p.17), 
which shape the approach to research and the choice of specific methods. Therefore, it 
is important to acknowledge the theoretical perspectives and assumptions made when 
conducting this doctoral research.  
Different paradigms have been associated with either quantitative or qualitative 
methods. The most prominent ones in mixed methods research include: postpositivist, 
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constructivist, participatory, and pragmatist (Creswell and Plano Clark 2011). Their 
overview is presented in Table 3.1 below. 
 




 Empirical observation and 
measurement 
 Theory verification 
Constructivist paradigm 
 Understanding 
 Multiple participant meanings 
 Social and historical construction 
 Theory generation 
Participatory paradigm 
 Political 
 Empowerment and issue oriented 
 Collaborative 
 Change oriented 
Pragmatist paradigm 
 Consequences of actions 
 Problem centred 
 Pluralistic 
 Real-world practice oriented 
 
The choice of the paradigm guiding this research was made based on the best fit with 
the research questions. Given the focus of this doctoral study on the problem of 
attrition and finding ways of optimising participant retention, a pragmatic logic of 
inquiry was chosen as it bases knowledge claims on practical grounds and allows for an 
integration of different research methods (Tashakkori and Teddlie 1998, Morgan 2013, 
Parvaiz et al. 2016). The use of both qualitative and quantitative methods has been 
argued to build on the strengths of each and at the same time to reduce limitations of 
each (Tashakkori and Teddlie 1998).  
Pragmatism focuses on the problem to be addressed by research by considering 
relevant questions and coming up with relevant solutions (Parvaiz et al. 2016). 
Furthermore, pragmatism supports mixing inductive and deductive logic (Johnson and 
Onwuegbuzie 2004), typically moving back and forth between them. Deduction is 
appropriate for testing hypotheses and theories, especially in quantitative methods. 
Induction allows for discovery of patterns and suits some qualitative methods. The use 
of both quantitative and qualitative methods has been argued to require adopting both 
the subjective and the objective points of view (Tashakkori and Teddlie 1998). Adopting 
pragmatism forces researchers to be careful and self-conscious about their practice in 
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order to choose the most appropriate method for the research question at hand (Seale 
et al. 2007).  
3.3.2 Mixed methods design 
Adopting a mixed method design allows for approaching the same research problem 
from different angles or ‘lenses’ (Silverman 2011, 2013), which can complement each 
other and draw on a range of relevant disciplines (Ritchie et al. 2014).  
Qualitative and quantitative data can be collected either sequentially or concurrently. 
In this study a convergent parallel mixed methods design was followed. This model was 
deemed most appropriate given the nature of the research questions and rationale for 
collecting each data set. Adopting this design allowed for converging quantitative and 
qualitative data to provide a comprehensive analysis and to add to the depth and scope 
of findings. In line with the features of concurrent triangulation design, quantitative 
and qualitative parts were treated with equal status.  
Integration of findings was planned according to how the different parts provided 
distinctive answers to the research questions. As a result, findings from all four parts 
were integrated at the interpretation phase and brought together in the discussion 
section of this thesis. An outline of all four studies and the structure within which they 
were conducted is provided in Figure 3.1.   
 
 
Study One:  
Systematic review and meta-
analysis 
Study Two:  
Individual patient data meta-
analysis 
Study Three:  
Qualitative study with trial 
researchers 
Study Four:  
Qualitative study with trial 
participants 
Figure 2.7 Sequence of the studies 3 1  f  i  
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 Chapter 4  
Attrition rates in randomised controlled 
trials of complex interventions for 
schizophrenia: systematic literature review 
and meta-analysis 
4.1 Chapter overview 
The aim of this chapter is to address two research questions: 1) What is the degree of 
attrition occurring in trials evaluating complex interventions for schizophrenia?; and 
2) What is the retention of patients with schizophrenia in RCTs evaluating complex 
interventions influenced by? To address these questions, a systematic literature search 
was conducted, looking at large-scale RCTs exploring the effectiveness of complex 
interventions for people with schizophrenia and related disorders. Data extracted from 
published trial reports were pooled together using random-effect meta-analyses to 
establish the proportion of participants who drop out of either experimental 
interventions or follow-up assessments. Meta-regression analyses were conducted to 
identify the potential predictors of attrition, particularly patient and study 
characteristics.  
The chapter first provides the details of the systematic literature search and its results. 
The subsequent sections present the findings of meta-analyses that followed the 
literature search. The discussion considers the main findings in the context of the wider 
literature and their implications for both trial and clinical practices.  
Although ‘retention’ is the key term used throughout this thesis, the results reported in 
this chapter will be mainly expressed as ‘attrition’ or ‘dropout’. This allows for making 
direct comparisons with the wider literature reporting attrition, rather than retention.  
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A version of the work presented in this chapter has been published in the Journal of 
Psychiatric Research (Szymczynska et al. 2017). The publication manuscript is provided 
in Appendix 2.  
4.2 Rationale 
The attrition rates in schizophrenia trials are currently known for studies evaluating 
antipsychotic medication (Leucht et al. 2013) and psychosocial interventions 
(Villeneuve et al. 2010). There is no such evidence about the dropout from non-
pharmacological interventions for schizophrenia at the levels of both experimental 
intervention and study. In addition, efforts have been made to identify what factors 
affect or predict dropout but this again bore relevance to pharmacological trials 
(Kampman and Lethinen 1999, Nose et al. 2003) and a limited range of complex 
interventions (Villeneuve et al. 2010). This evidence points to the need to establish the 
reported attrition rates in trials evaluating a range of current complex interventions for 
schizophrenia and to identify factors influencing discontinuation of interventions and 
loss to follow-up.  
The most robust method available to conduct a study that would allow for addressing 
this gap in the literature is a systematic review of literature followed by a meta-analysis 
of data extracted from trial reports identified in the literature search and/or obtained 
directly from authors of papers. This method has been chosen to address Research 
Questions 1 and 2 and the results are discussed in the present chapter.  
4.3 Objectives 
This study had the following objectives: 
1. To identify all relevant trials of non-pharmacological interventions for people 
with schizophrenia.  
2. To estimate the attrition rates reported at intervention- and study-level. 
3. To estimate the overall attrition rate reported across relevant trials.  
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4. To identify factors that may influence retention in RCTs of non-
pharmacological interventions for schizophrenia.  
4.4 Method 
4.4.1 Literature search 
A methodological framework and a protocol were developed according to the Preferred 
Reporting Items for Systematic Reviews and Meta-Analyses Statement (PRISMA) 
(Moher et al. 2009). Five bibliographic databases, including Medline, PsycINFO, 
Embase, Cumulative Index to Nursing and Allied Health Literature (CINAHL), and 
Cochrane Central Database were searched in January 2016 for manuscripts reporting 
results from RCTs evaluating complex (also referred to as non-pharmacological in this 
chapter) interventions for adults with schizophrenia and related disorders published 
between January 1996 and January 2016. As the study was interested in the dropout 
rates reported in published trial reports, the lower time limit was set based on the 
publication date of the first iteration of the CONSORT statement (Begg et al. 1996). As 
discussed in the previous chapter, the introduction of the guidelines for transparent 
reporting of participant flow information resulted in the expectation to include the 
CONSORT statement in trial publications and meant that since 1996 more peer-
reviewed papers would include the information required for the purposes of this review. 
In addition, hand searches of six key psychiatric journals: Schizophrenia Bulletin, The 
British Journal of Psychiatry, The American Journal of Psychiatry, The Journal of the 
American Medical Association (JAMA) Psychiatry, Acta Psychiatrica Scandinavica, and 
Trials; and reference lists of relevant systematic reviews were carried out to identify 
other eligible manuscripts.  
A comprehensive Medical Subject Headings (MeSH) and text-word search strategy was 
defined prior to database searching. Titles and abstracts were searched using the 
following MeSH headings and linking operators: ‘SCHIZOPHRENIA’ OR ‘PSYCHOSIS’ 
OR ‘PSYCHOTIC DISORDERS’ AND ‘CLINICAL TRIALS’ OR ‘RANDOMIZED 
CONTROLLED TRIAL/S’ and text words including ‘psychos*s’ OR ‘psychotic’ OR 
‘schizo*’ OR ‘therapy’ OR ‘intervent*’ OR ‘nonpharmacological’ AND ‘RCT’ OR 
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‘randomi*ed controlled trial’ OR ‘clinical trial’. These search terms were modified to 
match the specific requirements of each database. 
4.4.2 Study selection 
The following eligibility criteria were applied:  
(i) The study had an RCT design. This was decided based on whether a 
reference was made either to a randomisation procedure and/or the 
presence of a control condition.  
(ii) At least 100 participants were randomised to the trial. 
(iii) The experimental treatment condition was a non-pharmacological 
intervention delivered either individually or in a group. 
(iv) Participants were adults above the age of 18 with a diagnosis of 
schizophrenia (including undifferentiated schizophrenia, paranoid 
schizophrenia, hebephrenic schizophrenia, catatonic schizophrenia, and 
residual schizophrenia) and/or related disorders including schizotypal 
disorder (i.e. delusional disorder, persistent delusional disorder, and other 
persistent delusional disorders), schizoaffective disorder (i.e. 
schizoaffective manic, depressive and unspecified subtypes), as outlined in 
the Diagnostic and Statistical Manual of Mental Disorders (DSM) or the 
International Classification of Diseases (ICD) diagnostic manuals applicable 
at the time of trial publication.  
(v) Manuscript was written in English.  
 
Studies were excluded if they: 
(i) Involved, in any of the trial arms, healthy individuals, family members 
and/or caregivers, participants ‘at risk’ of schizophrenia, or participants who 
did not have a diagnosis of schizophrenia or a related disorder.  
(ii) Involved procedures considered to be physically invasive, for instance brain 
stimulation or electroconvulsive therapy.  
The decision to include RCTs with a sample size of at least 100 participants was made 
to increase the homogeneity of the set of trials and to produce more precise estimates 
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of the results through obtaining narrower confidence intervals. Interventions requiring 
involvement of a third party (for example relatives involved in family therapy) were 
excluded as involvement of other individuals could potentially influence decisions 
about trial participation made by people with schizophrenia. Interventions considered 
to be invasive were also excluded as they present a different type of risk and physical 
discomfort to be considered by individuals and are therefore likely to affect decisions 
about participation.  
A two-step screening process was performed. The doctoral candidate acted as the 
primary reviewer and screened all titles and abstracts in the first step and, 
subsequently, all articles at the full text review phase. To ensure study selection 
accuracy, a second reviewer (Sophie Walsh, SW) who was a researcher at the Unit for 
Social and Community Psychiatry, independently screened a random selection of 20% 
of the citations in both study selection phases using the agreed set of eligibility criteria.  
4.4.3 Data extraction  
Using a structured format, all papers that met the eligibility criteria were independently 
extracted by the doctoral candidate and 20% of them were subsequently checked by 
SW. Attrition rates were extracted either from the CONSORT diagram (if provided) or 
from the text of the article. Nineteen studies did not fully report these data and, 
consequently, their corresponding authors were contacted by the doctoral candidate 
with a request for information or clarification. Twelve responses were received. Papers 
of authors who were unable to respond were excluded from the analysis due to 
insufficient information. 
In addition to the attrition rates, data on participant and study characteristics were 
extracted to enable analyses of potential predictors. The following study information 
was extracted: year of publication, study setting (inpatient or outpatient), intervention 
delivery (individual or group), type of control intervention (experimental or treatment 
as usual), sample size, duration of intervention period, study duration, number of 
intervention sessions, number of evaluations, and quality score (more details are 
provided in section 3.4.5). Participant socio-demographic characteristics included: age, 
gender, and illness duration. The choice of the factors was made based on the 
consistency of reporting variables across publications. 
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For the meta-regression of study attrition data were extracted for all randomised 
participants. For the analysis of dropout from experimental intervention only data for 
those who were randomised to the active arm were extracted. 
4.4.4 Outcomes  
Two primary outcomes were identified for the purposes of the planned meta-analyses. 
The first was ‘dropout from experimental intervention’, defined as the proportion of 
participants randomised to receive an experimental intervention and who were 
reported as failing to complete the intervention (study authors’ definition of 
completion or dropout was used) after beginning it. The second outcome was ‘study 
dropout’, defined as the proportion of participants across all trial arms who failed to 
complete the last follow-up assessment. Participants who were lost prior to being 
randomised were not considered dropouts and were therefore excluded from the 
analysis.  
The distinction between the two types of dropout, experimental intervention versus 
study, was drawn in order to investigate the differences between treatment adherence 
and completion of follow-up appointments within the duration of the study.  
4.4.5 Quality assessment  
Most of the existing tools for assessing risk of bias, such as the Cochrane Collaboration’s 
Risk of Bias Tool (Cochrane Collaboration 2011), have been developed for the purposes 
of assessing clinical relevance and thus did not fit in with the purpose of this study, 
which was interested in the methodological and pragmatic aspects of retaining 
participants in a trial. In order to assess the methodological quality of the eligible 
studies a unique set of criteria was developed, including: 1) provision of the CONSORT 
diagram; 2) clear definition of intervention completion; and 3) information on sample 
size calculation. Each criterion was given a score of 0 or 1, with the total possible score 
ranging from 0 to 3. The total score was used in analyses as an indicator of study quality 
in the context of reporting information relevant to attrition.  
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4.4.6 Data analysis 
Meta-analytical techniques were used to statistically pool together findings from the 
eligible trials. 
The first set of meta-analyses investigated the reported attrition rates across trials. The 
two primary outcomes were calculated in Stata 11 software using the metaprop 
command. Calculating dropout from experimental intervention involved dividing the 
number of participants who discontinued any experimental intervention evaluated in 
the identified trials by the total number of individuals who began the intervention: 
𝐼𝑛𝑡𝑒𝑟𝑣𝑒𝑛𝑡𝑖𝑜𝑛 𝑑𝑟𝑜𝑝𝑜𝑢𝑡 =  
𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑝𝑎𝑟𝑡𝑖𝑐𝑖𝑝𝑎𝑛𝑡𝑠 𝑤ℎ𝑜 𝑑𝑖𝑠𝑐𝑜𝑛𝑡𝑖𝑛𝑢𝑒𝑑 𝑖𝑛𝑡𝑒𝑟𝑣𝑒𝑛𝑡𝑖𝑜𝑛
𝑡𝑜𝑡𝑎𝑙 𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑝𝑎𝑟𝑡𝑖𝑐𝑖𝑝𝑎𝑛𝑡𝑠 𝑤ℎ𝑜 𝑏𝑒𝑔𝑎𝑛 𝑖𝑛𝑡𝑒𝑟𝑣𝑒𝑛𝑡𝑖𝑜𝑛
 
In addition, a subgroup analysis was carried out to investigate any differences across 
different intervention types, including practical or educational interventions, CBT, 
cognitive or neurocognitive interventions, adherence strategies, and any other 
interventions.  
Study dropout was calculated by dividing the number of participants lost to follow-up 
by the total number randomised to all trial arms: 
𝑆𝑡𝑢𝑑𝑦 𝑑𝑟𝑜𝑝𝑜𝑢𝑡 =  
𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑝𝑎𝑟𝑡𝑖𝑐𝑖𝑝𝑎𝑛𝑡𝑠 𝑙𝑜𝑠𝑡 𝑡𝑜 𝑓𝑜𝑙𝑙𝑜𝑤 − 𝑢𝑝
𝑡𝑜𝑡𝑎𝑙 𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑝𝑎𝑟𝑡𝑖𝑐𝑖𝑝𝑎𝑛𝑡𝑠 𝑟𝑎𝑛𝑑𝑜𝑚𝑖𝑠𝑒𝑑 𝑡𝑜 𝑠𝑡𝑢𝑑𝑦
 
The 95% confidence intervals were calculated using the Freeman-Tukey double arcsine 
transformation as it can be used for data restricted to the range of 0% to 100%. Without 
this transformation, studies with an estimated percentage near either extreme would 
be automatically excluded from the analysis, leading to a biased pooled estimate.  
The second set of meta-analyses explored the effect of potential predictors on attrition 
rates. Data were pooled using a random-effects meta-analysis in Stata software. A 
random-effects model was used for meta-regression as it assumes that differences in 
the dropout rates are not just due to the sampling error but represent real differences 
between studies. The potential predictors used in the meta-regression of experimental 
intervention dropout included the following participant and study variables: age, 
gender, illness duration, study location, study setting, intervention delivery method, 
duration of the intervention period, study duration, number of intervention sessions, 
and study quality. For the analysis of study dropout the models included the following 
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variables: age, gender, illness duration, study location, study setting, type of control 
intervention, study duration, number of evaluations, and study quality.  
First, the above predictors were tested for associations in univariable models. Second, 
the variables showing an association with the dropout rate (p-value <0.1) in the 
univariable models were included in the multivariable models. 
The level of between-study heterogeneity was assessed visually and by calculating the 
Q-statistic and the I2 statistic. In order to assess the evidence for publications bias 
Egger’s test of the intercept with the Freeman-Tukey double arcsine transformation 
and a funnel plot of standard error against study attrition rate were computed.  
4.5 Results 
4.5.1 Characteristics of included studies 
The systematic search identified 5,450 studies (see Figure 4.1 below for the PRISMA 
flow diagram). After screening, 49 papers based on 43 studies were included. Some trial 
results were reported in multiple papers; therefore data were extracted per study, not 
per paper. Table 4.1 below presents details of the 49 papers. References of the papers 
reporting on the same trial are provided together with the key paper from which data 
were extracted and indicated with square brackets; for instance [Bell et al., 2005]. Two 
studies were excluded from the meta-analyses due to inadequate reporting of the 












Titles and abstracts screened for more detailed evaluation 
(n=3,610) 
Records excluded (n=3,395) 
Excluded on: 
 Not RCT (n=2,034) 
 Not including only adults with 
schizophrenia or schizophrenia 
related disorders (n=607) 
 Not non-pharmacological 
intervention (n=425) 
 Sample size smaller than 
n=100 (n=305) 
 Non-English (n=24) 
Full texts screened for more detailed 
evaluation 
(n=215) 
Full-text articles excluded (n=166) 
Excluded on: 
 Not including only adults with 
schizophrenia or schizophrenia 
related disorders (n=73) 
 Not RCT (n=38) 
 Sample size smaller than 
n=100 (n=25) 
 Not non-pharmacological 
intervention (n=14) 
 Potentially relevant studies with 
insufficient information to check 
eligibility (n=16) Papers included in review 
(n=49) 
Potentially relevant studies identified 
for retrieval 
(n=5,450) 
Figure 4.1 PRISMA Diagram for Paper Selection 
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Table 4.1 Description of studies identified in the systematic review 













Barkhof et al., 2013 Europe Motivational interviewing / 
Health Education 
114 Individual In- and out-patient 12 6.5 3 
Barrowclough et al., 
2006 
Europe Cognitive Behavioral Therapy 
(CBT) 
113 Group Out-patient 12 6 3 
Bell and Lysaker, 
1997 
USA Work program 150 Individual Out-patient 12 6 1 
Bell et al., 2003 USA Neurocognitive Enhancement 
Therapy with Work Therapy  
131 Individual Out-patient 12 6 0 
  [Bell et al., 2005]          
  [Bell et al., 2007]         
Bowie et al., 2012 USA Cognitive remediation / 
Functional Adaptation Skills 
Training/ Combined Treatment 
114 Group Out-patient 3 6 2 
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Chien et al., 2015 Asia Adherence therapy 114 Individual Out-patient 6 4 2 
Crawford et al., 2012 Europe Group art therapy/Activity 
Groups 
417 Group Out-patient 24 12 2 
Franck et al., 2013 Europe Individualized therapy / 
Cognitive Remediation Therapy 
(CRT) 
138 Individual Out-patient 9 3 1 
Freeman et al. 2015 Europe CBT 150 Individual In- and out-patient 6 2 3 
Gomar et al. 2015 Europe  Computerized Cognitive 
Remediation 
130 Group In- and out-patient 6 6 1 
Gouzoulis-Mayfrank 
et al. 2015  
Europe Implemented integrated 
treatment 
100 Group In-patient 12 Not reported 1 
Granholm et al. 2014 USA Cognitive Behavioral Social 
Skills Training / Active Goal-
Focused Supportive Contact  
149 Group Out-patient 21 9 1 
Gray et al. 2006 Europe Adherence therapy / Health 
Education 
409 Individual In- and out-patient 13 18 3 
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Gumley et al. 2003 Europe CBT 144 Individual Not reported 13 3 2 
  [Gumley et al. 2006]         
Hamann et al. 2006 Europe Shared decision aid 113 Individual In- and out-patient 18 0.03 1 
Hansson et al. 
2008 
Europe DIALOG (computer-mediated 
structured patient-key worker 
communication) 
507 Individual Out-patient 12 12 0 
Hogarty et al. 2004  USA Cognitive Enhancement 
Therapy / Enriched Supportive 
Therapy 
121 Group Out-patient 24 Not reported 0 
Jahn et al. 2011 Europe Neurocognitive training 122 Group In-patient 9 1 1 
Jones et al. 2001 Europe Personalized computer-based 
information / Community 
Psychiatric Nurse / Combined 
treatment 
112 Individual Not reported 3 Not reported 3 
Klingberg et al. 2010 Europe Cognitive Behaviorally Oriented 
Service 
169 Group In-patient 6 2 3 
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Klingberg et al. 2011 Europe CBT / CRT 198 Individual Out-patient 12 9 3 
  [Klingberg et al. 
2012] 
 CBT / CRT       
Li et al. 2015   Asia CBT / Supportive Therapy 192 Group In- and out-patient 21 6 2 
Montes et al., 2010 Europe Telephone-based nursing 
strategy to improve adherence 
to antipsychotic treatment 
928 Individual Out-patient 4 3 1 
Montes et al. 2012 Europe Short message service-based 
strategy for enhancing 
adherence to antipsychotic 
treatment 
340 Individual Out-patient 6 3 3 
Moritz et al. 2013 Europe Complementary Metacognitive 
Training  
150 Group In- and out-patient 6 Not reported 2 
  [Moritz et al. 2014]         
Mueller et al. 2015 Europe Integrated Neurocognitive 
Therapy 
156 Group Out-patient 9 3.75 1 
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Patterson et al. 2006 USA Functional Adaptation Skills 
Training 
240 Group Out-patient 18 6 1 
  [Mausbach et al. 
2008] 
        
Pitkanen et al. 2012 Europe Patient education 311 Group In-patient 12 1 1 
Salyers et al. 2014 USA Illness Management and 
Recovery / Problem-Solving 
Group 
118 Group Not reported 18 9 0 
Schirmer et al. 2015 Europe Medication training program 141 Individual Out-patient Not reported 1.64  
Schulz et al. 2013 Europe Adherence therapy 161 Group In- and out-patient 3 Not reported 3 
Sibitz et al. 2007 Europe Low intensity booster sessions 
of psychoeducation 
103 Group Out-patient 11.25 2.25 1 
Silverstein et al. 2014 USA Attention shaping 105 Group In-patient 5.5 5.5 1 
Staring et al. 2010 Europe Treatment adherence therapy  109 Individual Out-patient 12 6 1 
Terzian et al. 2013 Europe Social Network intervention 357 Not reported Out-patient 24 24 1 
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Van Der Gaag et al. 
2011 
Europe CBT 216 Group Not reported 18 6 1 
Van der Krieke et al. 
2013 
Europe Web-based information and 
decision tool 
250 Individual Out-patient 12 12 2 
Van Oosterhout et al. 
2014 
Europe Metacognitive group training  154 Group In- and out-patient 6 2 2 
Van Os et al. 2004  Europe Two-way Communication 
Checklist 
134 Individual Out-patient 2 1.5 1 
Velligan et al. 2013 USA Interventions for improving 
adherence to oral medications 
142 Group Out-patient 9 6 1 
Velligan et al. 2015 USA CBT / Cognitive Adaptation 
Training (CAT) / CBT and CAT 
166 Individual Out-patient 15 9 1 
Williams et al. 2003 USA Enhanced guideline 
implementation strategy 
349 Individual In- and out-patient 20 Not reported 0 
Xiang et al. 2007 Asia Community Re-Entry Module  103 Group In-patient 24 4 2 
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Geographical location of studies 
Twenty-nine studies were conducted in Europe, followed by eleven in North America 
and three in Asia.  
Interventions 
Fifty-nine interventions were evaluated in the 43 trials. Their details are presented in 
Table 4.1. Data required for the meta-analysis of intervention non-adherence or non-
attendance were available for 50 interventions reported in 34 papers.  
Reasons for dropout 
Extracting the reasons for discontinuing participation was limited by poor reporting of 
this information. Twenty-nine out of 43 studies (69%) provided the CONSORT 
diagram. Out of these, 18 did not provide the reasons for dropout. In addition, 11 papers 
did not provide the CONSORT diagram at all. In total, only 14 out of 43 trials (32.5%) 
reported the information required for the purposes of this study.  
Quality analysis 
Quality scores ranged from 0 to 3. Five studies scored 0, 17 studies scored 1, 10 studies 
scored 2, and 9 studies scored 3. The scores for each included study are provided in 
Table 4.1.  
Dropout from active intervention 
Dropout from active intervention was estimated at 14% (95% CI: 13-15%), with a range 
of 0-63% and a median of 19.4%. Heterogeneity was high at I2=93.13%.  
Subgroup analysis by intervention type showed overall estimates of intervention drop-
out of 25% (95% CI: 14-35%) for CBT interventions (n=8), 24% (95% CI: 16-32%) for 
cognitive or neurocognitive interventions (n=9), 21% (95% CI: 13-29%) for practical or 
educational interventions (n=8), 11% (95% CI: 6-17%) for adherence therapies (n=7), 
and 34% (95% CI: 23-46%) for other interventions (n=18). The results of the analysis are 
shown in Figure 4.2. 
Dropout from study 
Study dropout was estimated at 20% (95% CI: 17-24%), with a range of 4-71% and a 
median of 16%. Heterogeneity was high at I2=95.69%. The results of the analysis are 











Barkhof (2013) (1) 
Bowie 2012 (2) 
Crawford 2012 (1) 
Crawford 2012 (2) 
Franck 2014 (1) 
Granholm 2014 (2) 
Hamann 2006 
Hansson 2006 
Hogarty 2004 (2) 
Jones 2001 (2) 
Jones 2001 (3) 
Li 2015 (2) 
Patterson 2006 
Salyers 2014 (1) 
Salyers 2014 (2) 
Velligan 2015 (3) 
Xiang (1) 
Xiang (2) 







































Practical or educational interventions 
Barkhof 2013 (2) 
Bell 1997 
Bowie 2012 (2) 
Gray 2006 (2) 
Jones 2001 (1) 
Sibitz 2007 
Silverstein 2014 
Van der Krieke 2013 






















Granholm 2014 (1) 
Gumley 2003 
Klingberg 2011 (1) 
Li 2015 (1) 
Van der Gaag 2011 
Velligan 2015 (1) 



















Cognitive or neurocognitive interventions 
Bowie 2012 (1) 
Franck 2014 (2) 
Gomar 2015 
Hogarty 2004 (1) 
Jahn 2014 
Klingberg 2010 
Klingberg 2011 (2) 
Mueller 2015 
Velligan 2015 (2) 





















Gray 2006 (1) 





Subtotal (I⌃ 2=85.31%, p=0.00) 
  
 















Heterogeneity between groups: p=0.047 
























4.5.2 Predictors of dropout 
Dropout from experimental intervention 
Findings of the random effects meta-regression showed that the dropout rates from 
experimental interventions significantly increased as the number of intervention 
sessions increased (p-value=0.011). The results are shown in Table 4.2 and Table 4.3 
below. 
Table 4.2 Univariable meta-regression for intervention non-adherence 





Age 0.53 -0.77 1.83 0.410 
Gender 0.53 -0.03 1.11 0.065 
Illness duration 1.12 -0.12 2.37 0.075 
Study location -9.93 -22.49 2.63 0.117 
Study setting (inpatient vs 
outpatient) 
-6.38 -18.30 5.54 0.284 
Intervention delivery (individual 
vs group) 
-6.37 -18.30 5.54 0.284 
Duration of intervention period 2.37 0.51 4.23 0.014 
Study duration 0.83 -0.11 1.77 0.082 
Number of intervention 
sessions 
0.66 0.26 1.05 0.002 
Study quality -2.27 -6.64 2.09 0.300 
 
Table 4.3 Multivariable meta-regression for intervention dropout 





Gender 0.23 -0.53 1.00 0.235 
Illness duration 0.10 -1.44 1.65 0.884 
Duration of intervention period 0.09 -2.29 2.48 0.931 
Number of intervention 
sessions 
0.97 0.28 1.67 0.011 





Dropout from study 
None of the tested variables in the study dropout models showed any significant effects. 
The results of the univariable meta-regression are shown in Table 4.4 below. 
Table 4.4 Univariable meta-regression for study dropout 





Age 0.10 -0.70 0.90 0.803 
Gender 0.09 -0.27 0.46 0.606 
Illness duration 0.43 -0.37 1.23 0.279 
Study location 6.62 -1.56 14.81 0.110 
Study setting (inpatient vs 
outpatient) 
1.29 -2.74 5.33 0.521 
Study duration -0.20 -0.95 0.54 0.579 
Number follow-up assessments -0.23 -3.84 3.38 0.897 
Type of control (active vs 
treatment as usual) 
1.25 -4.31 6.82 0.651 
Study quality 0.05 -4.76 4.86 0.984 
4.5.3 Publication bias  
Egger’s test of the intercept calculated for study dropout showed no presence of 
publication bias (p=0.10). The funnel plot is presented in Figure 4.4 overleaf and can be 
interpreted as showing no evidence of publication bias with a few outliers. The lack of 
publication bias could be explained by this review including only RCTs with a sample 
size ≥ 100. This finding suggests that trials of this size are likely to be published despite 




Figure 4.4 Funnel plot of standard error by study dropout rate 
 
4.6 Discussion 
4.6.1 Main findings 
The objectives of this chapter were to establish the attrition rates reported in published 
trials of complex interventions for schizophrenia and to identify the factors that 
influence those rates. The overall study dropout rate of 20% obtained in this study 
suggests that retention in schizophrenia trials can be problematic; however the range 
of rates observed in individual studies suggests that good retention rates are achievable. 
Compared to study attrition, dropout from interventions estimated at 14% is lower; 
nonetheless it suggests that a proportion of patients can be expected to fail to complete 
experimental treatments.  
In the meta-analyses of factors influencing dropout from study and from active 
intervention, the only significant association was found between the number of 
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intervention sessions and dropout from treatment, with more sessions resulting in 
poorer completion. This finding suggests that predictors of retention or attrition in 
schizophrenia research identified in previous studies may not apply to RCTs evaluating 
complex interventions for schizophrenia. Before discussing the findings in the context 
of the wider literature and their implications for practice, the next section will present 
the key strengths and weaknesses of the study.  
4.6.2 Strengths and limitations 
The data were obtained in a wide and systematic literature search involving two 
independent reviewers, minimising the possibility of bias or oversight. The focus of the 
study was on complex interventions for schizophrenia and related disorders, which 
allowed for inclusion of a range of non-pharmacological treatments for schizophrenia. 
Some of these treatments would not have been considered in the previous meta-
analysis of treatment withdrawal rates solely in psychosocial treatment for 
schizophrenia (Villeneuve et al. 2010); nonetheless they are an important type of 
intervention available to this population. In addition, the current analyses included 
attrition at both intervention and study levels, a distinction that has not always been 
made in the literature but has critical implications for practice. A further strength is 
that many of the authors who were contacted with a request to clarify information or 
provide additional data responded to those queries and, as a result, their studies could 
be included in the analyses.  
The key limitations of this study are associated with the poor reporting of participant 
flow in the published reports of trials. Despite the established practice of providing the 
CONSORT flow diagram (Altman 1996, Begg et al. 1996, Moher et al. 2001), a large 
proportion of eligible papers failed to include it. To overcome this shortcoming, where 
possible, information that would normally be provided in the CONSORT diagram was 
sought in, and extracted from, the main body of papers. Poor reporting was also found 
in the provision of definitions of study and intervention completion. These were either 
not provided or, when present, were often inconsistent across studies, which restricted 
the analyses. The lack of detail about study and sample characteristics also limited the 
scope for testing other potential predictors of dropout, for instance incentives.  
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The applicability of the findings of the study is limited to trials with a sample size of at 
least 100. The review excluded smaller studies, which may observe different levels of 
engagement. Attrition in the control intervention was outside of the scope of the study, 
but it is important to acknowledge that engaging those randomised to the control arm 
is an important aspect of ensuring quality of a trial.   
4.6.3 Interpretation and comparison with wider literature 
The number of intervention sessions was found to predict intervention dropout. In 
contrast, study dropout could not be predicted by any of the tested variables. Overall, 
there was poor reporting of information about the retention methodology and practice, 
as well as participant treatment adherence and assessment completion. Each one of 
these findings will be discussed in turn and compared with the wider literature before 
considering their implications for trial and clinical practices and discussing the study’s 
strengths and limitations.  
Attrition rates 
Prior to the present study, there had been only one other systematic review focusing 
on attrition in trials evaluating non-pharmacological treatment of schizophrenia. The 
review focused on withdrawal from treatment and found it to be 13% (Villeneuve et al. 
2010). This result is very similar to the 14% active intervention dropout rate found in 
this study; despite Villeneuve’s (2010) study considering a complete withdrawal from 
treatment (as opposed to the current study considering treatment completion as 
defined by trial investigators), focusing specifically on psychosocial treatment and 
excluding other forms of non-pharmacological interventions, which were included in 
the current study.  
The findings of this doctoral study suggest that retention in both study and 
intervention is higher in non-pharmacological RCTs than in those evaluating 
antipsychotic medication. A large proportion of systematic studies investigating 
retention or attrition of individuals with psychotic disorders have been conducted on 
trials testing antipsychotic drugs. These have shown varying results, with study 
attrition ranging from 33% of patients who were treated with antipsychotics to 33.6% 
of those who received placebo in trials published from 1995 to 2000 (Wahlbeck et al. 
2001), compared to a later study reporting 48.9% dropout for those receiving 
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antipsychotics and 60.2% for patients in a placebo arm in studies published between 
1992 and 2004 (Kemmler et al. 2005). It is noteworthy that those studies define dropout 
as “patients leaving the study preterm due to any reason” (Wahlbeck et al., 2001, p.2), 
although they subsequently discuss the findings in the context of adherence to 
treatment – an issue treated separately in this thesis.   
Furthermore, a systematic review of studies estimating adherence to treatment 
programmes for people with psychosis offered outside of trial settings revealed that 
24.3% individuals did not keep appointments as scheduled compared to 29.74% failing 
to take drugs as prescribed (Nose et al. 2003). When compared with the 14% 
intervention dropout rate found in the current study, non-adherence to psychiatric 
treatment, either pharmacological or non-pharmacological, offered outside of trial 
settings can be higher than non-adherence to complex interventions provided in a trial 
context. Differences between trial and practice contexts can be expected as, despite 
most trials adopting a pragmatic design recreating clinical practice settings as much as 
possible, patients enrolled in a trial are subject to different procedures than those 
receiving treatment outside of a research setting. For example they are required to sign 
consent forms, attend follow-up appointments with researchers and complete 
assessment measures. In addition, some of these procedures can be expected to differ 
depending on the geographical location of the study, given the differences in national 
and local standards and norms applying to research. The additional procedures 
introduced by the nature of trial participation can be experienced as additional burden 
for the patients and can therefore lead to poorer retention. On the other hand, trial 
participants are often actively encouraged to remain involved in a study through 
various practices and strategies that aim to improve their engagement, consequently 
resulting in potentially higher retention rates in experimental interventions within 
trials than in treatment offered in routine clinical practice.  
Treatment non-adherence observed in trial settings bears importance for clinical 
practice as it gives an indication of the acceptability of an intervention and the likely 
retention rates once it has been implemented in practice. Adherence to or completion 
of treatment is also associated with the cost of delivering health care, with better 
retention having the potential to achieve long-term savings for treatment providers. In 
contrast, interpretation of the treatment dropout rates obtained in this study is difficult 
as there is no guidance on the acceptable non-adherence rates. Nonetheless, compared 
to both pharmacological treatment and non-pharmacological treatment for 
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schizophrenia provided outside of research settings, dropout from complex 
interventions evaluated in RCTs is lower. 
In contrast to treatment dropout, loss of participants from trials can be evaluated and 
interpreted against the evidence showing that attrition rates exceeding 20% introduce 
issues with bias and validity of the trials (Polit and Hungler 1995, Sackett et al. 2000, 
Schulz and Grimes 2002), as discussed in section 2.4.2 of Chapter 2. In light of the 
existing evidence, the overall rate obtained in the current meta-analysis can be 
interpreted as acceptable. In sum, the rate of 20% suggests that many non-
pharmacological RCTs may be at risk of bias and threat to validity, but a large number 
of trials succeed in achieving much lower attrition rates. The rate is not high enough to 
cause major credibility concerns (Xia et al. 2009), but it would be qualified as low-
quality evidence according to the accepted standards of EBM (Centre for Evidence-
Based Medicine 2009).  
Predictors of attrition 
In addition to estimating attrition rates in trials, the current study aimed to identify 
factors associated with these rates and to add to the existing body of literature 
attempting to identify predictors of dropout. Previous studies have shown inconclusive 
results, with significant effects found for different study and/or participant 
characteristics. For instance, in a meta-analysis of dropout from psychosocial treatment 
for schizophrenia Villeneuve et al. (2010) found higher dropout to be associated with 
higher age, male gender, longer illness duration, and longer treatment duration. In 
contrast, receiving psychosocial treatment in a hospital setting was associated with 
better adherence. Furthermore, in a meta-analysis of schizophrenia interventions 
provided outside of a trial setting, Nose et al. (2003) found “young male patients with 
poor insight of illness, a history of substance abuse, unemployed and with low social 
functioning” (p.1155) to be more likely to not adhere to treatment. Dropout from 
outpatient psychiatric treatment provided outside of a trial setting was also studied in 
a non-matched retrospective case-control study by Reneses, Munoz and Jose Lopez-
Ibor (2009). The factors predicting higher dropout in four community mental health 
centres included young age and male gender, as well as having more than one clinician 
involved in treatment. What these three studies have in common is the finding 
suggesting that male patients with schizophrenia are more likely to fail to adhere to 
treatment but there was no agreement on other factors. The current evidence on 
77 
 
adherence to treatment for patients with psychosis is difficult to compare due to the 
differences in definitions of dropout, methodologies and types of treatment. In 
addition, there have been no previous studies investigating predictors of study attrition 
in schizophrenia research.  
This doctoral study did not find significant effects for the predictors reported in these 
previous studies; however, in addition to treatment duration considered in Villeneuve 
et al.’s (2000) meta-analysis, it also tested the number of sessions offered to patients. 
This particular study characteristic was the only variable to be predictive of study 
attrition, with the higher number of sessions leading to higher dropout. One possible 
interpretation of this finding is that being asked to attend many intervention sessions 
can be seen by participants as a serious commitment to which they initially agree at 
enrolment but struggle to meet the demands as the trial progresses. This could be a 
particular challenge for patients with schizophrenia who often lead chaotic lifestyles 
and deal with fluctuations in their mental health. An alternative interpretation, 
although not rebutting the former one, is that missing one out of many sessions may 
be seen by patients as less problematic than skipping one of a limited number of offered 
appointments. This can also depend on the intensity of the intervention, in other words 
the number of sessions provided over a specified period of time.  
The lack of significant results for other variables tested in the current study could be 
due to high heterogeneity of trials identified in the systematic review and poor 
reporting of information about both study and sample characteristics found across a 
large proportion of included studies. The poor quality of details about recruitment and 
retention is a phenomenon also present in non-psychiatric studies and one previously 
reported to limit analyses of recruitment and retention rates and their predictors 
(Trivedi et al. 2013). Together with the differences in the findings from previous 
analyses, this doctoral study suggests that identifying predictors of retention using 
information reported in published trials is methodologically possible but it may be 
impeded by the quality of information provided in trial reports.  
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4.6.4 Implications of findings for trial conduct and further methodological 
research 
Currently, estimating sample size when planning trials is often based on arbitrary 
assumptions regarding the expected loss of participants to follow-up (Rutterford et al. 
2015). This has important pragmatic and cost implications as it directly influences the 
resources put into recruitment and retention of participants required to test new 
interventions. This study adds to the limited pool of evidence on retention or attrition 
rates in trials evaluating complex interventions for schizophrenia. Estimating an 
average dropout rate achieved across published trials provides insight into the practice 
of engaging patients with schizophrenia in RCTs and gives guidance on what level of 
retention is achievable in the specific type of trials. However, it is important to note 
that this is different to determining the acceptable rates of attrition, which was not the 
aim of this study.  
Moreover, looking at the range of attrition rates found in the current study, there are a 
large number of trials suffering from problematic loss to follow-up, questioning their 
validity and absence of bias. This study was unable to unpick which factors may lead to 
such low retention rates, suggesting the need for better reporting of information and 
more exploration of this issue. Exploring and demonstrating relationships between trial 
retention or treatment adherence and characteristics of studies or samples has 
important implications for the design of clinical trials involving people with 
schizophrenia. Beyond trial context, such relationships, if found, may also bear 
relevance to the issue of retaining patients with schizophrenia in treatment outside of 
trial settings.  
4.7 Conclusion  
The findings discussed in this chapter addressed the objective of estimating the 
attrition rates in RCTs evaluating complex interventions for schizophrenia expressed 
as dropout at both intervention and study levels. In addition, the study identified one 
potential predictor of intervention completion and did not confirm factors previously 
found to be significantly associated with retention rates. Poor quality of reporting 
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information about participant flow, especially using the recommended CONSORT tool, 
has emerged as a barrier to studies investigating participant retention. 
The following chapter will continue to explore the relationships between study and 
participant characteristics and retention rates drawing on a different type of data.  
80 
 
 Chapter 5 
Patterns of retention and factors predicting 
study completion in trials of complex 
interventions for schizophrenia: individual 
patient data meta-analysis 
5.1 Chapter overview 
This chapter addresses the second research question: What is the retention of patients 
with schizophrenia in RCTs evaluating complex interventions influenced by? The 
outline of this chapter is as follows. The first section presents the rationale for 
undertaking this study and explains how it is linked to the previous analyses presented 
in Chapter 4. Next, specific objectives are listed before presenting the methods and the 
process of the current study where individual patient data meta-analysis (IPD-MA) was 
applied to data from five trials involving people with schizophrenia. The results of the 
analysis are presented before they are discussed in the last section.  
5.2 Rationale 
The results of the systematic review and meta-analysis presented in the previous 
chapter (Chapter 4) highlighted poor reporting of information relevant to the retention 
of participants and revealed high heterogeneity of studies. This is a recognised 
challenge of undertaking meta-analyses of primary studies that rely on summary data 
presented in published reports (Stewart and Tierney 2002, Abo-Zaid et al. 2012). The 
lack or poor presentation of data readily available in a uniform or accessible format 
within trial publications, or directly from study authors identified in the systematic 
review, provided justification for conducting a more thorough exploration of potential 
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predictors of participant engagement. For this type of exploration IPD-MA has been 
suggested as a superior and more reliable approach to a synthesis of summary statistics 
by medical statisticians (Stewart and Tierney 2002, Simmonds et al. 2005, Tudur Smith 
and Williamson 2007). This argument has been made based on the advantages offered 
by IPD-MA, including: the ability to examine data in detail, more thorough data 
validation and quality assessment, standardisation of outcome definitions, and testing 
additional hypotheses associated with individual patient socio-demographic 
characteristics. For these reasons this approach was applied in the study presented in 
this chapter, looking to gain better understanding of the factors affecting participant 
retention in trials on the sample of five RCTs evaluating different complex interventions 
for schizophrenia. 
5.3 Objectives 
The two objectives of this study were: 
1. To identify patient and study characteristics that may influence retention in 
non-pharmacological RCTs involving people with schizophrenia.  
2. To compare the role of these characteristics in retention at the penultimate 
follow-up assessment and the final assessment.  
5.4 Method 
5.4.1 Individual patient data meta-analysis as a method 
As discussed in the previous chapters, systematic reviews sit at the top of the hierarchy 
of evidence, providing the most rigorous and robust method for evidence-based 
medicine (Elamin and Montori 2012). This method allows for identification of clinical 
trials evaluating similar outcomes in a methodical way and, subsequently, 
quantitatively synthesising data from those studies to enable relevant analyses. There 
are many types of meta-analyses, depending on the research question and data 
available, most commonly using the summary statistics reported in trial publications 
(Lyman and Kuderer 2005). However, using summary data, usually in a form of 
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weighted averages, has its limitations. For example, patient averages at the study level 
can suffer problems with aggregating data and confounding by trial-level covariates. 
Furthermore, as highlighted in the previous chapter and reported in the literature, 
systematic reviews are limited to mainly published reports often presenting inadequate 
information and suffering from publication bias (Stewart and Tierney 2002). It has been 
suggested that meta-analyses drawing on aggregate patient data may be used to decide 
whether or not it is worthwhile proceeding with a more resource intensive analysis 
using data recorded for individual patients (Lyman and Kuderer 2005). This type of 
analysis, called individual patient data meta-analysis, is relatively new and seldom used 
due to resource intensity, which will be discussed later in the chapter (Tudur Smith and 
Williamson 2007).  
Most trials report aggregate data, averaged across all participants in a study, for 
instance the mean age or proportion of participants who spoke English as their first 
language. In contrast, data recorded for each participant who takes part in a clinical 
trial are described as ‘individual patient data’ (IPD). These can include demographic 
characteristics such as gender or age, pre- and post-treatment outcome measures, or 
an indicator of arm allocation.  
Meta-analyses using IPD, like other meta-analyses, are applied to answer a specific 
question related to clinical practice by drawing on data from multiple similar trials. 
Traditionally, this type of analysis follows the same basic methods and philosophy as 
other types of systematic reviews; however the structure and the process of data 
collection and analysis are different (Chalmers 1993). The key premise of a conventional 
IPD-MA is using raw data obtained from studies previously identified in a systematic 
review of literature. Using raw data enables analyses that are difficult to perform on 
aggregate data; for example investigating whether a given treatment is more effective 
for patients with longer illness duration. If the distribution of illness duration is similar 
across studies there will be no relationship between treatment efficacy and duration of 
illness at the trial level. IPD-MA can be used to explore such relationships between 






The process of individual patient data meta-analysis 
Another difference setting IPD-MA apart from the ‘conventional’ aggregate data meta-
analyses is the process it needs to follow. Figure 5.1 illustrates the key stages.  
 
 
Figure 5.1 Stages of an Individual Patient Data Meta-Analysis (adapted from 
Stewart & Tierney 2002) 
 
The key consideration when undertaking an IPD-MA is deciding on the scope of the 
analysis and the ways of obtaining the required data. The traditional and most 
scientifically robust way of performing an IPD-MA is a systematic review approach 
(Tierney et al. 2015). Here, literature is systematically searched to identify all relevant 
trials and then the authors of those studies are contacted with requests for individual 
patient data. Depending on the scope of the literature search, especially publication 
date and study location, obtaining raw data can require significant effort on behalf of 
Write protocol with objectives, 
inclusion criteria and analysis plan
Identify all relevant and available trials
Obtain relevant datasets
Identify and extract appropriate data




researchers undertaking IPD-MA as well as those who are asked to provide raw data. 
Thus, adopting the systematic review approach normally involves forming a 
collaborative group responsible for the process. As a consequence, IPD-MA can be the 
most time consuming and costly type of study, often rendering them unfeasible due to 
lack of resources (Stewart and Tierney 2002, Simmonds et al. 2005, Abo-Zaid et al. 2012) 
or lack of willingness to collaborate (Jaspers and Degraeuwe 2014). In addition, the 
ethical and regulatory processes involved in sharing data vary across the world, with 
some countries (including the Unite Kingdom) requiring a formal review by a Research 
Ethics Committee (Phillips et al. 2017). As a consequence of these barriers, the majority 
of IPD-MAs have been possible in the fields considered to be major public health 
concerns, which attract substantial funding; namely cancer and heart disease 
(Simmonds et al. 2005).  
An alternative approach requiring fewer resources involves pooling resources with 
existing collaborators and, effectively, drawing on convenience samples (Riley et al. 
2010). Examples of such analyses are present in the literature and include prominent 
studies such as the pooled analysis of 18 datasets investigating prognostic markers in 
breast cancer carried out by the European Organisation for Research and Treatment of 
Cancer (Look et al. 2002). However findings of such studies need to be interpreted with 
caution as they might not be representative of all existing trials in the area of interest 
and might therefore be susceptible to bias. One example of an IPD-MA conducted on 
a convenience sample is a study examining participant attrition in 10 trials evaluating 
treatment of musculoskeletal disorders (Hewitt et al. 2010). The study aimed to 
investigate the impact of attrition on the imbalance in baseline characteristics of those 
randomised to a trial. The authors did not provide clear rationale for drawing on a small 
number of easily available trials but it could be inferred that this was due to resource 
constraints.  
Following acquisition of relevant datasets, all data need to be checked and cleaned 
before extracting relevant variables. Since different studies record different types of 
data, often in different formats, data extraction needs to be followed by checking 
consistency and combining different scales of measurement. Only after all covariates 




Prior to performing meta-analyses a decision needs to be made about how the analyses 
will be conducted. Researchers have two options at their disposal: a one-step and a two-
step approach. These should provide similar results, although they cannot be expected 
to be due to some key differences in the assumptions they require to be made (Jones et 
al. 2009, Debray et al. 2013). In the one-step analysis data collated from all available 
studies is analysed simultaneously, based on the assumption that the true effect is fixed 
across studies (Jones et al. 2009). Depending on the type of data and assumptions of 
the meta-analyses (fixed or random effects), an appropriate model needs to be 
specified. In contrast, the two-step approach treats each study separately. The first step 
involves analysing data in each separate study to produce aggregate data for each one 
of those studies. In the second step, these aggregate data are combined across included 
studies (Debray et al. 2013). This produces a summary effect size (for example the odds 
ratio) for the factor-outcome relationship of interest, simultaneously accounting for 
differences between studies.  
5.4.2 Sample 
In this study, a convenience sample of five RCTs evaluating complex interventions and 
involving people with schizophrenia and related disorders was subjected to an IPD-MA. 
Three trials were undertaken at QMUL and two at the University of Oxford. The 
characteristics of included studies are provided in Table 5.1.  
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Table 5.1 Characteristics of included trials 
Trial name Reference Total number 
of randomised 
participants  
Active intervention Control intervention Penultimate follow-
up point 
Final follow-up point 
EPOS Priebe et al. 2013 n=179 DIALOG+ (iPad-mediated 
procedure to discuss 11 
domains with patients) used 




6 months 12 months 
MECCA Priebe et al. 2007 n=507 DIALOG (computer-
mediated procedure to 
discuss 11 domains with 
patients) 
Standard treatment Not applicable 12 months 
NESS Priebe et al. 2016 n=275 Manualised group body 
psychotherapy 
Pilates class 6 months 12 months 
OCTET Burns et al. 2013 n=336 Hospital discharge on 
Community Treatment Order  
Hospital discharge on 
Section 17 leave 
12 months (end of 
Phase I) 
24 months (study 
extension) 
UK700 Burns et al. 1999 n=708 Intensive case management Standard case 
management 




Conducting this analysis following completion of a systematic review of literature and 
meta-analysis presented in the previous chapter allows to ascertain the extent to which 
the results from this IPD-MA study generalise to other trials evaluating non-
pharmacological interventions for people with schizophrenia. This can be achieved by 
comparing the characteristics of studies in the systematic review and those in the IPD-
MA convenience sample. However, it should first be noted that the trials in the 
systematic review were identified following applying specific inclusion and exclusion 
criteria, thus it was not representative of all trials evaluating non-pharmacological 
interventions for schizophrenia.   
Table 5.2 shows the comparison of key study characteristics, including average number 
of randomised participants, study setting (inpatient vs outpatient), type of control 
(active vs standard care), intervention delivery (individual vs group), and average study 
duration.   
 
Table 5.2 Characteristics of trials in the IPD-MA sample and the systematic 
review sample 
Study characteristic IPD-MA sample (n=5) 
(n, %) 
Systematic review sample (n=43) 
(n, %) 
Average number of randomised 
participants 
401 200.93 
Study setting Outpatient 5 (100) Inpatient 6 (14) 
Outpatient 23 (53.5) 
In- and out-patient 10 (23.2) 
No information 4 (9.3) 
Type of control  Active 2 (40) 
Standard care 3 (60) 
Active 15 (34.9) 
Standard care 20 (46.5) 
Other 8 (18.6) 
Intervention delivery Individual 4 (80)  
Group 1 (20) 
Individual 20 (46.5) 
Group 22 (51.2) 
No information 1 (2.3) 
Average study duration (last 
follow-up) 
16.8 months 11.92 months 
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Compared to trials identified in the systematic review reported in Chapter 4 the 
convenience sample in this study had, on average, larger sample size and longer 
duration. Nonetheless, these were within the ranges identified in the systematic review.  
All trials subjected to IPD-MA were conducted in outpatient settings. Thus, this IPD-
MA is limited to studies conducted in this context. Majority of trials in the systematic 
review were also conducted with outpatients (53.5%) or a combination of in- and out-
patients (23.2%).   
Four out of 5 evaluated interventions were delivered individually, compared to an 
almost even split in the systematic review sample. Thus, in the IPD-MA sample there 
is an underrepresentation of interventions delivered in a group format and the findings 
may only apply to studies evaluating individually-delivered interventions.   
Similarly to the trials in the systematic review, majority of studies in IPD-MA used a 
standard care control. However, there is representation from studies using both active 
and standard care controls.   
Overall, given the high heterogeneity of the studies identified in the systematic review, 
the characteristics of this convenience sample fall within the ranges reported in the 
review; however it is important to acknowledge the differences, which may limit the 
generalisability of the study.   
5.4.3 Definitions   
Retention was defined as completion of follow-up assessments at two time points for 
each trial. Completion was considered for both the penultimate and the final follow-up 
to allow for comparisons. These time points were chosen as it has been suggested that 
the pattern of retention varies over the duration of a trial, with the highest proportion 
of dropout occurring in the early stages (Carroll 1997, Hewitt et al. 2010).  
5.4.4 Data collection 
Researchers who worked on each of the identified studies were approached with a 
request for the data listed in Table 5.3 below. Researchers were free to provide data in 
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the most convenient format for them, given that the details of coding were supplied 
and the data were anonymised.  
Table 5.3 Data requested from trial researchers 
Trial level data Individual patient level data (as recorded at 
baseline) 
Setting (inpatient or outpatient) Age 
Population (inclusion and exclusion criteria) Gender 
Number of follow-up assessments Ethnicity 
Timing of follow-up assessments Country of birth 




 Employment status 
 Education level 
 Age of onset 
 Age of first admission 
 Diagnosis 
 Income  
 Number of children 
 Living situation 
 Type of residence 
 Treatment group allocation (active vs. control) 
 First language 
 Number of psychiatric admissions 
 Completion of penultimate follow-up assessment 
or outcome score recorded at penultimate 
follow-up assessment 
 Completion of final follow-up assessment or 
outcome score for final follow-up assessment 




5.4.5 Outcome measures 
The clinical outcomes of each study were not relevant to this meta-analysis but their 
availability was used as a proxy measure for assessment completion if the trial did not 
record completion as a separate variable.  
5.4.6 Data synthesis 
Upon acquisition of data for all included trials the candidate performed thorough 
checking to ensure consistency and quality of reporting. Any missing data, 
inconsistencies between variables, or extreme values were discussed with the 
researchers who worked on the trial that the results came from. Where studies used 
different classifications or measurements data were translated and combined to achieve 
consistency across studies, for instance some data sets did not record age as a numerical 
variable but provided date of birth and so enabled calculations of participants’ age. 
Following checks, data were inputted into a single database to build a ‘mega-trial 
database’.  
5.4.7 Data analysis 
A one-stage analysis was performed, where data are modelled simultaneously whilst 
accounting for the clustering of subjects within studies. Compared to a two-stage IPD-
MA, the one-stage approach is more statistically exact and is recommended for analyses 
of data available from few studies (Debray et al. 2013). A one-stage IPD-MA is a 
multilevel logistic regression model with mixed effects.  
The variables included in the analysis were selected based on the consistency of 
reporting across all included trials. The dependent variables (outcomes) were: 1) 
retention at penultimate follow-up and 2) retention at final follow-up. The covariates 
(potential predicting factors) included: allocation to arm, gender, age, ethnicity, 
education level, employment status, and marital status. 
Three sets of mixed-effects logistic regression analyses were carried out relating to the 
two outcomes, considered separately. The first set included two univariate logistic 
regressions of the effect of arm allocation on retention at two follow-up points. This 
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began to investigate confounding as well as provided an initial and unadjusted view of 
the importance of each variable, by itself. The second set comprised analyses to 
examine the associations between retention and each covariate separately. Arm 
allocation was kept as a fixed effect for calculations of the effect of age, sex, education, 
ethnicity, employment status and marital status. Finally, two last analyses examined 
the associations between retention and covariates in a multivariate way. These 
associations were expressed as odds ratios (ORs) with 95% CIs. Odds ratios were used 
to compare the relative odds of the outcome (i.e. completion of follow-up assessment), 
given the exposure to the variable of interest (i.e. socio-demographic characteristics 
and arm allocation) (Szumilas 2010). 
5.4.8 Ethics and governance 
This study did not require a separate ethics committee approval for the following 
reasons. First, investigators of each of the included studies obtained appropriate 
approval from their local ethics committee and written informed consent from patients 
prior to including the cohorts in this meta-analysis, which permitted secondary analysis 
of the data. Second, the current study used anonymised data preventing identification 
of the participants recruited to the original study.  
 
5.5 Results 
5.5.1 Sample characteristics 
The total sample size available for analysis achieved by combining the five trials was 
2,006. Data on the penultimate follow-up assessment completion were collected in four 
trials, with one having before/after design and therefore not included in the analysis of 
retention at penultimate follow-up point. Baseline covariates of interest measured at 
the patient level included: age, sex, ethnicity, education level, marital status, and 
employment status. Table 5.4 provides an overview of the counts observed for each 
variable across the five studies.  
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Overall, the majority of the total sample was male (64.4%), 41 years old on average, with 
11.6 years spent in education. Most participants were of White background (59.5%), 
followed by Black ethnicity (27.5%), Asian ethnicity (7.6), and ‘Other’ ethnicities (5.4). 
The majority lived alone (87.8%) and were employed (87%). In terms of trial 
involvement, 51.5% were randomised to the active arm and 48.9% received the control 
condition. Allocation to arm (active vs control) was also recorded for the purposes of 
the analysis.  
The IPD available for analysis included a wide range of outcomes and patient socio-
demographic characteristics with differences in definitions, completeness, and 
consistency between data sets. Some items were not reported consistently across all 
studies; this is because some trials did not collect specific variables, such as 
employment status, country of birth, or age of onset. The unrecorded data led to a 
reduced data set available for a multivariate analysis, with 984 patients available for the 
penultimate follow-up analysis and 988 for the final follow-up. For that reason only 
results of the univariate analyses are presented and discussed.  
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Gender (n, %) Age 
(mean) 
Ethnicity (n, %) Length of 
education 
(mean years) 
Marital status (n, %) Employment status 
(n, %) 
Allocation to arm  
(n, %) 
EPOS n=180 Female 56 (31) 
Male 124 (69) 
41.7 White 46 (25.7) 
Black 70 (39.1) 
Asian 49 (27.4) 
Other 14 (7.8) 
11.2 Live alone 146 (81.6) 
Live with partner 33 (18.4) 
Variable not reported Active 94 (52.5) 
Control 85 (47.5) 
MECCA n=507 Female 171 (34) 
Male 336 (66) 
42.3 White 431 (85) 
Black 53 (10.4) 
Asian 14 (2.8) 
Other 9 (1.8) 
Variable not 
reported  
Live alone 439 (86.7) 
Live with partner 67 (13.3) 
Working 348 (69.6) 
Not working 152 
(30.4) 
Active 271 (53) 
Control 236 (47) 
NESS n=275 Female 72 (26) 
Male 203 (74) 
42 White 142 (51.8) 
Black 80 (29.2) 
Asian 30 (1.1) 
Other 22 (9) 
10.9 Variable not reported Working 266 (99.2) 
Not working 2 (0.8) 
Active 140 (51) 
Control 135 (49) 
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OCTET n=336 Female 111 (33) 
Male 225 (67) 
40 White 206 (61.3) 
Black 78 (23.2) 
Asian 29 (8.6) 
Other 23 (6.9) 
12.6 Live alone 297 (91.4) 
Live with partner 28 (8.6) 
Working 322 (98.8) 
Not working 4 (1.2) 
Active 167 (49.7) 
Control 169 (50.3) 
UK700 n=708 Female 304 (43) 
Male 404 (57) 
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White 367 (51.8) 
Black 270 (38.1) 
Asian 30 (4.3) 
Other 41 (5.8) 
11.7 Live alone 626 (88.4) 
Live with partner 82 (11.6) 
Working 628 (89.2) 
Not working 76 
(10.8) 
Active 353 (49.9) 
Control 355 (50.1) 
Total n=2,006 Female 714 (35.6) 
Male 1,292 (64.4) 
40.8 White 1,192 (59.5) 
Black 551 (27.5) 
Asian 152 (7.6) 
Other 109 (5.4) 
11.6 Live alone 1,508 (87.8) 
Live with partner 210 (12.2) 
Working 1,564 (87) 
Not working 234 (13) 
Active 1,025 (51.1) 




5.5.2 The effect of arm allocation on retention 
For the penultimate follow-up completion there were data from 1,493 participants. The 
number of available observations was reduced due to one trial adopting a before/after 
design. Out of the available data, 1,236 participants were completers and 257 did not 
complete the follow-up. The results are presented in Table 5.5 below. 
Table 5.5 Summary data of penultimate follow-up retention by arm allocation 
Penultimate follow-up 
completion 
Arm (n, % completion) Total (n, % completion) 
Active Control 
Yes 631 (83.9) 605 (81.65) 1,236 (82.8) 
No 121 (16.1) 136 (18.35) 257 (17.2) 
Total 752  741  1,493 
 
For the final follow-up completion there were data from 2,005 participants. Out of 
those, 1,671 were completers and 334 did not complete the follow-up. The results are 
presented in Table 5.6 below.  
Table 5.6 Summary data of final follow-up retention by arm allocation 
Final follow-up 
completion 
Arm (n, % completion) Total (n, % completion) 
Active Control 
Yes 871 (85) 800 (81.6) 1,671 (83.3) 
No 154 (15) 180 (18.4) 334 (16.7) 
Total 1,025  980  2,005 
 
Univariate logistic regression 
The results of the univariate logistic regression suggest absence of substantial 
heterogeneity (Tau2 = 0.79). There was a marginally significant result with unadjusted 
OR of 1.27 (p=0.051) suggesting that the odds of participants in the active treatment 
arm completing the last follow-up were 27% more than in the control arm. The results 
are presented in Table 5.7 below.   
96 
 
Table 5.7 Univariate models of retention by arm allocation 














1.1, 0.89 to 1.56 
Final follow-up 5 2,005 0.051 1.27, 0.99 to 1.61 
 
5.5.3 Patient socio-demographic characteristics associated with retention 
Mixed effects logistic regression with multiple variables 
Possible associations between individual patient socio-demographic characteristics 
and retention were assessed using mixed-effects logistic regressions. Each model was 
adjusted for arm allocation. Age, gender, length of education, occupation status, and 
marital status were continuous variables and ethnicity was a categorical variable. 
Results for the penultimate follow-up point are reported in Table 5.7 and for the final 
follow-up in Table 5.8. None of the tested characteristics were found to be significantly 
associated with retention at either of the follow-up points. The difference between 
individuals with White and those with Black ethnicity approached an acceptable 
significance level (p=0.057), which suggests that White participants could have higher 
odds of completing the penultimate follow-up compared to those with Black ethnicity. 
However, this result does not allow for making any firm conclusions given the high p-







Table 5.8 Individual patient socio-demographic characteristics predicting 
retention at penultimate follow-up tested in multivariate models 






p-value OR (95% CI) 
Age (years) 4 1,493 0.481 0.99 (0.98 to 1.01) 
Gender 4 1,493 0.701 1.06 (0.79 to 1.42) 
Ethnicity: 4 1,492   
   White vs Black   0.057 0.74 (0.54 to 1.01) 
   White vs Asian   0.287 0.76 (0.46 to 1.26) 
   White vs Other   0.662 1.15 (0.62 to 2.14) 
Education (years) 4 1,435 0.927 1.00 (0.95 to 1.06) 
Employment status 
(working vs not 
working) 
3 1,293 0.469 0.79 (0.43 to 1.48) 
Marital status (live 
alone vs live with 
partner) 
3 1,216 0.568 1.14 (0.72 to 1.83) 
 
Table 5.9 Socio-demographic predictors of retention at final follow-up tested in 
multivariate models 






p-value OR (95% CI) 
Age (years) 5 2,005 0.501 0.99 (0.98 to 1.00) 
Gender 5 2,005 0.267 0.86 (0.68 to 1.11) 
Ethnicity: 5 2,004   
   White vs Black   0.092 0.78 (0.59 to 1.04) 
   White vs Asian   0.097 0.69 (0.44 to 1.07) 
   White vs Other   0.832 1.06 (0.61 to 1.86) 




(working vs not 
working) 
4 1,798 0.967 1.01 (0.65 to 1.56) 
Marital status (live 
alone vs live with 
partner) 
4 1,727 0.699 1.08 (0.73 to 1.59) 
5.6 Discussion 
5.6.1 Main findings  
This study analysed the potential impact of patient characteristics on study retention 
in a convenience sample of five randomised clinical trials of non-pharmacological 
interventions for schizophrenia. The average retention rates were 82.8% (17.2% 
attrition) and 83.3% (16.7% attrition) for the penultimate and the final follow-up 
assessment, respectively. Retention within the active intervention group was 83.9% 
(16.1% attrition) at the penultimate and 85% (15% attrition) at the final follow-up; and 
within the control group, it was 81.65% (18.35% attrition) at the penultimate and 81.6% 
(18.4% attrition) at the final follow-up.  
The present study suggests that patients with schizophrenia randomised to 
experimental interventions evaluated in RCTs are more likely to complete the final 
follow-up assessment compared to those who receive control conditions. However, 
given that the result fell just short of the traditional definition of statistical significance, 
the finding should be treated with caution.  
Further meta-regressions showed no evidence of a significant relationship between any 
of the tested patient characteristics and completion of assessment at either time point. 
This result is similar to the findings of the systematic review and meta-analysis 
presented in Chapter 3 and builds on them to widen the evidence about retention of 
participants with schizophrenia in non-pharmacological trials.  
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5.6.2 Strengths and limitations 
This IPD-MA represents the first, albeit limited in scope, of its kind in the context of 
mental health. It has demonstrated that this type of analysis is feasible and can provide 
important insight into what factors predict or do not predict retention in trials 
involving people with schizophrenia. Conducting a full IPD-MA employing a systematic 
review was not feasible given the constraints of this doctoral study. However, IPD-MAs 
based on convenience samples have been deemed useful for gaining insight into 
specific issues (Hewitt et al. 2010, Riley et al. 2010) and such was the intention of this 
study. 
The main limitation of this study is the limited number of and the crude nature of the 
tested characteristics. The choice of variables was limited to those present in the 
available trial databases, but there may be other factors affecting the completion of 
follow-up assessments.    
5.6.3 Interpretation and comparison with the wider literature 
Previous meta-analysis conducted as part of this thesis analysed trials of non-
pharmacological interventions for schizophrenia reported in the literature and 
compared attrition at both intervention and study levels. The findings showed that a 
higher number of sessions led to higher intervention dropout (Chapter 3). Other 
patient and study characteristics did not show significant associations with either 
intervention or study dropout.  
The IPD-MA presented in this chapter aimed to explore the patterns and predictors of 
study retention further. Given that study attrition is defined by the loss of participants 
to follow-up and most trials involve multiple assessments over an extended period of 
time, it was possible to explore the differences in retention across the duration of a 
project. This analysis was able to include patient socio-demographic characteristics and 
allocation to arm as potential predictors of study retention.  
Impact of age and gender 
Like in the preceding meta-analyses exploring predictors of dropout, no effect was 
found for age or gender. As discussed in the previous chapter, this lack of association 
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is not consistent with the findings of Nosé et al. (2003) and Villeneuve et al. (2010), 
which identified age and gender as predictors of dropout of people with psychotic 
disorders. Although it is important to note that the two studies disagreed on the 
direction of association for age, with the former study reporting higher dropout to be 
associated with lower age, and the latter reporting older participants to be more likely 
to withdraw from treatment.  
Impact of employment status and education 
Unlike Nosé et al. (2003) (although the focus of their study was on treatment 
adherence) this IPD-MA did not find a significant effect of employment status on 
retention. Similarly, while Villeneuve et al. (2010) reported living alone and having high 
education to lead to better adherence to psychosocial treatment for schizophrenia, the 
current study did not find employment status or length of education to be associated 
with completion of follow-up assessments.  
Impact of ethnicity 
The association between ethnicity and study retention approached significance level, 
suggesting that there might be differences between the groups included in the analysis 
(i.e. White, Black, Asian and Other) and that individuals of different ethnic 
backgrounds might not be equally likely to complete follow-up assessments. However, 
further analyses are required to ascertain this finding.  
The presence of such association would have implications for the involvement of 
patients from ethnic or racial minorities in mental health research, which has been the 
subject of considerable debate in the literature (Brown et al. 2014). Individuals from 
ethnic minority groups have been found to be more likely to refuse participation in 
mental health research (Miranda 1996, Hussain-Gambles 2004, Jackson et al. 2004, 
Woodall et al. 2010, Williams et al. 2012). The same has been shown specifically for 
patients with psychotic disorders (Patel et al. 2017).  
In comparison to the initial agreement to participate less evidence is available about 
the likelihood of completing treatment and research assessments within a trial context, 
especially in the area of psychotic disorders. However, retention has direct implications 
for the representation of minorities in clinical studies as, if they are also more likely to 
drop out after being recruited, the problem of unequal representation would remain 
throughout studies. Research conducted by Baekeland & Lundwall (1975) found 
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patients receiving psychotherapy to be more likely to prematurely discontinue 
treatment if they had ethnic minority background. It is difficult to judge the relevance 
of these findings in today’s practice given the societal and political changes that have 
occurred since its publication. One the one hand, one would anticipate that people 
from ethnic minorities are better integrated into communities and thus not as affected 
by the barriers they have been reported to experience (Hussain-Gambles 2004, Yancey 
et al. 2006, Woodall et al. 2010, Brown et al. 2014, Hartlieb et al. 2015), resulting in less 
ethnic inequalities. On the other hand, research on the use of mental health services 
has shown that individuals from ethnic minorities are less likely to engage and to 
complete treatment (Alvidrez 1999, Hines-Martin et al. 2004, Gary 2005, Carpenter-
Song et al. 2010). Nonetheless, it is not possible to ascertain from the evidence 
generated by the current study whether this phenomenon translates into non-
pharmacological treatments provided within trial settings and completion of research 
assessments.  
Impact of arm allocation 
A marginally significant association was found between arm allocation and completion 
of the final follow-up assessment. A similar effect was found in a meta-analysis of 
dropout rates in trials of antipsychotic drugs, showing that participants receiving 
placebo were more likely to drop out than those receiving medication (Kemmler et al. 
2005). The present study suggests that participants who receive an active intervention 
may be more likely to complete final assessments, which can be interpreted in different 
ways.  
The first potential explanation is linked to the research on treatment preferences and 
their effect on attrition in trials. Although Sidani et al. (2015) highlight that the evidence 
is inconsistent, two meta-analyses (Preference Collaborative Review Group 2009, Swift 
et al. 2011) and two individual studies (Raue et al. 2009, Kwan et al. 2010) showed that 
patients who received treatment that matched their preference were less likely to 
withdraw from trials. If one assumes that most individuals want to receive the new 
treatment evaluated in a trial they are invited to participate in (something that will be 
explored in the subsequent chapter), especially when the other option is standard care, 
those randomised to the active arm can be considered as ‘matched’ to their preference 
and thus less likely to drop out. The current study would suggest however that this 
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effect is significant only for the final follow-up, indicating that a different factor might 
explain the difference between the penultimate and the final assessments.  
The second interpretation takes into consideration potential researcher bias and the 
possibility that trial researchers somehow influence completion of final follow-up 
assessments, despite blinding. Hewitt et al. (2010) suggest that “researchers often focus 
increased efforts on data collection at the final time point” (p.1266), although they do 
not provide any empirical evidence to support this statement. If this were true, the 
effect on retention in trials where researchers are blinded to participants’ treatment 
allocation would be equally observed across both arms. This was not the case in the 
current study. However, it is possible that the efforts are influenced, perhaps 
unconsciously, by unblinded researchers responsible for arranging appointments with 
participants. This would mean that the effort made to make sure that participants 
attend their final follow-up appointments is greater with those who received an 
intervention than those who were in the control condition.  
An alternative potential explanation considers the varying levels of involvement in a 
trial depending on arm allocation. Participants randomised to an active arm, especially 
in case of non-pharmacological treatment, are expected to attend individual or group 
sessions, or to complete regular activities comprising an intervention. As a 
consequence, they often receive reminders, are in frequent contact with providers of 
an intervention and other patients (in case of group interventions), and are likely to 
discuss their experience of treatment with their clinician. A different level of 
involvement can be expected in some control conditions; this however will depend on 
the type of control offered in a given trial. In trials offering ‘standard care’ or ‘treatment 
as usual’ as a control intervention, the differences can be more pronounced as taking 
part as a control participant would not subject one to a new treatment. However, in the 
case of an active control (two out of five trials analysed in this study), the level of 
expected involvement would be more or less the same across trial arms. And, again, 
this would not explain the lack of effect for the penultimate follow-up completion.  
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5.6.4 Implications of findings for trial conduct and further methodological 
research 
This study addresses a gap in the evidence on factors affecting retention in 
schizophrenia trials. Although this study did not find strong evidence for an effect of 
participant characteristics on retention, it shows that IPD-MA provides a reliable 
approach to examine the issue of study completion and can therefore be treated as an 
exemplar for future investigations of retention patterns and predictors. A systematic 
review IPD-MA could yield a larger sample and thus more powerful analysis; however 
given the resources it would require, it would be difficult to justify.  
Whilst the previous meta-analysis (Chapter 3) was limited by poor reporting in 
published research, this study had to deal with lack of consistency in variables recorded 
across different trials. Although, it is important to note that this study was sufficiently 
powered to identify any effects of relevant magnitude. Difficulties with extracting data 
for the purposes of meta-analyses of prognostic factors have been acknowledged in the 
literature (Abo-Zaid et al. 2012). A larger study with variables more consistently 
reported across individual trials is needed to generate a more precise estimate of the 
effect. However, the issues with the consistency and quality of data recorded in trial 
databases encountered in this study highlight the need for a careful consideration 
before undertaking a systematic IPD-MA in the future.   
Since none of the participant socio-demographic characteristics tested in this meta-
analysis were identified as having being significantly associated with study retention, it 
is suggested that multiple strategies for achieving study completion are necessary, 
without the need to tailor the approach based on specific socio-demographic 
demographic characteristics.  
5.7 Conclusion 
This chapter discussed the findings of an analysis of predictors of retention, which 
aimed to extend the results from the systematic review and meta-analysis reported in 
Chapter 4 by drawing on individual patient data from relevant RCTs. The findings 
confirmed the lack of strong associations between the tested socio-demographic 
characteristics and retention. However, the study identified a relationship between 
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receiving an intervention and completing the last follow-up assessment. Consequently, 
this suggests that there is no need in focusing retention strategies on specific subgroups 
with a higher risk of dropping out, since they cannot be identified given the available 
data.   
The following two chapters will continue to examine retention in RCTs, including 
potential predictors, by employing qualitative methods. Chapter 6 will investigate the 






 Chapter 6 
Qualitative study of trial retention 
practices 
6.1 Chapter overview 
Chapter 5 addresses the second and the third research questions: 2) What is the 
retention of patients with schizophrenia in RCTs evaluating complex interventions 
influenced by?; and 3) How can patients with schizophrenia be retained in trials?  
This chapter begins with an overview of the method before it describes the study 
sample and the recruitment strategy. The details of the materials used to recruit 
participants and to collect data, as well as the overall procedures followed during data 
collection are also provided. The findings from the qualitative study are presented and 
discussed in the ‘Findings’ section before they are interpreted in the following section.   
6.2 Rationale 
Chapters 4 and 5 of this thesis presented results of two quantitative studies, both 
conducted to identify factors affecting retention in trials of complex interventions for 
schizophrenia. These investigations identified some issues with analyses relying on 
both published data as well as individual patient data obtained directly from 
researchers. Nonetheless, they have provided insight into which patient socio-
demographic characteristics and study characteristics may or may not have impact on 
retention.  
Simultaneously to conducting these quantitative analyses, a qualitative study was 
conducted investigating the experiences and practices of trial researchers and 
therapists working on studies relevant to the focus of this thesis. Conducting these 
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studies in parallel allowed for prompting interviewees about some of the factors being 
tested in the meta-analyses. The primary purpose of adopting a qualitative 
methodology was to identify, analyse and report the patterns of retention and trial 
professionals’ understanding about retaining participants with schizophrenia in non-
pharmacological trials. The importance of qualitative research, especially in the context 
of medicine and clinical research, has been emphasised in a recent debate about 
publishing qualitative studies in the British Medical Journal, with 76 senior academics 
from 11 countries arguing that “Qualitative studies help us understand why promising 
clinical interventions do not always work in the real world, how patients experience 
care, and practitioners think” (Greenhalgh et al., 2016, p.2). The purpose of the present 
study was to grasp the understanding of trial practices that would be beyond the 
quantitative approach, not least because of the reporting inconsistencies highlighted in 
the previous chapters. As a secondary aim, the findings from this study, together with 
the literature identified in Chapter 2, the results of quantitative studies presented in 
Chapters 4 and 5, and another qualitative study presented in the subsequent chapter 
will be used to inform conclusions about retention and recommendations for trial 
methodology and practice.   
6.3 Objectives 
This study had the following objectives: 
1. To examine the process of recruiting patients with schizophrenia to non-
pharmacological RCTs and its impact on retention of this population. 
2. To identify the points in the research process where retention is considered. 
3. To explore the reasons for dropping out provided to trial researchers by 
participants. 
4. To identify retention strategies used by trial researchers and therapists.  




6. To identify lessons to be learned about how retention in future trials of 
complex interventions for schizophrenia might be improved.  
6.4 Method 
6.4.1 Study design 
This study’s prime interest was individual stories and perspectives of working on trials 
and, more specifically, retaining people with schizophrenia in complex interventions 
and follow-up assessments. For this reason individual interviews were chosen as the 
most appropriate method of data collection. Group interviews were considered as a 
data collection method but it was thought that the trial researchers would be less likely 
to share their practices and strategies with those working in other groups or 
institutions, since they may wish to project a certain image or protect their practices as 
they often compete for the same funding.   
The choice of method was dictated by the research question. The aim was to 
understand the experience of managing retention of people with schizophrenia in trials 
from the perspective of trial staff who have worked on RCTs evaluating complex 
interventions. Qualitative methods are uniquely positioned to collect data on 
experiences, allowing to explore their breadth and depth (Ritchie and Spencer 2002, 
Creswell 2003, Seale et al. 2007, Yin 2010). Particular attention was paid to the factors 
which affected or which could modify participant retention and strategies used to 
increase retention or prevent attrition.   
Framework Method was chosen as a type of qualitative content analysis and thematic 
analysis, the choice and application of this method will be discussed in more detail 
below. The aim of this method is not to generate theory, but it allows for the use of 
constant comparative techniques [a feature of Grounded Theory (Bryant and Charmaz 
2010, Charmaz 2013)] through the review of data in the matrix.  
Approach to data  
When developing explanations, the doctoral candidate applied retroductive logic, 
which aims to identify explanatory mechanisms or structures (Blaikie and Priest 2017). 
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This logic of inquiry was applied in order to identify key factors or processes that could 
explain patterns appearing in the data. As a result, alternative explanations were 
developed and proposed to make logical sense of the patterns. These drew on both emic 
and etic perspectives. The emic perspective, focusing on explicit accounts provided by 
participants, “attempts to capture participant’s indigenous meanings of real-world 
events” (Yin, 2010, p.11) and “looks at things through the eyes of members of the culture 
being studied” (Willis, 2007, p.100), thus allowing to gain in-depth understanding of 
the participant’s perspective. This approach has been combined in the present study 
with the etic perspective, which takes an external view on the studied phenomenon by 
applying the “structures and criteria developed outside of the culture as a framework 
for studying the culture” (Willis, 2007, p.100). These implicit accounts involved making 
inferences and applying logical sense to the participants’ accounts; these drew on 
relevant theories or existing empirical studies where appropriate.   
6.4.2 Ethics approval 
Prior to data collection, approval for the study was granted by the Queen Mary Ethics 
of Research Committee (see Appendix 3). 
6.4.3 Recruitment 
Participants were sought from various academic research institutions across the UK, 
especially trial units known for conducting studies evaluating non-pharmacological 
interventions. They were identified using different strategies: Internet searches, 
network contacts, and snowballing. Subsequently, each potential participant was 
contacted directly by e-mail or by phone with an invitation to take part. Compensation 
was not offered for participation. 
Eligible individuals needed to have experience of working on trials evaluating non-
pharmacological interventions involving people with schizophrenia, in a role that 
involved direct contact with patients. This requirement excluded PIs who were deemed 
to be too removed from the direct practice of retaining patients in a trial to provide 
information pertinent to the study objectives.  
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Participant information sheets were presented together with an invitation letter, either 
by post or email. After one week, email reminders followed. Participants were offered 
the option to be interviewed either at their site or in a neutral private location.  
6.4.4 Materials 
An information sheet was developed to invite potential participants to the study and to 
provide information about the purpose of the study and the nature of participation. 
The document included details of the type of data collected, the likely length of the 
interview and the types of questions, the intended use of the findings, and the details 
of the funder of the study and the candidate’s supervisor. The potential participants 
were advised about data confidentiality and given the details of the ethics approval. 
Contact details of the candidate were also provided. The full information sheet can be 
found in Appendix 4.  
A consent form was provided together with the information sheet to make the data 
collection process transparent to potential participants. The consent form complied 
with the requirements of the Queen Mary Ethics of Research Committee and was 
designed to confirm that the participants fully understood the contents of the 
information sheet and agreed, in writing, to take part in the study. The form advised 
the participants about their right to withdraw at any point and the confidentiality of 
their personal information (see Appendix 5).  
The interview schedule comprised four parts: participant introduction and 
background; experience of recruitment and retention; factors affecting retention and 
issues specific to trials in schizophrenia; and interview end. The purpose of the 
interview schedule was to first establish the relevant knowledge and experience of each 
participant and, subsequently, to ask questions about the experience of recruiting and 
retaining participants, with emphasis on the latter. This included any specific practices 
and strategies used and the factors observed by participants as affecting retention in 
trials. Prompts were used to enable participants to elaborate on points of interest 
further, as well as to elucidate reflections on their own experience in greater depth. 




Once contacted individuals expressed their willingness to take part, the interviews were 
scheduled. Potential participants were given the option of being interviewed over the 
telephone or Skype if meeting in person was problematic. Twenty-four interviews were 
conducted in person, three over the telephone, and one using Skype. All interviews 
were conducted at a convenient time and location for the participant. All face-to-face 
interviews took place at the participants’ workplaces, in a confidential space.    
Following obtaining written informed consent and prior to the interview, participants 
were asked to complete a short demographic details form.   
All interviews were recorded with a digital voice recorder. The duration of the 
interviews ranged from 28 minutes to 2 hours and 27 minutes, with an average duration 
of 51 minutes. The majority were between 28 minutes to 1 hour, with variations in length 
depending on interviewees’ availability. Interview notes were taken immediately after 
the interview. Six interviews were transcribed by a graduate student volunteer recruited 
specifically for this purpose and the remaining 22 by the candidate. All transcripts were 
checked for accuracy by the candidate before being included in the analysis. 
All questionnaire data were kept in a locked filing cabinet and digital information was 
kept on a secure, password-protected computer. Each set of data was allocated a code 
to ensure participant anonymity. 
6.4.6 Data analysis 
The data were analysed using the Framework Method. This type of analysis was 
considered to be more appropriate than traditional thematic analysis for the purpose 
of this study because it enables both a priori issues and emergent data to guide the 
development of the analytic framework (Ritchie and Spencer 1994, Parkinson et al. 
2015). The Framework has been defined as a set of techniques or a data analysis strategy 
falling under the umbrella of thematic analysis (Gale et al. 2013). The analysis followed 
five stages described in the original Framework Method (Ritchie and Spencer 1994), as 




The familiarisation stage involved reading and re-reading the transcripts and 
studying interview notes, with the aim of gaining an overview of the data 
gathered and starting conceptualisation. Although all data were collected by 
the doctoral candidate this stage was important in ensuring that the 
recollection of interviews was not partial. Key ideas and recurrent themes were 
listed during this process, using analytic memos.  
2) Identifying a thematic framework 
A thematic framework was developed by drawing upon a priori issues included 
in the interview schedule and key themes identified during the familiarisation 
stage, combining inductive and deductive approaches to research. This allowed 
for incorporation of the interview schedule, ideas from the existing literature 
and prominent themes identified from a preliminary review of the transcripts.  
The first version of the framework was then applied to a selection of transcripts 
with the aim of refining the categories. The categories were developed to 
facilitate organising data into manageable portions, enabling subsequent 
mapping and interpretation. A definition for each code was developed to ensure 
consistency of coding. To improve the reliability of coding, the thematic 
framework was consulted with the candidate’s second supervisor (ST). 
Throughout the process, the relationships of themes and interpretation of data 
were discussed.  
3) Indexing 
The final coding structure was applied to all interview transcripts by coding 
systematically line by line using NVivo 10 software. Based on the structure, the 
framework matrix was created.  
4) Charting data into the framework matrix 
Once appropriate categories and codes were assigned, the matrix was populated 
with summaries of coded data organised by both participant and theme. The 
summaries were carefully written to reduce the data for the ease of analysis; 
however effort was made to retain the original meaning.  
5) Mapping and interpretation 
In this stage the whole data set was reviewed to compare and contrast the 
accounts of interviewees, search for any patterns, and develop explanations for 




6.5.1 Study sample 
Fifty-three individuals were invited to participate in an interview. Data saturation was 
reached after 28 interviews, when no new information was arising from the collected 
data. The data collection period lasted between the 17th April and 16th October 2016. 
Characteristics of the sample are shown in Table 6.1 below.  
Table 6.1 Characteristics of the sample (n=28) 
Characteristic n (%) 
Gender  
   Female 23 (82) 
   Male 5 (18) 
Mean age  34.5 
Education Level  
  Undergraduate 4 (14) 
  Postgraduate 18 (64) 
  Professional degree 2 (7) 
  Doctoral 4 (14) 
Professional role  
  Research Assistant 11 (39) 
  Trial Manager 5 (18) 
  Senior Researcher 5 (18) 
  Clinical Psychologist 4 (14) 
  Research Nurse 2 (7) 
  Clinical Study Officer 1 (4) 
 
Experience of working on trials varied from one year to 20 years, with a median of 5 
years. Twenty-three out of 28 participants were female. The greater proportion of 
females in this sample may be reflective of the greater proportion of women 
undertaking a degree in psychology (Howard et al. 1986). This type of degree is likely 
to be held by most professionals working on trials in mental health. The age of 
participants ranged from 24 to 57, with an average of 34.5 years. Thirty-nine percent of 
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the sample worked as research assistants. This reflects the traditional spread of 
professional roles within a trial team, usually comprising one trial manager and 
supporting staff responsible for recruitment and follow-up (i.e. assistants, senior 
researchers, and clinical study officers). The sample also included therapists delivering 
the interventions under evaluation who worked on trials as clinical psychologists. 
Professional roles and demographic characteristics of each participant are provided in 
Table 6.2 below.  




role and ID applied in text 




1 Trial Manager 1 Male 34 6 
2 Trial Manager 2 Female 35 8 
3 Trial Manager 3 Male 28 4.5 
4 Research Assistant 1 Male 29 5 
5 Research Assistant 2 Male 28 1 
6 Research Assistant 3 Female 28 4 
7 Research Assistant 4 Female 33 4 
8 Research Assistant 5 Female 24 1 
9 Senior Researcher 1 Female 50 11 
10 Senior Researcher 2 Female 39 11 
11 Senior Researcher 3 Female 29 8 
12 Research Assistant 6 Female 36 8 
13 Research Assistant 7 Female 26 2 
14 Senior Research Nurse 1 Female 42 20 
15 Clinical Psychologist 1 Female 27 3 
16 Research Assistant 8 Female 44 5 
17 Trial Manager 4 Male 35 6 
18 Research Assistant 9 Female 29 3 
19 Senior Researcher 4 Female 57 13 
20 Research Assistant 10 Female 28 3 
21 Senior Researcher 5 Female 31 3 
22 Trial Manager 5 Female 32 7 
23 Research Nurse 1 Female 57 3 
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24 Clinical Psychologist 2 Female 31 5 
25 Clinical Psychologist 3 Female 34 6 
26 Research Assistant 11 Female 38 3.5 
27 Clinical Psychologist 4 Female  29 6 
28 Clinical Studies Officer 1 Female 34 3.5 
 
6.5.2 Presentation of study findings 
The findings will be presented in three parts. The first part includes two themes: the 
complexity of trial participation by patients with schizophrenia and mechanisms of 
attrition in complex intervention trials. The second part comprises four categories of 
factors identified as key to retention of participants with schizophrenia in complex 
intervention trials, including: participant, researcher, study, and context factors. Third 
part deals with practices and strategies reported by trial staff as important to 
participant retention. These are presented in three categories: minimising participant 
barriers, dealing with study factors, and addressing contextual challenges. All 
categories are divided into their component sub-themes, to allow for an in-depth 
discussion. Interpretations of the themes are accompanied with illustrative extracts 
from the transcripts where appropriate. The quotes are accompanied by the job title 
and order number of the interviewee to provide additional context and to distinguish 
between different participants.  
6.5.3 The complexity of involving patients with schizophrenia in trials 
The impact of schizophrenia symptoms  
A typical presentation of a person with schizophrenia was described by trial researchers 
as characterised by disorganised thinking, apathy, suspiciousness, difficulty with 
opening up, anxiety and tiredness, paranoid thoughts and beliefs and chaotic lifestyle. 
This is similar to the symptomatology presented in medical literature, as described in 
Chapter 2, with most characteristics relevant to negative presentation of schizophrenia. 
Chaotic lifestyle was described as emerging from a combination of chronic mental 
health problems and ‘socio-economic problems’; for instance many patients were 
described as struggling with money, housing, and relationships.  
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Experiencing paranoid thoughts was also a symptom affecting engagement. The 
struggle to use a phone by some patients was seen as an obvious barrier to getting in 
touch with them about research. Suspiciousness and paranoia were also found to 
directly impact how potential participants perceived research, with concerns voiced 
around the use of medical records and being treated as subject of experimentation, for 
example:  
 “I find that there’s a few that don’t [want to take part] and there’s usually valid 
reasons, they’re pretty suspicious because of the psychosis and they just think 
you’re using them as a guinea pig.” (Senior Research Nurse 1) 
“We had some people who were paranoid about medical records, about ‘Oh, 
where are you going to store my data? Is it going to be used by X, Y, and Z?’” 
(Trial Manager 5) 
A distinction in terms of engagement was made based on the type of symptoms. For 
example, Trial Manager 1 noted that patients with negative symptoms were challenging 
to engage in general, but especially in group interventions: 
“[Patients with negative symptoms] are not people that will naturally engage in 
a social environment. So encouraging people to go regularly to an active group 
with people is obviously going to impact upon their attendance in a way that 
patients with other presentations may not.” (Trial Manager 1) 
This symptom-based distinction also revealed disparity in trial professionals’ 
perceptions of the implications of symptoms for participation in research. One view 
was that those with negative symptoms were easier to recruit, compared to those 
experiencing positive symptoms, because of leading less chaotic lives and having more 
availability. Those with a contrasting view discussed the anxiety and lack of motivation 
experienced by those patients as a barrier to engagement. It is difficult to ascertain the 
cause of these two contrasting views but they might be caused by the differences in the 
understanding of schizophrenia or various experiences of working with patients. 
In addition, in case of patients experiencing positive symptoms, Research Assistant 2 
emphasised the importance of the research space in which follow-up assessments were 
carried out. It was important for the researcher to ensure that the environment 
provided limited amount of stimulation outside of the research assessment:  
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“I think it’s just being aware of things that could perpetuate their positive 
symptoms if there was voices in the room or something, other hallucinations 
going on in the room, just making sure that there was space to just sit.” (Senior 
Research Assistant 2) 
In contrast to the challenges experienced by participants, as identified by trial 
researchers, the symptomatology of schizophrenia was not always presented as a 
barrier to participation in trials and many patients were able to engage in research 
activities regardless; for instance: 
“Generally if people have agreed to meet with us, they do turn up and they do 
engage, most of the people engage quite well in the study and the dropout rate 
isn’t that high. So I would say that diagnosis in that sense […] isn’t a huge 
predictor of whether or not someone’s likely to engage.” (Research Assistant 2)  
“I found that the people who actually took part were the ones who had the 
better insight about their illness in a way, so I think that’s, in terms if you’re 
looking at why someone would take part in research, especially if it’s like a 
treatment type of research, I think that insight would probably be up there.” 
(Research Assistant 1) 
However, the second quote seems to suggest that those who decide to take part in 
clinical trials may differ in their presentation (for instance having insight about the 
illness) from those who are prevented from taking part because of the severity of the 
symptoms they experience.   
 
The impact of employment status  
Another distinction was made based on the trial participants’ employment status. 
Unemployed individuals were described as having more time to participate, but also as 
having a more “laissez-faire attitude towards research” (Research Assistant 2). To 
illustrate, Research Assistant 2 described the challenge of engaging participants who 
had the time but lacked the structure to organise their day as “a catch-22”: 
“It’s kind of a catch-22, because the lack of… if somebody’s in unemployment, 
the lack of structure they have to their day means they have more free time to 
do these interviews. But then at the same time I think people who’ve been out 
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of employment for long periods of time, they’re perhaps not as used to having 
structure to their day, and kind of agreeing to be here at this time, on this day 
to do this thing. And so quite often you find participants who have like a very 
laissez-faire attitude towards actually kind of doing the research.” (Research 
Assistant 2) 
On the other hand, those who are able to work had to be met outside of normal working 
hours and researchers needed to be flexible in order to schedule an appointment, with 
some having to offer meetings in the evening or weekends in order to complete follow-
up assessments. Another challenge was contacting participants with jobs during the 
usual working hours, which required researchers to adjust to the participants’ 
particular preferences as much as possible given researchers’ working hours and any 
restrictions imposed by the employing institution.  
Moreover, homelessness at the time of recruitment was recognised as an issue directly 
linked to the higher risk of dropping out and the lower level of engagement in clinical 
trials. These socio-economic issues were described as often resulting in a large 
proportion of patients being difficult to contact as they often lose phones and have little 
contact with family. Consequently, some trials excluded homeless individuals at 
screening. 
 
The impact of illness duration 
A distinction was made between patients who were fairly new to services, often 
experiencing their first episode of psychosis, and therefore more likely to be young, and 
those who were long-term service users. Participants who have experienced only their 
first psychotic episode were described as young, likely to lead chaotic lifestyle and “not 
being that keen on engaging with services in general” (Clinical Psychologist 3). This was 
in contrast to patients with longer illness duration who were more likely to be 
suspicious of staff and to experience delusions. However, despite the suspiciousness, 
these patients were described as motivated to take part in order to use their experience 





The impact of geographical location of the trial 
Another source of diversity noted by interviewees in the context of engagement in 
clinical trials was geographical location of the trial. The ‘type of participant’ varied 
depending on the NHS Trust and the available services. In areas with more specialist 
services there were higher rates of psychosis in secondary services (through which most 
complex intervention trials recruit).  
“What I found in the Trust I was working in [was that it] had high levels of 
psychosis, it was about 60 to 65% of everyone who entered the crisis team had 
one of those [psychotic disorder] diagnoses. […] From talking to colleagues it 
seems that the numbers of people with psychosis who use crisis teams is partly 
affected by what other services are in the borough for people with psychosis.” 
(Research Assistant 4) 
In areas with lower specialist capacity patients would utilise alternative services, such 
as third sector support, which were not always accessible by researchers for the 
purposes of trial recruitment. Availability of services was also described as having an 
impact on the threshold of severity required to access a specific type of service. 
Consequently, it yielded differences in the presentation of trial participants. This bore 
particular relevance to multi-site trials operating across different NHS Trusts with 
different service capacity and therefore with varying rates of patients with psychosis 
eligible to participate in trials.  
  
The impact of researchers and clinicians 
Researchers reported that resilience of patients with schizophrenia was not always 
recognised by mental health professionals. There was a feeling that staff, sometimes 
including trial researchers themselves, can sometimes be defensive and overprotective 
of patients. For example, it was felt that patients with a different diagnosis would have 
been “pushed a bit more” (Trial Manager 2) to complete follow-up assessments. Clinical 
gatekeepers were described as often hesitant to approach eligible patients because of 
the low likelihood of them engaging, a phenomenon widely recognised in the literature 
(Bartlett and Canvin 2003, Patterson et al. 2011, Fletcher et al. 2012, Bucci et al. 2015, 
Joseph et al. 2016). This was referred to as “diagnostic overshadowing” by one of trial 
managers in the example below: 
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“Because of the topic of the project, a big thing that we explore is something 
called diagnostic overshadowing, which you are probably aware of. So when we 
go into GP practices and they say ‘Well, this group don’t engage, what’s the […] 
point of trying?’” (Trial Manager 2) 
Diagnostic overshadowing is generally referred to in the literature as misattribution of 
physical symptoms to mental illness (Nash 2013, Shefer et al. 2014). Nash (2013) argues 
that this phenomenon occurs due to mental health stigma and negative attitudes of 
clinicians and requires education and training. In the example above Trial Manager 2 
uses the term to describe instances where clinicians do not attempt to engage their 
patients in research as they assume their motivation is low due to the diagnosis of 
schizophrenia. This type of gatekeeping was described as potentially preventing some 
patients eligible to take part in trials from even considering this opportunity. 
In the context of risk assessment, people with psychosis were presented as more likely 
to be screened out for risk in trials involving other diagnostic groups. However, the 
approach to risk varied depending on the geographical area. For example, Research 
Assistant 5 reported that screening out certain patients with psychosis was a measure 
to prevent putting strain on those delivering the intervention: 
“If someone has… say had quite unstable periods of psychosis, they 
[gatekeepers] feel that it’s putting the [person who delivers the intervention] at 
risk because they can’t predict what it would be like to go to their house or 
something like that. So they [gatekeepers] tend to screen out people with 
psychosis a lot more.” (Research Assistant 5) 
The candidate observed that the trial staff were careful when discussing their practices, 
making references to good practice and ethical conduct. The importance of applying 
the same, non-stigmatising approach across all populations was emphasised. However, 
a more nuanced picture emerged when specific cases were discussed. It suggested that 
practices could be or were in fact adapted specifically to people with psychosis. As the 
following sections highlight, there are specific complexities associated with dealing 
with people with psychosis as trial participants. 
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6.5.4 Mechanisms of attrition in complex intervention trials 
The interviews revealed the nuances of retention and attrition in trials evaluating 
complex interventions, which were not unique to mental health research. Interviewees 
distinguished between ‘dropout from study’ and ‘dropout from intervention’. Dropout 
from study was referred to as ‘full withdrawal from the study’ and was described as easy 
to define. Dropout at the intervention level was associated with missing data or poor 
attendance. Trial researchers highlighted the difficulty of defining dropout from a 
complex intervention, normally comprising numerous sessions or multiple uses of an 
intervention. Some trials set a specific proportion of attendance or completion required 
to qualify a participant as a ‘completer’, for example the number of attended sessions 
out of all offered sessions. These definitions were however described as arbitrary, given 
the lack of strict rules of what comprises a ‘completed intervention’: 
“I mean to me it’s absolutely clear that there must be a difference and also that 
depends on what you call a completer. If you say someone who completed, a 
therapy completer is one who attended say 75% of the sessions, then the 
numbers would also be different.” (Senior Researcher 2) 
Another nuance of retention was the mechanism of participants communicating the 
decision to drop out. Where patients communicated this directly, researchers had the 
opportunity to explore the reasons for the decision and to offer some options, for 
example full withdrawal versus withdrawal from intervention only. Other mechanisms 
occurred when the decision could not be communicated directly. One such mechanism 
was the inability to contact participants. After making a number of failed attempts to 
get in touch with a participant randomised to the study, the researchers would make a 
decision to withdraw the participant and “send a letter saying that they had to be 
withdrawn” (Research Assistant 1). In addition, in those cases where contact could not 
be made, there was no opportunity to explore the reasons for ceasing involvement. In 
some cases, where researchers could make contact with care coordinators, some 
information about the status of the participant was obtained through those means.  
The involvement of care coordinators also presented a challenge when the decision to 
drop out was communicated through them. This ‘proxy dropout’ was another 
mechanism of communicating dropping out but this was not always seen as acceptable 
by those trial researchers who preferred to discuss the different options available to the 
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participants wanting to drop out. A need for separating the trial and the relationship 
with care coordinators was emphasised in the following extract:  
“The patient might just have a shocking appointment with them […], it might 
be that the care coordinator just thinks that actually this person… they [care 
coordinator] make their own judgement call and that’s not a true withdrawal 
for me.” (Senior Researcher 5)  
This quote illustrates Senior Researcher 5’s discomfort with the decision to withdraw 
from the trial being seemingly made on the basis of the care coordinator’s judgement 
and not the patient’s will. In order to ensure ethical conduct, the researcher felt they 
needed to speak to the patient directly.  
6.5.5 Influential factors in the retention of trial participants with 
schizophrenia 
A number of factors influencing the retention of trial participants were identified by 
trial researchers, with “not any one particular reason that determines a high follow-up 
rate” (Trial Manager 1). These fell into four categories of factors: participant, researcher, 
study, and context.  
The diagram below (Figure 6.1) provides a visual interpretation of the categories of 
factors affecting retention of trial participants in complex intervention trials. The four 
categories are arranged in nested layers that represent various influences on an 
outcome of trial participation. This model was developed inductively based on the 
findings of this qualitative study but similar paradigms appear in the literature. For 
example, the Ecological Theory of Research Participation (Marcellus 2004), discussed 
in Chapter 2, stresses the importance of the interactions between participants and 
researchers, study, and environment. In addition, the theory recognises the influences 
between each layer and how these impact on the retention strategies used in trials.  
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The presentation of findings will begin from the centre of the diagram representing the 
participant-related factors, moving outwards. 
 
 
Category 1: Participant factors 
Participant factors were defined for the purposes of the analysis as inherent 
characteristics, for example gender, age, and diagnosis or attributes in control of the 
participant, for example interest in the intervention.  
Socio-demographic characteristics 
People with schizophrenia were described by trial professionals as very diverse in terms 
of background, with details often unknown to the researcher. When some details were 
known, trial staff were able to comment on the possible relationship of a characteristic 
and engagement in research.  
Age was one characteristic associated with retention. Young patients, especially males, 
were described as most challenging to retain in studies. Some possible explanations for 
this phenomenon were offered by interviewees, including not having a true interest in 







the intervention, being attracted only by the initial incentive, and experiencing a first 
episode of psychosis, leading to the lack of engagement in services or the lack of desire 
to engage. This type of participant was compared to older participants who were 
described as “just quite lonely and stuff, and quite happy to receive a phone call” 
(Research Assistant 7). This finding points to the potential differences in study 
retention based on age of the trial participants; an association that was not found to be 
significant in the meta-analyses presented in Chapters 4 and 5.  
Socio-economic status was another characteristic discussed in interviews. Divergent 
observations were made about its impact on engagement and retention in research. 
One argument was that patients with higher socio-economic status were more engaged 
and showed more interest in research compared to those with lower status. This was 
also echoed in the views that socio-economic status had impact on how much people 
are willing and able to express themselves; something that was attributed to the 
amount of life stressors and perceived assessment burden. It was proposed that those 
who experience a lot of stress might find it difficult to talk in interviews or to think 
about their situation to answer questionnaires and therefore experience assessments as 
challenging. The opposing argument centred on the role of incentives with the 
indication that participants living in deprived areas were more engaged and more 
willing to remain involved in a study if financial incentives were available. This is 
reflected in the following extract, describing people from deprived areas as more willing 
to help:  
 “We have really good engagement from the actual, more deprived areas. When 
I think of [city anonymised] as a map, the [city part anonymised] is notoriously 
deprived and we’ve got really good engagement from people. They were willing 
to help. Whereas in the other areas we wouldn’t get as much engagement. Areas 
with people with more money.” (Research Assistant 11)  
This “good engagement” could be linked to, but was not always directly attributable to, 
monetary incentives. This will be discussed further in the section titled ‘Motivation to 
participate’ on page 125.  
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Understanding of trial procedures 
Explaining (for trial researchers) and understanding (for patients) the concept of 
randomisation in trials presented a challenge. The ability to understand randomisation 
was described as hindered by the symptoms of schizophrenia and side effects of anti-
psychotic medications, for example poor retention of information. When compared to 
those who end up not participating in trials, trial participants were described as having 
better insight about their illness and wanting additional help through participating in 
a trial, for example: 
“I found that the people who actually took part were the ones who had the 
better insight about their illness in a way […] especially if it’s like a treatment 
type of research, I think that insight would probably be up there, you know. 
That’s what I’ve experienced. If they had good insight about…something, you 
know, wanting something extra to help themselves, I found that they were quite 
keen to actually [take part] because they wanted some help. While a lot of 
people [might] not even [be] thinking about the possibility of being helped by 
the… by the research, you know, just a burden in a sense…” (Trial Manager 4) 
Trial professionals’ familiarity with the possible side effects of medication and the 
ability to judge the extent to which a patient is able to understand the information was 
described as necessary to having a de-stigmatising approach. Other issues not directly 
linked to psychosis such as illiteracy and expecting research to be complicated were 
also identified as barriers to understanding randomisation.  
This presented a plausible dilemma for trial researchers. On the one hand, they had to 
make sure that potential participants receive all information about the trial, including 
randomisation, before they could provide informed consent. On the other hand, they 
also needed to make sure that the information was easy to understand, which could 
result in what was described as “downplaying randomisation” (Trial Manager 3) as 
giving all information could “freak them out” (Trial Manager 3). This weighing of good 
practice against the pressure to recruit and retain participants was described as a 
“conflict of interest” (Research Assistant 3).  
In case of the trials evaluating monetary incentives (for example to adhere to 
treatment) it was particularly important for the participants to understand that there 
was an equal chance of being assigned to the intervention and the control arm as this 
125 
 
was directly associated with the total amount received by participants in either arm. A 
manager of a trial evaluating financial incentives provided an example illustrating this 
specific issue:  
“The point is to explain to them that there’s two groups and there’s a 50:50 
chance of them ending up in either of the group and that if they are offered 
incentives, if they stick with the whole period it would be £240.” (Trial Manager 
4) 
One possible solution used by researchers and therapists in order to ensure ethical 
conduct was explaining to participants that the intervention itself may or may not be 
helpful, for example:  
“We’re always absolutely sure that there are no incentives to be in the 
intervention apart from the possibility of the intervention helping. And we, with 
that as well, we don’t say ‘Oh, it’s great’. We sort of say ‘This is helpful for some 
people; this is the way it works. It may be helpful for these things, it may not. 
And it’s up to you whether you want to give it a go.’” (Clinical Psychologist 2) 
Another area of difficulty in understanding the nature of RCTs observed by trial 
researchers was a failure to differentiate between research and treatment, a 
phenomenon recognised in the literature as therapeutic misconception (Henderson et 
al. 2007). This challenge occurred on two levels: staff and treatment. Patients were 
reported to sometimes struggle to make a distinction between research staff and 
clinicians external to the trial. This was exacerbated in studies where patients were 
introduced to a researcher by their care coordinator. On the treatment level, this 
conflation meant that patients did not always understand the difference between trial 
procedures and standard practice. Consequently, having previous negative experience 
of care was found to affect patients’ attitude to research and the likelihood of remaining 
involved in a trial.  
Motivation to participate 
The initial appeal of participation in a trial was considered in the context of retention 
later in the process, connecting the motives for taking part in the first place to making 
decisions about continued participation in an intervention and/or follow-up 
assessments. Patients’ motives to participate identified by trial researchers included 
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having an interest in the intervention, receiving monetary incentives, and altruistic 
reasons. Some of these factors are also described in Section 6.5.6 from the perspective 
of what is offered as an incentive in trials.  
Having an interest in the intervention on offer was considered to be important for 
retention. Those who did not show initial interest in the intervention were found to be 
more difficult to contact after randomisation. Complex intervention trials were 
described as easier to attract potential participants to, compared to pharmacological 
studies, given that patients were assured about the non-pharmacological nature of the 
treatment they would receive, for example:  
“A lot of people worried about research thinking it’s drugs, so [it was important] 
to go in and explain that we wouldn’t be changing their medication and we 
wouldn’t be getting them to do anything extra medication-wise.” (Clinical 
Psychologist 1) 
As the quote above illustrates, this attitude to trial participation was explained by the 
patients’ hesitation to either take medication or to change current pharmacotherapy 
and pointed to the potential appeal of complex interventions.  
An interesting aspect of motivation by treatment was the difference between the active 
and control conditions. While having an interest in the intervention applied to both 
active and control condition in the context of retention, trial researchers highlighted 
that the active arm could be expected to have higher retention rates compared to the 
control arm, especially given that most complex intervention trials offer ‘treatment as 
usual’. This was in line with the findings of the IPD-MA presented in Chapter 5. One 
explanation offered for this phenomenon was more contact with staff and therapists 
for those in the active arm, resulting in more commitment and identification with the 
trial as a participant for this group. The following excerpt illustrates this explanation:  
“If someone’s allocated to therapy they have potentially weekly input from 
someone in our team, in which case I suppose more contact with their team 
would be beneficial in order to kind of maintain that relationship. And that is 
encouraged but understood to not always be feasible considering the 




Moreover, it was implied that a lot of complex interventions focused on patients’ goals, 
which could potentially result in better engagement and higher retention. One 
highlighted exception was some participants preferred to be randomised to control 
treatment as they were openly motivated by monetary incentives and preferred the 
lowest level of involvement possible; an option offered by the control condition.   
Some patients were described as motivated by receiving compensation for 
participation. Trial researchers also described instances of patients expecting to be paid 
for taking part in the intervention. However, in most trials, with the exception of those 
evaluating monetary incentives in mental health care, participants received payment 
for completing assessments and not for attending or completing the intervention. 
Paying for attending treatment sessions was discussed as a hypothetical option to 
increase retention at the intervention level but this was dismissed due to two reasons: 
first, it was seen as unfair to the participants randomised to the control group; and 
second, it was argued to potentially interfere with any effect of the intervention as any 
changes in outcome measures could then be attributed to the effect of money.  
In most trials participants were offered money or vouchers for completing an 
assessment. Some researchers described either themselves or clinical gatekeepers 
explicitly mentioning payment to entice patients to complete follow-up, although 
caution was applied when discussing the monetary incentives due to potential coercion 
and the concern around participation only because of being offered money, as 
illustrated in the following excerpt:  
 “I think [offering monetary incentives is] so much better. I think for the person 
taking part. But I do think there’s a big element of coercion and many people 
will take part simply because of the money. So the one that I’m particularly 
involved in is an inpatient one where quite often they have limited access to 
funds. And so £5 can mean a pack of cigarettes and it’s quite, it’s quite important 
to them. People will outright say, you know, ‘Do I get money for this?’” (Clinical 
Studies Officer 1) 
Money was explicitly described as a motivating factor for retention, with some 
exceptions involving refusal of compensation. It was also seen as an opportunity for 
researchers to directly and tangibly express gratitude to participants for their time and 
effort. The motivational aspect of money was in some cases explained by the difficult 
financial situation experienced by people with psychosis. Trial researchers’ descriptions 
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suggested that this population often receives benefits, lives in deprived areas, or 
struggles financially and so the payment from the trial can be helpful:  
“So people get £20 for questionnaires at baseline and again at follow-up. I do 
think there are some people who do it just to get the 20 quid. Which I think 
given the client group is quite understandable. For some people 20 quid is a lot 
of money.” (Research Assistant 4) 
Some potential implications of money being the main motivation for trial participation 
were discussed. The implications included reliability of follow-up data, impact on 
therapy, and impact on retention. Trial researchers indicated that in cases where money 
is the main or sole motivator participation can lack meaningful engagement and there 
is also a risk of coercion. This echoes previous findings showing that participants 
motivated mainly by compensation were more likely to not adhere to treatment and to 
drop out (Gross et al. 2001). A sign of this type of motivation described by interviewees 
included repetitive and dismissive in tone responses to (often long) questionnaires. In 
addition, working with trial participants motivated by money was described as a 
potential therapeutic challenge as it can distract from the goals of the intervention, for 
instance: 
“And there’s the group who just want money or… that’d… personally that’d be 
tricky, that’d be very tricky to find a goal to work on then.” (Clinical 
Psychologist 3)  
Despite money being identified as the main influence, altruism was another motivating 
factor for taking part in trials. This was especially evident in instances described by trial 
researchers where participants refused payment, explaining that their intrinsic 
motivation was to help. Altruistic motives were also presented as a potential means of 
encouraging participants to remain involved in a trial. Researchers appealed to the 
participants’ sense of selflessness by emphasising how their involvement in the trial will 
potentially help other people, for example: 
“I always try to stress that, you know, their views now may help other people, 
you know, who may experience their participation to help other people, who 
may experience similar problems.” (Research Assistant 1) 
“But some of the things I might say is that, you know, ‘[…] I know I’m not 
allowed to know whether you got the group or not, but either way I just want 
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to thank you for your time because even if didn’t get the group, your 
participation and your scores and results will help towards the… see whether 
this intervention’s effective and it will be able to help people’s lives in the future, 
hopefully’. So I kind of try and kind of say something like that as well, because 
you know, I do sometimes feel it is hard.” (Research Assistant 3) 
In addition to money and altruism being appealing factors when considering 
participation, receiving an intervention and seeing it through to the end was also 
described as a motivator. This view however was described as not always shared by 
participants, especially those expecting to receive payment for attending intervention 
sessions.  
Some trials offered other benefits associated with being in the intervention arm, such 
as transport to the sessions, materials, gadgets or snacks. Trial researchers considered 
these as incentives. However, given the design of an RCT, not all participants receive 
the intervention under evaluation and some are randomised to the control group, often 
with treatment as usual. Not being able to offer an intervention to everyone in a study 
was seen as problematic for researchers wanting to offer it to everyone. This dilemma 
is illustrated in the following quote: 
“I find randomised control trials, I think all of us would agree that sometimes 
we’re like ‘Argh, I wish we could offer it to everybody but we can’t, and there’s 
the chances. A lot of people I know as well, just as conscious human beings, you 
don’t want to disappoint people, and it is quite hard sometimes to kind of 
explain and say ‘You might not get it, I know your care coordinator might have 
told you about this wonderful intervention, but actually there's only a 50% 
chance.” (Research Assistant 3) 
The above quote illustrates the concern of Research Assistant 3 about the satisfaction 
of participants with the outcome of their allocation to treatment and shows how the 
initial expectations need to be managed when explaining how randomisation works, 
especially for those motivated by the prospect of receiving an intervention.  
Barriers to retention 
Poor health or wellbeing was provided as a potential factor negatively affecting 
retention. It was not always made clear to trial researchers by trial participants whether 
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the issues related to physical or mental health but in a lot of instances it was due to 
fluctuations in mental health or negative symptoms of schizophrenia.   
“I think it could be mental illness symptoms getting worse and so they’re not 
really in a mental state that means that they can consent to carry on with the 
research.” (Research Assistant 2) 
Another factor identified as a barrier to retention was losing interest in the intervention 
or in the study as a whole. Exploration of this issue, especially in regards to the 
differences between participants randomised to the active versus control arm, was 
limited in this study as majority of interviewees were blinded to the allocation. 
However, the following quote illustrates this type of challenge:  
“I remember there was a subset of people who were recruited to the trial and 
you were randomised to the intervention and you had absolutely no interest in 
doing the intervention whatsoever. We’d call them every week and they 
wouldn’t pick up or they would pick up and make an excuse.” (Research 
Assistant 7) 
Lack of time was a common reason for dropping out provided by patients. This was 
sometimes linked to a change in circumstances and taking on new responsibilities, for 
instance childcare, college, and work), which prevented participants from being able to 
keep to their commitment to appointments, for example:  
 “Some people are like ‘I’ve gone back to work and I’m just too busy’. We do 
offer to do weekends and evenings so it’s a bit, you know, some people when 
they’re back in work are just like ‘I just wanna get on with work now.’” (Research 
Assistant 5)  
 “They’ve come up with certain excuses… well; one person says he now has to 
look after his child on that day when his partner goes to work, so he can’t come.” 
(Research Nurse 1) 
 
Like with losing interest, the explanation of this factor by trial participants was vague 
due to blinding and prevented the trial researchers from elaborating on the matter.  
The tendency to lose phones and forget appointments was presented as a barrier to 
retention, for example: 
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“With people with psychosis […] in general, not tied to any age, they tend to 
lose their phones and they tend to forget appointments even if you send them 
a text message right before the intervention […]. I basically think that they 
change their phone numbers so often it’s unbelievable.” (Senior Researcher 1) 
This forgetfulness and frequent changes of contact details were described as 
consequences of a chaotic lifestyle, discussed earlier in Section 6.5.3 , making it difficult 
to contact participants after they have lost their phones and were also often estranged 
from their families, precluding this as an alternative way of getting in touch.  
 
Category 2: Researcher factors 
Rapport between researcher and participant 
Establishing a good rapport with trial participants, among other factors like the 
usefulness of an intervention and researcher’s skills, was discussed as key to 
engagement and retention. Having a good relationship led to establishing trust and this 
in turn increased the chance of people completing a follow-up assessment.  
“I think [what] relates to having a good relationship with the patient, and if they 
generally liked you as a researcher, [is] the way you explain the information, all 
of that, and they have that level of trust, chance are they’re happy to come back 
and do a second interview.” (Trial Manager 3) 
This was seen as a skill and something that some researchers were better at than others. 
The valuable skills included mirroring participants’ language, creating a supportive 
environment where participants felt listened to, informing participants about their 
rights, and sharing some personal information to establish rapport and to have 
something to talk about at the next interview. Power dynamics were considered 
important and establishing an equal relationship with a shared goal was seen as 
desirable. This was achieved by being clear about what trial participation involved, 
empowering individuals by telling them about their right to withdraw or to refuse to 
answer a particular question, informing them about the goal of research and showing 
gratitude for their time and input. Work culture at the level of trial unit was presented 
as an external force that defined the values underpinning research, especially when it 
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was driven by empathy, recovery, and empowerment. However, one factor impeding 
rapport was the tension between a target-driven culture of trials and the importance of 
building relationships with participants involved in longitudinal research. For instance, 
researchers were under pressure to complete assessments efficiently, allow the time to 
listen to people and build rapport, but also to avoid assessment fatigue with prolonged 
and frequent meetings. The challenge of juggling these responsibilities is illustrated in 
the following quote:  
“It’s important to sort of build the trust first and I think that (…) the amount of 
work that it can often take for people to, it can be quite substantial. I think it’s 
hard to build that into a modern research project cause, you know, it’s so target-
driven nowadays, you’re trying to get as many people as possible to justify the 
numbers you promised in the grant because you kind of want more and more 
impact, knowledge exchange and all these wonderful words on the back of the 
research but the practicality side of it is, there is a lot of stress on the research 
team to not maybe to spend the time they might want to just building the core 
and I think the soft skills I would say are very vital in quality research. Maybe 
they should focus more on quality not so much on quantity with evaluating how 
the study went on.” (Senior Researcher 3) 
Another factor affecting rapport was researcher continuity. In trials where researchers 
were assigned to a particular participant this practice was described as enabling 
building relationships and ensuring retention because participants “know the deal, they 
know who you are. Once they are engaged in the process, they’re easy to maintain, to 
retain in the study” (Trial Manager 1). Maintaining continuity was found to decrease 
anxiety about meeting a stranger who asks personal questions. Researcher continuity 
across assessments was a factor that was not in the direct control of trial researchers 
and often depended either on the study design decided by the PI and the management 
team, or on the rate of trial staff turnover. There were also pragmatic reasons for 
maintaining the consistency of the researcher, including researchers being assigned to 
a specific geographical location and therefore being the default researcher to complete 
an assessment with patients based in that area. 
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Researchers’ persistence  
Being persistent with approaching participants for follow-up assessments was 
discussed as an important trait of effective researchers. The degree to which researchers 
felt confident in their persistence varied. One approach was to “contact people pretty 
relentlessly” (Research Assistant 2) and not stop until the participant has been 
contacted. Often different means of contact were used, such as phone calls, letters, and 
contact via care coordinator until all options have been exhausted. A more relaxed 
approach involved trying but also considering when it was appropriate to give up. This 
was a grey area requiring judgement calls made on an ad-hoc basis, for example: 
“But sometimes people just don’t want to talk to you [laughter], so you need to 
give up at some point, otherwise you’re stalking them [laughter].” (Clinical 
Psychologist 1) 
“So we have… there is this thing about so how many times should you contact 
someone before the interview? And then should you give up? So that’s a trick 
question.” (Senior Researcher 1) 
The first quote, although expressed humorously, suggests a certain level of discomfort 
experienced by the therapist with putting too much pressure on nonresponsive 
participants. It also raises a question about the limit of pressure to be put on 
participants to remain in a study, as expressed in the second quote. The data show it is 
a matter of judgement of individual researchers, putting the responsibility for the 
ethical and yet effective conduct in their hands.  
 
Category 3: Study factors 
Consistency of procedures 
Having clearly defined systems and procedures was identified as important for ensuring 
retention. This involved both externally- and internally-oriented procedures. 
Externally-oriented procedures included what was communicated to participants in 
terms of their involvement, process and their expectations, for instance provision of 
transport to intervention sessions, reimbursement, and number of follow-up 
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appointments. Making participants aware from the outset about the procedures was 
described as helpful in increasing the chances of them remaining in a study. Internally 
oriented procedures comprised maintaining efficient systems for facilitating 
appointments and reminders about them. This included therapists recording 
intervention attendance, for example:   
“We’ve created a database of all the sessions attended and the session 
adherence, tick boxes as variables. So we will know by the end of the trial how 
many sessions people have completed. In a sense of who’s had a good dose if 
you like. It’s probably not the best term, a good amount of sessions.” (Clinical 
Psychologist 3) 
The level of details kept in study databases varied, with some trials recording detailed 
notes about each participant and each contact made with them and others leaving this 
up to individual researchers.  
Experience of assessment 
The extent to which participants enjoyed assessments was described as important for 
retention. Factors facilitating retention included positive experience of the first 
assessment, and enjoyment of receiving the attention and time of a researcher. An 
enjoyable first meeting or assessment was described as likely to encourage trial 
participants to meet with the researcher again and complete follow-up assessment: 
“I think it really depends on their experience at baseline and whether they 
actually want to do the follow-up […] So as long as the first one has gone fine I 
think the second one isn’t something that people will actually worry about.” 
(Research Assistant 5) 
In contrast, what impeded retention was assessment burden caused by using numerous 
outcome measures. This was especially pronounced in the cases where patients 
struggled with literacy and consequently found questionnaires especially challenging, 
for instance: 
“The person who did drop out just struggled with reading and writing. So the 
idea of being confronted with lots of paperwork I think was quite scary for her.” 
(Senior Researcher 5) 
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 Having shorter follow-up appointments increased the chances of patients completing 
them more fully and also returning to a subsequent appointment. Another potential 
issue was described as interview burden, where participants were asked personal 
questions, increasing the intensity of the assessment. Having to answer a lot of personal 
questions about one’s illness or quality of life made some trial participants emotional 
or tense, which led to them to weighing up the effort against the reimbursement on 
offer and, in some cases, withdrawing from the trial.  
“I do remember one or two people I did a baseline with them and then they 
were getting emotional throughout the interview and then they decided that 
they didn’t want to do it there and then […] and I think that it largely arose from 
questionnaires like the MANSA [Manchester Short Assessment of Quality of 
Life] which are really, really… it’s like a stranger coming in and asking you, you 
know, ‘Do you feel guilty about things? Do you have regrets about the past?’, all 
of that. It’s quite intensive.” (Research Assistant 8) 
In addition to the intensity of the follow-up interview, the nature of the questions in 
some questionnaires or interviews could be quite invasive and personal, although the 
extent to which participants and researchers could perceive this as problematic can be 
expected to vary depending on personal views and cultural background. 
Experience of intervention 
The willingness to remain involved in a trial was discussed in the context of the 
interventions offered to patients. The relationship between the experience of 
intervention and study retention spun beyond mere enjoyment. There were aspects 
associated with attending intervention sessions that were identified as catalysts for 
drop out, including inconvenient location of therapy sessions, lack of reliable transport, 
disliking group interventions, and anxiety associated with attending therapy. Group 
interventions in particular presented a challenge for participants who found them 
anxiety provoking. Group interventions also tend to offer less flexibility than individual 
sessions, which only need to consider two people’s availability. A potential consequence 
of the lack of flexibility with rearranging times is increased non-attendance and non-




“[Offering flexibility with assessments] may also explain why our treatment 
group attendants were so much lower than our assessment attendants, cause 
obviously we couldn’t really be flexible with the groups because it’s group 
intervention. The rooms are booked, everyone has to come at that time.” (Trial 
Manager 1) 
Intermittent attendance and missed appointments were presented as common issues, 
echoing previous trial reports and methodological literature (Barrowclough et al. 2009, 
2010, Swift and Greenberg 2012, Fouad et al. 2014).  
Similarly to when motivation to participation was considered (see section titled 
“Motivation to participate” above), interventions were experienced differently by those 
in the active arm and patients receiving in the control condition. Participants in the 
active arm are often expected to attend more appointments, especially in trials 
evaluating talking therapies. This naturally results in more opportunities for missing 
sessions or dropping out “because they’re having to go to their intervention 
appointments as well as do the follow-ups” (Trial Manager 2). On the other hand, they 
have more contact with staff and have higher level of engagement, which was described 
as aiding retention.   
Trial participants were usually still offered to complete follow-up assessments even if 
they disengaged from the intervention, which is in line with the ITT analysis (discussed 
in section 2.4.2, p.33). In trials where researchers were blinded to the allocation 
dropping out of the intervention would often not come up as an issue as follow-up 
assessments would be completed in complete separation to intervention sessions.  
 
Category 4: Context factors 
Organisational factors 
The level of overall research activity in trial sites was discussed as a factor impacting on 
retention. Areas with a lot of research activity were described as having the grounds for 
running a successful trial due to staff experience and familiarity with the trial processes. 
Clinicians and other mental health professionals who often act as gatekeepers during 
recruitment were also found to be important in keeping patients involved in trials, alas 
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not always helpful. This emphasised the importance of researchers making an effort to 
build relationships at the recruitment phase that could carry on until the trial end, or 
even beyond. It was however highlighted that in areas with high research activity 
gatekeepers can be “desensitised to people coming in and being engaged in research” 
(Trial Manager 1). This phenomenon was referred to as ‘research burden’ and applied 
also to patients who were potential trial participants and who would be approached 
about research numerous times.   
Organisational culture was a factor permeating trial researchers’ accounts. This was 
identified at two levels: the internal organisational culture and the culture of other 
organisations involved in trials, in most cases the NHS. Successful retention was 
attributed to flexible and accommodating culture of trial teams, but also to good 
reputation built over time. There was criticism of the ‘target culture’ resulting in 
consenting and retaining patients who should not be involved in trials. When 
considering the cultures of other organisations, trial researchers’ experiences ranged 
from liaising with supportive care coordinators who would remind their patients about 
trial appointments at one extreme, to dealing with “old-fashioned attitudes towards 
research” (Senior Research Nurse 1) of clinicians, discouraging patients with 
schizophrenia from taking part in trials in case it would destabilise them.  
Geographical factors 
A number of factors affecting retention related to the geographical location of the trial 
operations or the intervention delivery were identified.  
Transport presented a challenge for patients needing to travel to sessions or 
appointments over long distances or experiencing issues with using public transport in 
terms of cost, location of stops and stations, frequency, etc. These issues were 
pronounced in trials involving group interventions, which required a centrally located 
venue. Patients experiencing negative symptoms and leading chaotic lifestyles were 
identified as particularly struggling with transport to interventions and appointments 
and therefore more likely to drop out. The mobility of patients presented an issue at a 
different scale depending on the type of geographical area. Trial sites located in cities 
were described as more likely to observe high mobility and frequent changes in 
circumstances, especially high turnover of patients and staff, whereas small cities and 
rural areas did not experience it to the same extent.  
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“I know in [city anonymised] [retention is] even more problematic than maybe 
here in [city anonymised] and in small communities. And I remember in [city 
anonymised] when I was involved in observational studies, not in a trial, it was 
so, so difficult to follow patients because basically they were moving all [the] 
time, et cetera. My feeling is it’s much easier kind of in small areas like small 
communities like [city anonymised] and also in rural areas, but it still happens.” 
(Senior Researcher 1) 
Participants moving away from the original location presented an issue, with the extent 
of the problem depending on the new location. It was not always possible for 
researchers to travel to new locations and this resulted in an automatic exclusion of 
those participants even if they were willing to provide follow-up data. Researchers who 
worked directly with participants highlighted limited resources and needing to check 
any decision about going to the participant with a more senior member of the team.  
Another factor contributing to the geographical limitations was the need to conduct 
follow-up assessments in person. This was often dictated by the nature of outcome 
measures, for example the BPRS described by Research Assistant 2:  
 “Some of the way the interview is scored is like using measures like the BPRS, which 
means that you have to be able to like see the person to do the interview with them. 
It’s not really something you can do over the phone or whatever.” (Research 
Assistant 2) 
The inclusion of observational measures in the study protocol often automatically 
required a face-to-face appointment, even if there were other measures that could have 
been completed independently by the participants who moved away.  
6.5.6 Practices and strategies for participant retention 
The previous section presented the findings pertaining to the factors influential in 
retaining trial participants organised into four categories: participant, researcher, 
study, and context. This section will focus on the ways in which trial researchers 
manage participant retention and how they address some of the issues they identify as 
key to retention. These are organised into three categories, which correspond to the 
139 
 
issues presented in the previous section. Participant and researcher factors are 
discussed together as they are difficult to disentangle in the context of trial practice.  
 
Category 1: Minimising participant and researcher barriers 
Negotiating exit 
As discussed in section 6.5.4, there are different mechanisms of participants dropping 
out of trials and communicating this decision. In situations where the decision to 
withdraw was communicated directly to researchers, it presented an opportunity to 
present available options to the participants. For example, for those wanting to drop 
out of the intervention there was the option to remain involved in the study and have 
data collected either directly in follow-up appointments or indirectly from medical 
records:  
“We train our researchers if you have a patient who doesn’t want to be involved 
in the study anymore, accept it, absolutely, and it’s up to them, they have right 
for that, but try to introduce this conversation with them and find out what are 
the reasons and because it is important for us as researchers to know that and 
especially for the randomised controlled trials. And it is important whether, to 
find out whether they don’t want to be interviewed in that time point, but you 
can come back in the next time point; whether they don’t want to be 
interviewed at all but you can collect data from their medical records. So all this 
stuff is important because you don’t actually want to have missing data.” (Senior 
Researcher 1) 
The practice of discussing the reasons for the decision to drop out varied. Three main 
approaches were identified in trial researchers’ accounts. The first was recording this 
information routinely, if the participant was willing to provide it. This was facilitated 
by a system providing space for storing these data about attrition. The second approach 
was not requesting the reason for withdrawal. This was explained by low rates of 
attrition and, as a result, lack of interest in understanding why such a small proportion 
of participants decided to withdraw. Third was an ad-hoc approach allowing 
researchers to make a judgement about whether to explore the reasons or accept the 
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decision without trying to understand the underlying causes. This was especially 
applicable in cases of participants experiencing health fluctuations. Those individuals 
were described as not wanting to make a decision to drop out entirely and so, if 
possible, researchers would offer to contact them again at a later data. This rendered 
the option of returning to the study or the intervention at a later point.    
In scenarios where the conversation about the decision was opened, trial researchers 
described their careful attempts to negotiate participants' exit. Interviewees 
emphasised the importance of ethical conduct when trying to convince patients to 
remain involved in a trial and presenting them with alternatives to a complete 
withdrawal: 
“I may just say one last time that what the importance of that study was and 
what it would mean to us if they carried on and that we’re really grateful that 
they’ve already given up their time and we’d make it as, least intrusive as 
possible by coming to their home at whatever time they like. But one… if it’s 
still a no, then you just have to say no – I mean agree and help them.“ (Clinical 
Studies Officer 1) 
This commitment to ethical conduct was also emphasised when talking about trials 
collecting data from medical records, often in addition to data collected in follow-up 
appointments. In those studies participants consented to researchers accessing their 
records for the duration of the study. Discontinuing an intervention or refusing follow-
up did not automatically withdraw the initial consent to medical records access. 
However, trial researchers considered it good practice to remind participants about this 
fact and ask them to re-confirm if they are happy for their medical records to be 
accessed for the purposes of collecting data without their involvement. 
The data suggest that researchers were aware of good practice, but there was an 
element of judgement when it came to deciding whether or not to negotiate different 
withdrawal options with the participant or not.  
The importance of adaptability 
The ad-hoc approach outlined in the previous section is one example of researchers 
adapting processes to suit the participant and help them to remain in the study if they 
are willing to do so. Trial researchers who emphasised the importance of adaptability 
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discussed the importance of understanding schizophrenia and its symptoms. Having 
an appreciation of what the patients were experiencing was described as helpful in 
interpreting their behaviour and responding appropriately. Examples of situations 
requiring adaptation of standard procedures included participants never answering the 
phone the first time it rang, struggling to complete a questionnaire or an interview 
when hearing voices, or being worried about sharing personal information. This view 
was however accompanied by caveats about non-stigmatising approaches to dealing 
with people with schizophrenia, juxtaposed to the medical model of dealing with 
patients:  
“I think in services so much of the time they’re seen as their diagnosis; they’re 
seen as a number, whereas [in research] you get to communicate to that person 
on that person to person level…” (Trial Manager 5)  
When considering adaptations, trial researchers recognised three types of triggers: 
risks, needs, and preferences. Assessing participants’ needs and risks at the beginning 
of the trial was identified as “quite important to learn a little bit about that person and 
how they like to be approached” (Research Assistant 10). This was done either directly 
with the participant, with their clinician or via medical records. Different types of needs 
were recognised, including logistical issues with organising time and getting 
participants to appointments, physical health issues, and anxiety. Risks were 
particularly relevant to interventions requiring physical activity (for example body 
psychotherapy) but also were routinely considered for the safety of both patients and 
researchers meeting face-to-face to complete follow-up assessments. Identifying those 
needs and risks allowed researchers to make necessary adjustments to enable patients 
to participate and remain involved in the trial, for example asking care workers to help 
patients living in sheltered housing with getting organised for appointments, allowing 
anxious patients to attend appointments with a support person, organising taxi 
transport to intervention sessions, and sending text reminders before each session.  
Preferences presented a different type of trigger, which required an element of 
judgement on behalf of trial staff due to requiring additional resources. Examples of 
specific requests included a preference for the researcher’s gender, seeing the same 
researcher throughout the study, receiving letters instead of phone calls or texts, 
meeting in specific locations, and being called from a mobile showing caller’s number 
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(as opposed to a hidden number often imposed on researchers by their employing 
organisation).   
Empowering the participant with information 
In line with the non-stigmatising approach, trial researchers discussed the importance 
of equipping participants with sufficient information about the study, including their 
rights, to make decisions about their involvement at and beyond recruitment. Whilst 
all trials were subject to ethical scrutiny and consequential procedures, the extent to 
which these were followed through and communicated to participants was described 
as controlled by the researchers. This required careful judgement about the level of 
detail to be given to participants, especially in the context of explaining randomisation, 
for example: 
“Some people ask if they can be randomised again [laughter] […] If someone 
isn’t used to the idea of an RCT then it’s kind of hard explaining how it kind of 
works.” (Research Assistant 9)  
As discussed in the section titled ‘Understanding of trial procedures’ on page 124, this 
aspect presents particular challenges for both researchers and participants. Researchers 
identified the following practices to overcome this challenge: investing time to explain 
the study, using videos to accompany written information sheets, organising an event 
for participants to inform them about the research, and involving service users to 
present the study.   
Reminding participants about incentives 
As already discussed in the section titled ‘Motivation to participate’ on page 125, trial 
researchers identified incentives as a motivating factor for participants as they offer 
something in exchange for their time and effort. Bearing this in mind, researchers 
admitted to mentioning money as soon as possible when contacting participants about 
a follow-up either by phone or text. Other incentives offered to participants included 





Category 2: Dealing with study factors  
Study-related barriers presented a challenge that was more in control of trial 
researchers compared to participant and context factors. This control was applied 
throughout the duration of the project and will be presented chronologically.  
Study design  
When designing a study, it was possible to improve retention by planning closely 
spaced appointments. This was argued to decrease the risk of forgetting about them. 
Another strategy applied at that stage of the study was planning to recruit over the 
required sample size. Over-recruiting was put in place “to allow for attrition” (Research 
Assistant 3) as trial researchers expected patients to drop out at some point. In trials 
evaluating group interventions these included running additional groups to help 
“against the possibility we may have slightly higher dropout at six months than we 
thought we would” (Trial Manager 1). 
Recruitment; reaching beyond the low hanging fruit 
Researchers described it as common practice to take consent to follow-up at baseline. 
Depending on the trial, this also could have given researchers access to medical records 
even if a patient stopped attending intervention sessions and follow-up appointments. 
A common recruitment strategy described by trial researchers was using multiple 
services to access potential participants, “with the idea that we basically get the low 
hanging fruit as it were, relatively easy people to recruit and then we move on” (Trial 
Manager 4). Selecting trial participants on the basis of their commitment was at odds 
with the pressure on recruiting sufficient numbers of patients and avoiding a biased 
sample, nonetheless trial researchers proposed it as one potential strategy to aid 
retention. Screening meetings were found to serve as “a good indicator if people […] 
weren’t really gonna turn up for the three assessments and potentially therapy” 
(Clinical Psychologist 1). However, this was described only as a hypothetical option 
requiring further investigation, rather than actual practice.  
Another retention strategy linked to recruitment was particularly relevant to group 
interventions requiring bringing a number of patients together, namely arranging 
interventions as close to randomisation as possible. This was explained by preventing 
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loss of interest between the point of trial entry and start of intervention, so “that people 
are still interested, don’t change their mind, don’t lose contact” (Research Assistant 3). 
Trial researchers found this challenging but also important for minimising loss of 
participants prior to intervention start.  
Intervention 
The way participants in the active arm experienced an intervention was described as 
central to retention. However, researchers had little control over the extent to which 
patients enjoyed the interventions and therefore their focus was on offering flexible 
arrangements. This included, for example, always welcoming back participants who 
have missed sessions or even offering therapy breaks if needed:  
 “In terms of study retention I think we did a really good job there actually. In 
terms of treatment retention, I don’t think we were quite as systematic in the 
level of support that we provided patients to attend groups, and particularly at 
the beginning cause I think that was, it was a bit of a learning process as to what 
the logistical issues might be and then how we would help to resolve them.” 
(Trial Manager 1)  
As the above quote illustrates, the flexibility was not always a carefully planned strategy 
and was a result of a “learning process”.  
Follow-up assessments 
Ensuring retention at the study level offered the most scope for control, both in terms 
of managing resources and conduct of assessments. Resources were managed in two 
ways: prioritising retention by blocking out time to focus only on arranging follow-up 
assessments and moving staff to sites requiring help with follow-up assessments. The 
main theme permeating the conduct of assessments was flexibility. Trial researchers 
emphasised the importance of having a person-centred approach focused on finding 
out the particular barriers experienced by an individual and investing effort into 
coming up with a suitable strategy that would enable the participant to be retained in 
the study.  
The first assessment strategy was flexibility with the timing of the appointments, linked 
to adaptability discussed in the ‘The importance of adaptability’ section on page 140. 
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For researchers, this often meant meeting participants in the early mornings, evenings 
or weekends. As a result, this enabled those patients who were in full-time employment 
or had other commitments to remain involved, for example: 
“So they would, if they got a job, they couldn’t see us during the hours of 9 to 5, 
so we had to stretch to evenings or weekends. So we would do that.” (Senior 
Researcher 1)  
Although, it is important to note that this strategy did not guarantee better retention 
in all cases: 
“And then some people are like ‘I’ve gone back to work and I’m just too busy’. 
We do offer to do weekends and evenings so it’s a bit, you know, some people 
when they’re back in work are just like ‘I just wanna get on with work now.’” 
(Research Assistant 5) 
The second strategy involved using alternative venues for appointments. Usual practice 
was to either see patients in their usual community services or at home. However, some 
participants preferred to meet in a more neutral space, such as a park, pub, or a coffee 
shop. The third strategy involved selectivity when choosing outcome measures for 
follow-up for patients struggling with completing numerous questionnaires. 
Assessment burden due to the number of and/or intrusive nature of questions can have 
negative impact on the decisions to remain involved in a trial (Gross and Fogg 2001).  
Achieving continued interest with regular contact 
The main ways in which trial researchers ensured continued interest was sending 
reminders and staying in touch. The strategies varied across trials from a structured 
approach with “a little hierarchy that we tried calling at least three times, if that didn’t 
work we’d send letters” (Trial Manager 5) to a more ad-hoc approach “reflective of their 
attendance as opposed to this will be something that we’ll prescriptively do to everyone 
from the beginning” (Trial Manager 1). A participant-centred approach was taken in 
trials where reminders were tailored to specific preferences of a participant. This was 
especially important for people who did not like to use telephones but still needed to 
be reminded about an upcoming appointment.  
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Six means of reminding participants about their appointments were identified in trial 
researchers’ accounts: phone calls, text messages, e-mails, letters, cards, and 
newsletters. Despite the widespread use of mobile phones and general departure from 
postal communication, letters with the details of the appointment were found to be 
effective. This was attributed to patients being used to receiving such letters from the 
NHS, although this was an interesting observation given the high non-attendance rates 
reported in mental health services in the UK (Stone et al. 1999, Department of Health 
2003, Mitchell and Selmes 2007).   
Regular reminders were also identified by interviewees as central to “personal 
engagement, reducing burden on people [achieved by] warm and empathetic listening 
stance and giving people time” (Research Assistant 10). This approach was however in 
contrast to sending text messages, a method preferred by participants who “couldn’t 
quite bring up the courage or the motivation to talk” (Clinical Psychologist 1). This 
discrepancy in strategy highlighted the importance of participant-centred approach, 
putting participant needs at the core and having a repertoire of strategies to choose 
from when getting in touch. In addition to reminders about specific appointments, 
contact was also made in trials involving telephone follow-up and in between 
intervention sessions contact (also described as “an economic measure” by Research 
Assistant 11). Two purposes of these types of contacts were identified: completion of a 
trial procedure and keeping in touch.  
“A member of our trial steering committee who suggested that [study 
newsletter] is a good way of improving retention basically said it’s a way of 
thanking people for their time and effort in the trial really does improve people’s 
willingness to kind of engage basically.” (Trial Manager 4) 
Thanking participants for their involvement, mainly through newsletters and cards, 
like in the quote above, was described as a retention strategy within a trial but also as 







Category 3: Addressing contextual challenges 
As outlined in section 6.5.5. two types of contextual factors influencing retention in 
trials included organisational and geographical aspects. Ways of addressing these will 
be presented in turn.  
Liaison with care coordinators 
The extent to which trial researchers were able to affect the organisational factors was 
limited and involved mainly liaising with care coordinators based in the NHS. The 
liaison was described as key to good retention and requiring long-run effort as: 
 “That sort of trust and relationship seem to build up over the years, [it] helps 
the study retain patients that maybe other studies may not get to if they were 
sort of starting afresh, building up these pathways.” (Senior Researcher 3)  
Liaising with care coordinators served the following functions: seeking advice about 
retaining particular patients, contacting patients through care coordinators, getting 
information about trial participants, asking care coordinators to remind patients about 
appointments or to encourage them to contact researchers, and receiving updates 
about patients.   
Working against geography 
As discussed in the section ‘Geographical factors’ on page 137, trial researchers 
experienced issues with participants’ mobility and location. These became even more 
pronounced when using observational measures. Ways in which trial researchers dealt 
with those issues included six preventive strategies.  
The first strategy was applied at the recruitment stage of the trials and involved 
excluding homeless individuals when screening. These patients were described as “very 
transient” (Trial Manager 4) and therefore at high risk of dropping out of a trial. The 
awareness of high mobility of patients with schizophrenia led to two strategies applied 
at baseline assessment: recording alternative contact details and providing researcher’s 
details to participants. The former was a simple task but it provided researchers with 
“more avenues to get hold of [participants]” (Trial Manager 4). This was achieved by 
taking contact details of family members and friends, recording participant’s date of 
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birth to enable medical records search, and contacting patients’ care coordinators to 
check for any changes in circumstances. Contact information was also checked 
throughout the duration of the trial, to prevent losing participants who change their 
number or location. Frequent changes of address have been previously reported to 
cause low retention rates. Another simple strategy included leaving researchers’ details 
with the participant, for example on a thank you card, “to all patients who were involved 
because, as usual, so they could ask, they could get in touch” (Senior Researcher 1).   
Following enrolment into a trial, intervention adherence became an important 
consideration. This was ensured by either supporting participants with getting to 
sessions using public transport, for example purchasing and posting train tickets in 
advance of intervention sessions, or by providing door-to-door taxi transport.  
Two strategies came into play once a participant had already moved away. One was 
travelling to the participant to complete a follow-up assessment. This was possible 
within the available travel budget, and therefore was subject to geographical 
limitations. In cases of patients who moved outside of the geographical cut-off point, a 
second strategy was considered: using alternative means of collecting data. This 
however was not always possible due to resource limitations and the protocol approved 
by the REC. In some cases, researchers were able to complete measures that did not 
require face-to-face meeting with the participant: 
 “A small questionnaire you can ask people over the phone and we did collect 
patient data.” (Senior Researcher 1) 
This was contrasted by Research Assistant 4 who could not offer the option of 
completing follow-up assessments over the phone:  
“We can’t do these [self-rated] questionnaires say over the phone or by post with 
people cause our research ethics says it has to be done in person and that is a 
barrier […]. Can we post them the questionnaire and get them to at least do most 
of the data? But they say we can’t because of the research ethics and it would take 
too long to go and apply to get that amended. And I think that that’s a pity. It’s a 
shame that it does affect the potential rate of the number of follow-ups we do cause 
you’re losing a lot. You’re losing data. They would do most of it, most of it is easy, 




Research Assistant 4 explains that the need to conduct assessments in person was 
dictated by the protocol approved by the research ethics committee and any changes 
would require an amendment to the original application, which can be timely.  
 
6.6 Discussion 
6.6.1 Main findings 
Failure to retain study participants in a trial was an important methodological and 
pragmatic concern for trial professionals. Retaining participants with schizophrenia in 
RCTs presented issues that are both specific to this population and those that apply to 
trials in any area of medicine. Trials evaluating non-pharmacological interventions 
provide a specific context for retention, with a different combination of issues to those 
reported in pharmacological trials. 
Trial researchers identified two types of attrition: loss to follow-up and intervention 
non-attendance, which are affected by different factors and require different 
approaches to deal with dropout. There are a range of factors affecting trial retention 
that are attributable to different agents involved in the trial system, including 
participants, researchers, study, and wider context. These factors correspond to the 
actions taken to increase retention; however the actions vary from standard practices 
to ad-hoc or intentional strategies. The interrelations between the main influential 






6.6.2 Strengths and limitations 
This study makes a contribution to the sparse literature on participant retention in 
mental health trials by exploring the factors researchers deal with and the ways in 
which they minimise retention. Data saturation was achieved, allowing for a thorough 
exploration of the emerging themes.  
Influential factors Practices and strategies 
Socio-demographic characteristics 
Understanding of trial procedures 
Motivation to participate 

















Consistency of procedures 
Experience of assessment 















Empowering with information 
Reminding about incentives 
Recruitment 
Minimising intervention wait time 
Regular contact 
Closely spaced appointments 
Over-recruitment 
Additional intervention groups 
Consent to follow-up at baseline 
Recruitment based on commitment 
Liaison with care coordinators 
Excluding homeless patients 
Figure 6.2 Interralations between influential factors and practices and strategies 
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Collecting data in face-to-face interviews allowed for an in-depth exploration of 
relevant issues and additional probing following responses. However, it is possible that 
some responses were influenced by social desirability bias given the focus on practice 
and conduct.   
The use of purposive sampling may have limited the representativeness of the 
population, however the character of the study was explorative and the final study 
sample reflects the characteristics reported for academic researchers.  
6.6.3 Interpretation and comparison with the literature 
Meta-analyses presented in the two previous chapters showed that it was difficult to 
identify the factors influencing retention in trials evaluating non-pharmacological 
interventions for schizophrenia, especially socio-demographic characteristics of 
participants. This qualitative study adds to the previous findings of this doctoral study 
by gaining in-depth insight into the practice of managing retention in trials involving 
people with schizophrenia.  
Framework analysis of the interview transcripts uncovered four categories of factors 
important for retention in non-pharmacological RCTs in schizophrenia and ways in 
which trial researchers address some of those factors. These findings address the 
second and the third research questions concerned with the factors influencing 
retention of patients with schizophrenia in complex intervention RCTs and the current 
practices of retaining patients in trials. Together, they provide insight into the 
challenges and practices of retaining patients with psychotic disorders in trials.   
The way in which the doctoral candidate structured and presented the findings 
corresponds closely to the Ecological Theory of Research Participation proposed by 
Marcellus (2004) (see Chapter 2) and provides further support for seeing attrition as a 
complex issue involving interactions between multiple variables, as well as between 
individuals and their environment. Although the ways in which factors affecting 
retention were categorised in the present findings are related to the Marcellus’ model, 
they do not correspond to all types of factors identified by in the model. For instance, 
Marcellus lists values, beliefs, and personal meaning as participant factors; however, 
these were not discussed by the trial researchers in the present study. Thus, beyond the 
core layers, the findings of the current study reveal different sets of factors specific to 
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trials involving people with schizophrenia and evaluating complex interventions. 
However, the notion of a participant-centred approach to research in the model 
permeates a number of themes identified in the data presented in this chapter and 
provides further support for this aspect of the theory.     
In addition to the four categories of factors, the study was able to identify the diversity 
of schizophrenia presentation and the different mechanisms of attrition. As Buckley et 
al. (2009, p.383) put it “The clinical heterogeneity of schizophrenia is indisputable. 
Virtually no 2 patients present with the same constellation of symptoms.” Furthermore, 
symptoms such as hallucinations, antisocial behavior, anhedonia, depressive 
symptoms, emotional processing, and mood induction have been shown to vary across 
cultures (Banerjee 2012). This heterogeneity is also present in other mental disorders, 
where individuals with the same diagnosis can differ in the type and severity of the 
symptoms they experience (Goldberg 2011, Wardenaar and de Jonge 2013). In addition, 
fluctuations in mental health as well as psychiatric, physical and substance use 
comorbidities are common across severe mental illnesses, further contributing to their 
complexity (Buckley et al. 2009, de Hert et al. 2011, Naylor et al. 2012, Hartz et al. 2014). 
Many of the challenges experienced by people with schizophrenia are also present in 
other populations. However, there are challenges unique to people with this diagnosis 
such as paranoid thoughts and anhedonia, which can have impact on their retention in 
trials. This group is generally thought to be difficult to engage in services and research 
and perceived as ‘high risk’ to themselves and others, especially among public 
(Humphreys et al. 1992, Dickerson et al. 2002, Thompson et al. 2002, Lecomte et al. 
2008). The researchers interviewed in the present study identified similar attitudes 
among staff facilitating access to potential trial participants, demonstrated in 
gatekeeping and risk aversion, which presented barriers to retention. This emphasised 
the importance of liaison between researchers and care coordinators to engage patients 
in an ethical and effective way throughout the duration of a trial.  
Participant factors 
The first of four categories, participant factors, can be compared to the results of the 
quantitative studies presented in chapters 4 and 5 as they tested the impact of 
participant characteristics on retention. The findings of this qualitative study partially 
support the results of the meta-analyses. Trial researchers were able to identify factors 
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affecting retention in schizophrenia trials, such as age and socio-economic factors, but 
they had diverging views on some characteristics, yielding them ambiguous in the 
context of predicting retention. This suggests that retention strategies applied across 
the whole sample should not be developed based on specific patient characteristics, for 
example introducing additional measures for participants with a specific socio-
economic status. Thus, a more individualised approach taking into account a 
combination of socio-demographic factors may be needed to retain participants in a 
trial.  
Despite none of the patient characteristics emerging as a clear predictor, the data 
included ideas explaining why some patients are more likely to be retained than others. 
These included having insight about own illness, understanding trial nature and 
procedures, and having an interest in the intervention. Randomisation was a 
particularly difficult concept to understand for patients, a challenge previously 
reported in other, non-psychiatric populations (Featherstone and Donovan 1998, 2002). 
The complexity of randomisation presents a challenge for researchers responsible for 
making sure patients sufficiently understand what they can expect from their 
participation and what is expected of them as participants. Nonetheless, the findings 
suggest some ways of effectively equipping participants with the required information, 
taking into account the potential difficulties experienced by people with schizophrenia, 
especially those experiencing side effects of antipsychotic medication affecting their 
cognitive abilities. Aside from allowing time for explanations, the focus was on the 
method of delivering information, including interactive and collaborative methods 
such as videos, events and patient-led information sessions.   
Offering incentives for research participation was a major theme, which had important 
implications for retention. Previous attempts to understand the impact of incentives 
on research participant behaviour have drawn on the principles of the exchange theory 
in proposing that research participation is dependent on the estimate of the anticipated 
reward (Woolard et al. 2004). The exchange theory, which has been seminal in 
understanding power and behaviour, provides a cost-benefit formula for predicting 
behaviour: ‘behaviour = rewards of interaction – cost of interaction’ (Cook and Rice 
2006). In the context of retention in trials, the behaviour can be seen as completion of 
intervention or follow-up assessments, the rewards are either tangible (money, 
vouchers, materials) or intangible (receiving an intervention, interaction with others), 
and the cost is the time and effort spent on attending sessions and completing outcome 
154 
 
measures. Considering retention through the lens of the exchange theory once again 
shows that there are multiple components affecting participant behaviour and the 
resulting retention. The interviews with trial staff allowed for identification and 
investigation of some of those components, which will be discussed next. 
This study has identified three main motivators for retention in non-pharmacological 
trials or schizophrenia. First, having an interest in the intervention led to better 
retention, especially in the active arm. This finding corresponds to the results of the 
IPD-MA presented in Chapter 4 showing that those in the active arm are more likely to 
complete follow-up assessments. Assuming that most patients prefer to receive an 
active intervention, the finding also relates to the literature showing that participants 
who receive an intervention they prefer are half as likely to drop out than those who do 
not receive their preferred treatment (Swift and Callahan 2009). This qualitative study 
generated some potential explanations for better retention rates in the active arms, 
including having more contact with staff and better engagement resulting from the 
nature of most complex interventions. However, it is important to note that some 
patients preferred to be randomised to the control arm as they perceived interventions 
as high commitment. This should be taken into account when making predictions 
about the likelihood of an individual to drop out. 
The findings show that monetary incentives were the most effective but also most 
problematic motivator. The effect of financial incentives on retention rates has been 
shown in a systematic review of retention strategies (Robinson et al. 2007). However, 
similarly to the findings of the present study, the impact of money has been recognised 
as a controversial issue (Roberts et al. 2004) and the respondents in the current study 
were wary of the risk of coercion, or perhaps revealing such practice, when discussing 
this type of incentive. This could have impacted on how much information they were 
willing to disclose. In addition, money acting as a main motivator was linked to issues 
with engagement, reliability of data, and benefit of treatment, mirroring the findings 
of Gross et al., (2001) who proposed that “monetary rewards may effectively get a 
participant’s attention but that may not be sufficient to sustain their interest over time” 
(p.246). The evidence suggests that although monetary incentives can be effective in 
improving participation levels, their use for the purposes of retention in trials should 
be studied further.  
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The third type of motivation observed by trial researchers was altruism, which is a 
concept that has received a lot of attention in the literature. In the specific context of 
trials, two main notions have been proposed: ‘weak altruism’ and ‘conditional altruism’. 
Weak altruism occurs when individuals consent because they see ‘no positive net 
difference’ between interventions and perceive no potential loss (Edwards and 
Braunholtz 2000). Conditional altruism proposes that although people may initially 
agree to participate in order to help others, they will remain engaged only if it brings 
some benefit to them (McCann et al. 2010). Although the reverse has been found; with 
helping others emerging as a by-product of participation in a clinical trial rather than 
a primary motivation (Locock and Smith 2011). The present study found that appealing 
to altruistic instincts was one of the strategies for recruiting and retaining participants 
in a trial but this was used in combination with other incentives, usually monetary.  
Researcher factors  
The second category was concerned with factors dependent on the researchers. The 
leading theme here was the relationship between the researcher and the participant. 
While a lot of literature has been produced on the subject of clinician-patient 
relationship (Street et al. 2009, Thompson and McCabe 2012), less is known about the 
researcher-patient relations, particularly in the context of trials. Some evidence is 
available on these relations in qualitative enquiry (Wilde 1992, Pitts and Miller-Day 
2007, Eide and Kahn 2008, Guillemin and Heggen 2009) and survey research (Jacomb 
et al. 1999, Lavin and Maynard 2001, Evans et al. 2002) but there seems to be a gap when 
it comes to the specific context of trial research, which often combines the two types of 
methods (i.e. interviews and questionnaires) in follow-up assessments.  
Some literature has emphasised the importance and the intensity of the interface 
between researcher and patient for the ethical conduct and the success of research 
(Bookman et al. 2013). The present study suggest that this requires skills and points to 
the importance of recruitment of staff who have the ability to work with people with 
mental health disorders and provision of training on rapport building among other 
important skills. Linked to the relationship was the persistence of researchers, which 
seemed to balance on the fine line of ethical conduct in terms of the amount of contact 
with participants and the methods used to do so.  
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Although a lot of activities were enforced by the standard operating procedures, which 
will be discussed in the next section, a lot of actions key for retention were down to the 
efforts of individual researchers. These were previously categorised by Sullivan (2004) 
as logistical and personal factors that have impact on the researcher-participant 
relationship, for example negotiating the decision to drop out could be seen as 
reflective of the level of researcher’s personal investment in the study. The level of 
researcher’s adaptability was also a factor dependent on personal circumstances and 
the work ethic of the researcher. In addition, not assigning researchers to specific 
patients for the duration of the trial could be reflective of an unstable research team, a 
logistical factor. There were also factors that hinged on both logistical and personal 
circumstances, for instance the way in which information was communicated to 
patients and reminders about incentives can be built into the trial procedures but 
putting it into practice and the nuances of communication are in the hands of the 
researchers.  
Study factors 
Study factors comprised the third category and dealt with the decisions that affected 
the operations of the whole trial. The themes revolved around key activities and 
procedures, which introduced the risk of losing patients’ engagement, namely research 
assessments and interventions.  
Underpinning all of trial activities were procedures and systems. The consistency of 
these was emphasised as important for retention. The feasibility and acceptability of 
interventions and procedures can be tested in pilot studies preceding full trials if similar 
studies do not exist (Donald et al. 2009, Thabane et al. 2010, Shanyinde et al. 2011, 
Hubbard et al. 2016). However, neither of these options was discussed in the interviews. 
This could mean either that the interviewees did not have much experience with pilot 
trials, or that they did not make a link between the procedures they described as 
important and the option of testing them before a full trial. It is also possible that it is 
the role of the Principal Investigators (PIs) to assess the likelihood of success of the 
intervention and study procedures and this group was purposefully not included in this 
study.  
The discussion of the impact of the enjoyment of an intervention provided further 
insight into the finding of the IPD-MA (see Chapter 5) pointing out the differences 
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between retention in the active versus the control conditions. In this qualitative study 
trial researchers also gave emphasis to the impact of arm allocation on the nature of 
engagement in a trial, pointing to the intensity of engagement and increased contact 
with therapists.   
Having a person-centred and flexible approach was identified as a strategy to deal with 
some of the study factors. This echoed the literature on retention advocating tailoring 
study procedures and interventions to individuals; for example “A retention strategy 
related to the study itself is to develop interventions and procedures that take the needs 
and resources of participants into account” (Marcellus, 2004, p. 93). The practices 
described by trial researchers provided evidence of a person-centred approach, 
especially in the context of organising follow-up assessments. It is interesting to note 
that, despite the widespread efforts to increase patient and public involvement in 
research (Staniszewska et al. 2011), there was no mention in the interviews of the role 
participant advisory groups have in advising on the conduct of research, and especially 
retention strategies or procedures used to maximise retention.  
Context factors  
Factors concerned with the external context were outside of the control of the 
researchers but their impact could be mediated. This required a more proactive 
approach utilising preventive measures compared to the reactive ones described in the 
previous sections. Interestingly, this category of factors attracted the most well-defined 
strategies, compared to the other three categories.  
A number of organisational factors were determined by the research site and the 
clinical staff involved in recruitment and retention of their patients. Liaison with care 
coordinators has been described in the literature but mainly in the context of 
recruitment to trials (Yancey et al. 2006, Howard et al. 2009). The present study 
highlights the importance of a continued relationship with care coordinators 
throughout the duration of a trial to achieve a good retention rate.  
The geographical location was another contextual factor researchers could not alter but 
often had to deal with given the mobility of the population, especially those living in 
urban areas. The trial literature has mainly focused on the travel burden for the 
participants needing to attend sessions (Hussain-Gambles 2004, Karlson and Rapoff 
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2009, Kanarek et al. 2012, Kaur et al. 2012). What the current study highlights is the 
efforts made by researchers to reach participants who have changed their location or 
contact details. This was described as a particular issue when working with people with 
schizophrenia who often led chaotic lifestyles. Some preventive measures helped with 
tracking participants and locating them after they have moved, for example recording 
alternative contact details at recruitment. This corresponds to the existing literature, 
for example Bindman (1993) found that recording details of three other people was the 
most useful resource in following-up. In instances when the move was far, it was up to 
the study resources and the researcher’s flexibility to travel to the patient and collect 
data.  
6.6.4 Conclusion 
This chapter presented findings from qualitative interviews with trial researchers about 
their experiences with engaging people with schizophrenia in RCTs of complex 
interventions. It has developed themes around four categories of factors influencing 
retention and strategies used to address those factors. The perspectives shared by the 
different types of professionals seem to complement one another, presenting a picture 
of trial practices in the context of retaining people with schizophrenia in trials 
evaluating complex interventions. The findings have pragmatic implications for 
improving participant retention as they make links between common issues and the 
ways in which they can be addressed. The research and practice implications of the 
findings will be discussed in the final chapter.  
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 Chapter 7 
Qualitative study of trial participants’ 
perspectives on retention: the EPOS trial 
7.1  Chapter overview 
The study reported in this chapter sought to provide insight into trial participants’ 
perceptions of retention in complex intervention trials, as defined by the fourth 
research question: ‘What are the experiences of patients with schizophrenia in the 
context of retention in trials?’ This was achieved by examining key facets of patients’ 
attitudes towards trial participation and their role within it: decisions about continuing 
or discontinuing participation, motivation for enrolling and staying engaged, and 
understanding of the trial procedures. 
The chapter will first provide the rationale for conducting this qualitative study with 
its specific objectives. This will be followed by an outline of the context for this study 
and the methods used to collect data. Finally, the findings will be presented and then 
interpreted in light of the wider literature.  
7.2 Rationale 
The previous chapter explored the experiences of researchers working on trials 
involving people with psychotic disorders. When planning this study, it was important 
to also gain the perspective of trial participants who are the decision-makers in the 
context of engaging in research.  
The importance of involving patients in both their care and research relevant to them 
has gained significant interest in the literature. The level of the involvement can vary 
and this has been placed on a continuum, from low to high involvement (Hanley et al. 
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2004). Other literature talks about the move from a participatory model of research, 
where individuals with relevant experience act as advisors on a study, to emancipatory 
research, which gives the individuals control over the process (Beresford 2002, Henn et 
al. 2009). This variation has resulted in multiple terms used to define the type and 
model of patient involvement (Sweeney and Morgan 2009). Despite the challenges 
surrounding the terminology, patient engagement has become an ethical mandate to 
democratise medical care and research in order to make their processes and results 
more relevant to patients’ concerns and preferences (Kitchin 2000, Domecq et al. 2014). 
In addition, Kitchin (2000, p.39) proposes that “such partnership approaches seek a 
democracy between (non-disabled) re-searcher(s) and disabled co-researchers that is 
based upon recognising that both parties have expertise but from differing frames of 
reference.” However, it has been argued that the shift towards valuing patient 
perspectives has been more influential in healthcare than in research (Sacristán et al. 
2016) and it has received criticism based on the risk of tokenism and increased cost 
(Domecq et al. 2014).  
Public and patient involvement in research can take on different conceptualisations 
and formats, depending on the research question, resources available, and overall study 
design (Barello et al. 2014). Previous efforts aimed at understanding patients’ 
experiences of participating in trials have included retrospective questionnaire studies 
(for example: Tallon et al., 2011; Wendler et al., 2008), studies involving rating 
hypothetical research opportunities (for example: Leathem et al., 2009; Moser et al., 
2002; Roberts et al., 2002), and qualitative investigations of experiences, for instance of 
completing questionnaires or of reasons to enrol into trials (for example: Holmberg et 
al., 2014; Howard et al., 2009; Kost et al., 2011). These studies have yielded important 
findings relevant to recruitment and retention strategies, decisional capacity, ways of 
supporting participants with completing assessment measures, and their motivations 
to participate. Out of the existing methodological options, employing qualitative 
methods seems to yield most in-depth data about the participation experiences, which 
are not easily quantified, and for exploring issues identified as pertinent by participants.  
However, identifying former trial participants for the purposes of a qualitative study is 
challenging given the guaranteed anonymity of participation. This important ethical 
consideration can also create a barrier to giving participants a voice. One option would 
be to seek such individuals in the general population, however given the focus of this 
doctoral study on the complex interventions for psychosis, this approach would be 
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likely to yield a small number of eligible participants. An alternative would be to 
identify eligible patients through specific studies. This approach however requires 
either an existing ethics approval allowing for approaching participants to invite them 
to a qualitative study or an application for a new approval, which defines the study as 
a separate endeavour linked to the main trial. If such qualitative investigation is built 
into a trial from the outset, the process is made much easier (Holmberg et al. 2014). 
This can also be part of a wider study nested within a main trial, allowing for 
investigating the effectiveness of different recruitment and/or retention strategies 
(Graffy et al. 2010, Rick et al. 2014, Madurasinghe et al. 2016). Such trials within trials 
have been conducted and can be considered gold standard in research on recruitment 
and retention, however this model requires considerable resources and time (Graffy et 
al. 2010, Bower et al. 2014). The timing of this doctoral study unfortunately did not allow 
for embedding it within a planned or on-going trial. Thus, the best available option was 
to conduct this qualitative study as a follow-up to the EPOS trial, which was in its final 
stages when the candidate began the doctoral studies. The trial and the procedure 
followed will be discussed in the subsequent sections. 
7.3 Objectives 
The specific objectives of this study were: 
1. To examine patients’ reasons for continuing or discontinuing participation in 
the EPOS trial. 
2. To explore their perceptions of EPOS and their understanding of this particular 
trial, and how these perceptions and understanding contributed to their 
decisions about participation. 
3. To identify lessons to be learned about how retention in future trials similar to 





7.4 Study context: the EPOS trial 
7.4.1 Trial overview 
The trial titled “Effective Patient-Clinician Communication in Community Mental 
Health Care” (EPOS) was an exploratory pragmatic cluster RCT on the effectiveness 
and cost-effectiveness of the DIALOG+ intervention (Priebe et al. 2013, 2015). The study 
was funded by a National Institute of Health Research (NIHR) Programme Grant for 
Applied Research and the access to it was facilitated through the Unit for Social and 
Community Psychiatry where the candidate was based for the duration of her doctoral 
research. The study was conducted in seven community mental health teams (CMHTs) 
in East London. 
The intervention was delivered using an iPad, which was shared between patient and 
clinician (also referred to as ‘care coordinator’ throughout this chapter) during the 
routine appointments. Each session began with patients rating their satisfaction with 
eight life domains: mental health, physical health, job situation, accommodation, 
leisure activities, friendships, relationship with family or partner, personal safety; and 
three treatment aspects: medication, practical help, meetings with professionals. Each 
item was rated on a Likert-type scale from 1 (‘totally dissatisfied’) to 7 (‘totally satisfied’) 
and this was followed by asking if the patient needed additional help in the given 
domain. A graphical summary of the ratings was produced for the benefit of both the 
patient and the clinician after each session, allowing for comparisons with previous 
ratings. Appendix 7 provides screenshots of the DIALOG+ intervention.  
Following the rating exercise, the results were used to inform the discussion between 
the patient and the clinician. First, clinicians offered positive feedback on the domains 
showing improvement or attracting high scores. Second, the patient and the clinician 
together chose any domains they wanted to discuss in greater depth. The selected 
domains were addressed using a four step approach based on the principles of solution-
focused therapy, which involved: 1) understanding the patient’s concerns and coping 
strategies effective in the past; 2) identifying best-case scenarios and small steps for 
improvement; 3) exploring options and resources available to the patient; and 4) 




The control condition included treatment as usual and an assessment of the patient’s 
satisfaction with the different life domains using a tablet without the involvement of 
clinicians. Clinicians involved in the trial were trained in using DIALOG+ and 
instructed to use it at least once per month over six months, allowing for variations due 
to the practical organisation of care.   
7.4.2 Trial recruitment 
Recruitment to the EPOS trial was through clinicians who first identified eligible 
patients on their caseloads and then approached the person to ask for consent to be 
contacted about the trial. Each assessment was conducted in one-to-one meetings 
between an EPOS researcher and a patient and involved an observer rated structured 
interview for the Positive and Negative Syndrome Scale (PANSS) as well as the 
following self-report measures: the Manchester Short Assessment of Quality of Life 
(MANSA), Camberwell Assessment of Need Short Appraisal Schedule (CANSAS), Client 
Satisfaction Questionnaire (CSQ-8), General Self-efficacy Scale (GSS), Warwick-
Edinburgh Mental Well-Being Scale (WEMWBS), and the Scale for Assessing 
Therapeutic Relationships in Community Mental Health Care (STAR-P). All outcomes 
were measured at baseline and at three follow-up assessments at 3, 6 and 12 months. 
The assessments took place at the CMHTs or in patients’ homes. Participants received 
£20 for completing each assessment.  
The principal inclusion criteria for the EPOS study included: aged between 18 and 65 
years; a diagnosis of schizophrenia or a related disorder; capacity to provide informed 
consent; treatment in a CMHT in the NHS for at least one month; and a mean score of 
less than 5 on the MANSA. Exclusion criteria included: insufficient command of 
English; a mean score of 5 or more on the MANSA; and learning difficulties. 
7.4.3 Participant Flow 
A total of 709 patients were assessed for eligibility. Following baseline assessments, 188 
patients were randomised to the DIALOG+ or control condition. Of those patients, nine 
either withdrew from the study or were discharged from the clinician’s caseload before 
randomisation, without the knowledge of the research team. This group was deemed 
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as ‘randomised in error’ due to no longer being eligible and, as a consequence, excluded 
from the analysis. The correctly assigned sample included 179 patients, of whom 94 
were randomised to the intervention arm and 85 to the control condition. Of those, 14 
participants (11 experimental, three control) did not receive the allocated intervention, 
for example because of clinician changes.  
The primary outcome was assessed in 120 (61 experimental, 59 control) out of 179 
patients at three months, representing 67% retention. At six month follow-up, 147 (73 
experimental, 74 control) patients were assessed, with 82.1% retention rate. At 12 
months, 129 (61 experimental, 68 control) patients completed follow-up, accounting for 
72.1% retention. A full CONSORT diagram for the EPOS trial can be found in Appendix 
8.  
7.5 Method 
7.5.1 Study design 
As the main objective of the study was to explore the experiences of the EPOS trial 
participants, in-depth interviews were chosen as the most suitable data collection 
method. Given the focus on individual experiences and decision-making, it was decided 
to conduct individual, semi-structured, face-to-face interviews. This type of interview 
can be used to elicit a holistic understanding of the interviewee’s point of view and 
provides an opportunity to further investigate interesting areas arising during an 
interview. The choice of a semi-structured format allowed for asking open-ended 
questions and probing wherever necessary to obtain relevant data.  
As in the qualitative study with trial researchers presented in the previous chapter, 
Framework Method was used to analyse the data. The approach to data and the process 
were the same as in the preceding study and further details can be found in Section 
6.4.1 (p.107) of Chapter 6.  
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7.5.2 Ethics approval 
The initial plan was to obtain an ethics approval from the NHS REC to conduct this 
qualitative study as an extension of the EPOS trial. This was possible as the doctoral 
candidate’s supervisor was the PI and had access to the trial data. The main advantage 
of submitting the qualitative study as an amendment to the EPOS trial was a much 
shorter review process compared to a full application and review. This was particularly 
important given the anticipated impact of the time lag on participants’ recall of their 
experience of the trial, a limitation of any retrospective study (Beckett et al. 2001). It 
was important to begin interviews as soon as possible after the last follow-up 
assessment, which took place on the 3rd of November 2014. 
Consequently, an application was made for an amendment to the main trial adding a 
qualitative follow-up investigation of patients’ decisions about their participation 
throughout the duration of the trial. This amendment was submitted on the 7th of 
January 2015, approximately three months after the start of this doctoral study. The 
Committee declined the application as they perceived the qualitative study to be 
separate from the original trial and therefore requiring a full review by the NHS REC.  
Following the rejection of the amendment, a full application was prepared by the 
doctoral candidate and submitted on the 13th of May 2015. This process was subject to 
delays caused by the local Research and Development department, which were outside 
of the candidate’s control.  
The final approval letter was granted seven months after the last EPOS follow-up 
assessment by the National Research Ethics Service (NRES) Committee London – 
Stanmore, REC on the 30th of June 2015 (reference 15/LO/0991) and can be found in 
Appendix 9.  
7.5.3 Recruitment and sampling 
Participants were recruited through the EPOS trial, with assistance from the original 
trial team and patients’ care coordinators. Multistage stratified purposive sampling was 
used to identify the final sample. 
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In the first step, trial records were reviewed to identify the study completion status of 
each participant. If the patient withdrew consent and specified that he or she did not 
want be contacted again, they were not approached about the study. Following 
exclusion of those patients, the remaining participants were first stratified into those 
who completed all follow-up assessments (henceforth referred to as ‘completers’) or 
completed the assessments only partially (‘partial completers’). Once the participants 
were categorised into one of the two strata, 15 participants per strata were selected on 
the basis of achieving maximal variation of demographic characteristics and trial arm 
allocation. One of the reasons for selecting stratified sampling was to minimise the 
amount of contact with the clinicians (and thus the potential burden on them) who 
potentially had more than one trial participant on their caseload. In these cases, the 
candidate needed to explain the purpose of the study only once for multiple patients. 
The doctoral candidate contacted the care coordinators of these 30 patients, providing 
information about the study and asking care coordinators to ask their patient for 
permission to be contacted by the candidate. Participant information sheets were sent 
to the care coordinators by email (see Appendix 10). If the patient agreed to be 
contacted by the candidate, their contact details were obtained from the care 
coordinator and they were sent an invitation to participate in an interview together 
with the participant information sheet. Potential participants were contacted again at 
an agreed time and date to discuss their decision to participate or not. All participants 
were offered the option to be interviewed in person in a convenient location with 
confidential space, such as a local community centre or a CMHT. Each participant 
received £20 for his or her time upon completing the interview.  
Out of the initial sample of 30 patients, 12 were impossible to contact following several 
attempts to call, seven refused contact and 11 were interviewed (Round 1). Once all 
responses had been received, another sample of 30 was identified from the list of 
eligible participants in each strata (Round 2) and the same procedure followed for 
obtaining assent. Out the second sample, 18 were impossible to contact, seven refused 
contact and five were interviewed. Preliminary analysis of the 16 completed interviews 
suggested data saturation point was being approached but had not been achieved. 
Consequently, given a small number of interviews anticipated to be required to reach 
data saturation, a different strategy was adopted in Round 3, with potential participants 
invited to the study one by one and these interviews reviewed using the same approach. 
The last round yielded four interviews. Once 20 interviews had been completed the 
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candidate determined that data saturation was reached. This was decided, in line with 
the Fusch and Lawrence's (2015) guidance, on the basis of further coding being no 
longer feasible (Guest et al. 2006, O’Reilly and Parker 2012), having sufficient 
information to replicate the study (O’Reilly and Parker 2012), and the ability to collect 
additional new information has been attained (Guest et al. 2006). The process resulted 
in 20 interviews, following selection of 64 patients and contact made with their care 
coordinators. Figure 7.1  overleaf presents the process of recruitment with the numbers 
obtained at each stage. 
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Interviews n=3 Interviews n=2 
Interviews n=2 Interviews n=2 
ROUND 3 
Participants identified 




Partial completers Completers 
Eligible Withdrew from trial or 
not to be contacted 
Eligible Withdrew from trial or 
not to be contacted 
ROUND 1  
Sample of n=15 
identified 
ROUND 1 
Sample of n=15 
identified 
Contact with care 
coordinator 
Permission to contact 
patient 









one by one  
Interviews n=6 Interviews n=5 
ROUND 2 
Sample of n=15 
identified 
ROUND 2 
Sample of n=15 
identified 




A participant information sheet was developed to invite potential participants to the 
study and to provide information about the purpose of the study and what their 
participation would involve. This was also used to provide information for the care 
coordinators acting as gatekeepers to their patients, in addition to a verbal explanation 
during the first contact made by the candidate.  
The information sheet was written in lay language and followed guidance provided by 
the NRES (2009). The invited individuals were given information about the purpose of 
the research, the reasons for being invited, the voluntary nature of their participation, 
the reimbursement, the nature of their involvement, the advantages and disadvantages 
of taking part, the course of action in case of a problem, the confidentiality and privacy 
of the participation and the data, the organisation of the study and the ethical approval, 
the details of a complaint procedure and an explanation of how the findings will be 
used. In addition, contact details of the candidate were provided. The full information 
sheet can be found in Appendix 10.  
When contacted to arrange an interview, each participant was offered the option of 
completing a Participant Preference Form, which recorded any preferences they had in 
regards to the interview. This allowed the candidate to make appropriate arrangements 
and also have a record of the participant’s wishes in different scenarios, for example 
what to do if the participant does not turn up for the interview or is unwell during the 
interview. This form can be found in Appendix 11.  
There was a separate written consent form presented to the participants before the 
interview. The form was also prepared in accordance with the requirements of the 
NRES (2009). It comprised seven statements allowing the participant to express in 
writing their agreement to the different aspects of taking part in the study. The form 
informed the participants about their right to withdraw at any point and the 
confidentiality of their personal information. Participants could also express their 
agreement to being recorded and to receive a summary of findings upon completion of 
the study (see Appendix 12).  
Two interview schedules were developed: one for completers and one for partial 
completers. Both interview schedules began with an introduction to the study and 
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asking them to describe their involvement in the EPOS trial. Once their recollection of 
the trial was established, the interview moved on to the topics of being invited and 
making the decision to take part, expectations about the participation, involvement in 
the study, and experience of any retention strategies. The only section that differed 
between the two schedules was ‘Involvement in the study’. This was done to explore 
specific reasons for completing assessments versus failing to complete some. Here, 
completers were asked questions about what motivated them to stay involved 
throughout the study, whether anything would have made their participation easier or 
more interesting, whether they considered dropping out at any point. In contrast, 
partial completers were asked about how long they stayed involved, what made them 
cease their participation, whether anything could have changed their mind, and 
whether they experienced any effects of their partial completion of assessments. The 
interview was flexible as it depended on the recall of the trial experience; however, some 
predetermined prompts were used to encourage participants to elaborate on points of 
interest further, if possible. The interview schedule also included the opportunity for 
the participant to add more information that they considered pertinent and to ask any 
questions. Appendix 13 provides the full interview schedule for those who completed 
all assessments and Appendix 14 for those who failed to complete some of the 
assessments. 
7.5.5 Procedure 
Once the contacted patients expressed their willingness to take part, the interviews 
were scheduled. All interviews were conducted at a convenient time and location for 
the participant. Six out of 20 interviews took part in participants’ homes. The duration 
of the interviews ranged from 17 to 38 minutes, with an average of 23 minutes per 
interview.   
Written informed consent was obtained prior to the interview. Participants were asked 
to confirm their demographic details and diagnosis obtained from the trial records. Any 
updates were noted. Two out of 20 participants chose not be recorded. In these cases 
notes were taken during the interview. The candidate transcribed the remaining 18 
audio-recordings of interviews.  
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All data were kept in a locked filing cabinet and digital information was kept on a 
secure, password-protected computer. Data was coded to ensure participant 
anonymity.  
7.5.6 Data Analysis 
Interview transcripts were analysed using NVivo qualitative data analysis software 
version 10 using the Framework Method. The process was conducted in five steps, as 
per the original Framework Method (Ritchie and Spencer 1994). The details have been 
provided in Section 6.4.6 (p.110) of Chapter 6.   
7.6 Findings 
7.6.1 Study sample 
Thirteen out of 20 participants were female and the average age was 42 years, ranging 
from 31 to 62. Out of 10 participants who received the intervention, eight completed all 
follow-up assessments (indicated in the findings as ‘Intervention, Completer’) and two 
missed some assessments (‘Intervention, Partial completer’). In the group of 10 
participants in the control arm, four completed all follow-up (‘Control, Completer’) 
assessments and six completed only some (‘Control, Partial completer’). This is 
presented in Table 7.1 below. Demographic characteristics of the sample are provided 
in Table 7.2 and compared to the total trial sample. The profile of the participants is 
indicated in the findings section, where direct quotes are used. 
Table 7.1Total sample by type of trial participant 




Completer n=8 n=4 




Table 7.2 Characteristics of the qualitative study sample (n=20) and the total 
EPOS sample at baseline (n=179) 
Characteristic Qualitative study sample  
n (%) 
EPOS sample at 
baseline 
n (%) 
Gender   
   Male 13 (65) 123 (69) 
   Female 7 (35) 56 (31) 
Ethnicity   
   White 5 (25) 46 (26) 
   Black 6 (30) 70 (39) 
   Asian 7 (35) 49 (27) 
   Mixed/other 2 (10) 14 (8) 
Mean age  42 41.6 
Primary diagnosis (ICD-10)   
  Schizophrenia 13 (65) 141 (79) 
  Delusional disorder 1 (5) 2 (1) 
  Schizoaffective disorder 4 (20) 24 (13) 
  Not provided  2 (10) N/A 
Trial arm allocation   
  Intervention 10 (50) 94 (52.5) 
  Control 10 (50) 85 (47.5) 
Retention status   
  Full completion 12 (60) 95 (50.5) 
  Partial completion 8 (40) 93 (49.5) 
N/A = not applicable 
 
The sample included in this qualitative study had similar characteristics to the total 
EPOS sample. The majority of participants were male, which corresponds to the median 
male to female risk ratio of 1.4:1 reported for the population with schizophrenia (Saha 
et al. 2005) and the gender ration of the participants in the EPOS trial. The original trial 
sample was ethnically diverse and this was also reflected in the profile of the 
interviewees, with interviewees from each of the four ethnic categories specified in the 
EPOS trial, the majority of whom were Asian in this study and Black in the trial. The 
average age of participants was 42 years, which is similar to the 41.6 reported in the 
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EPOS trial. The majority of patients were diagnosed with nonspecific schizophrenia, 
similar to the trial. The spread of arm allocation and retention status is a result of the 
sampling strategy.  
7.6.2 The initial participation experience; invitation to take part in the EPOS 
trial 
Assessing patients’ experiences after the study is one of the possible ways of engaging 
them in clinical research, although more active patient participation methods are 
possible, for example advising on study design (Sacristán et al. 2016). Gathering the 
experiences and opinions of former research participants has been shown to have the 
potential to inform future studies and improve their design to achieve greater 
acceptance and effectiveness (Kost et al. 2011, Tallon et al. 2011) . 
The interviews in the present study began with establishing how the patients’ were first 
invited to participate in the trial. Care coordinators were identified as those who 
introduced the participants to either the EPOS trial or the trial researcher directly. This 
was in accordance with the study protocol, which specified that clinicians would ask 
for their patient’s permission to be approached by the researcher and to be given more 
information. Involvement of clinicians or key workers as gatekeepers to potential 
research participants is considered good practice and often expected by the REC issuing 
necessary approvals. Gatekeeping bears particular importance in populations 
considered as ‘vulnerable’, a category which normally includes people with mental 
illness (Patterson et al. 2011, Probstfield and Frye 2011). 
Participants who were completers were more likely to remember who approached them 
about the EPOS trial in the first instance; partial completers did not recall this very 
well. This could be due to the completers either being more engaged in the study or 
having better wellbeing in general, which would affect their memory of the trial. 
Nonetheless, it is interesting to note that those who had no recollection of being 
introduced to the trial still suspected it was their clinician, as expressed by Participant 
17:  
“I see him on a regular [basis], so we talk a lot. I think he was the one because 




This assumption of clinician’s involvement could be a reflection of the care 
coordinators being the main source of contact and the gatekeepers to both services and 
research. 
The data on this part of the patient experience illustrate the importance of the 
clinicians’ role in introducing the study to patients and communicating about research. 
It is worth pointing out that in the case of the EPOS trial, the health professionals were 
recruited to the study to deliver the intervention and they had a stake in finding a 
number of eligible patients on their caseloads to enrol in the trial. Those who were 
completers recalled the researchers explaining the study to them; partial completers 
had trouble remembering this. However, interviewees who did recall meeting the 
researchers did not refer to them as ‘researchers’, suggesting they may have not been 
aware of their professional background. This is similar to one of the findings reported 
in the previous chapter (section titled “Understanding of trial procedures” on p.125), 
where trial researchers reported participants confusing care coordinators with 
researchers. The initial meeting with a researcher took place either in the presence of 
care coordinators (for example Participant 4 below) or in a separate meeting that took 
place either at the CMHT or in participants’ homes, as described by Participant 18 
below: 
“When I had my appointment with my social worker I had somebody come in 
and tell me that they were trying to find out something about my mental health 
without trying… giving me lots of different drugs… And so I said ‘Why not?’ and 
signed some papers…” (Participant 4, Intervention, Completer) 
“I said ‘Okay’ and they came to my house and explained everything and I… there 
were like some papers, forms that I had to sign […] and they explained what was 
going to happen.” (Participant 18, Intervention, Partial completer) 
Overall, the interview data were limited by the time gap between being invited to the 
EPOS trial and being recruited to this qualitative study, often resulting in poor memory 
of some events and decisions made at the time. However, the differences noted between 
the two types of participants indicate that those who completed all assessments 
remembered more than those who were partial completers. In addition, completers 
who could remember the initial meeting recalled signing forms (although, importantly, 
giving little detail on what they understood that they were signing) and had different 
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perceptions of being asked to do so. In the quotes below, Participant 18 and Participant 
7 were not particularly wary of entering the trial:  
“It was fine, it was okay. I don’t worry too much.” (Participant 18, Intervention, 
Partial Completer) 
“Oh yeah, there were some forms or something. I did sign.” (Participant 7, 
Intervention, Partial Completer) 
In contrast, Participant 16 highlighted his or her worry over signing forms in general, 
which was overcome by receiving an explanation about the study: 
“I don’t like signing things because you hear so much about things going wrong 
but I had to and they explained what was going to happen.” (Participant 16, 
Intervention, Completer) 
In the example below, Participant 4 made it clear he or she did not think a lot about 
what the study involved at the point of giving consent to take part in the study. The 
focus was more on making the initial decision and the importance of the study. The 
specific information was obtained later, when the patient had already enrolled in the 
study and was able to understand what would be involved in outcome assessments, i.e. 
completing the same set of questions for follow-up every couple of months.  
“I didn’t think too much about what I would have to do [at first]. I was asked, I 
thought it was important, and I said ‘yes’. It was later I found out that I had to 
do some questions every few months and meet with someone. […] I probably 
didn’t think much of it. I meet different people at the [CMHT] all the time. I 
listened when they were talking but then I was like ‘I want to get on with my 
day, if they want something, they have my details now.’” (Participant 4, 
Intervention, Completer) 
Moreover, being able to refuse to answer questions or to change one’s mind later 
seemed to provide some reassurance to individuals and in some cases delay their 
curiosity about the trial until a specific procedure (for example being contacted by a 
researcher or completing a questionnaire) was happening. The option to refuse will also 
be discussed in the following section in the context of motivation to take part. 
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7.6.3 Facilitators of retention; motivation to enter and to remain in the trial 
The second theme emerging from the data focused on the reasons for deciding to take 
part, both initially and at follow-up assessments. As per the EPOS trial protocol, 
following receiving information about the study, potential participants were asked to 
make a decision about their involvement and asked to confirm their consent at every 
follow-up assessment.  
Different types of motivators emerged from participants’ responses. The first 
motivation was the desire to help others. Participants described their appreciation of 
the importance of research and saw their involvement as an opportunity to help other 
people with mental health problems. These quotes illustrate this reasoning:  
“Oh, I wanted to help. If it’s going to help other people and it’s trying out 
something then I will do it. It’s like doing something good for others, other 
people. And I know how it is to live with this, in this condition.” (Participant 17, 
Control, Completer) 
“I say yes to things if I think they will help […] I like to help if I can. I can’t do 
much but if I can sit and think and answer and it helps someone, why not? And 
they give me money for every time, that doesn’t hurt [laughter]. So I help others 
and I help myself.” (Participant 2, Control, Partial completer) 
Similar to the first quote above, other participants were also able to make a direct 
connection to mental health and the NHS, emphasising the potential usefulness of their 
experience and input for other people with mental health disorders: 
“It’s good, people need to get involved to give more information to the NHS, or 
whoever is doing the research […] then clearly it’s of future benefit.” (Participant 
4, Intervention, Completer) 
“I wanted mental health people to become, if they wanted to, more involved. 
And I do it myself. For mental health service users, they’ve got to have a say 
because… […] And any treatment, any change in life, like they’ve moved out, 
and any change in any part of their lives has to be handled and has to be based 
on the individual. You can’t turn around and say all schizophrenics would 
benefit from this. You can’t assume everyone is the same basically.” (Participant 
14, Intervention, Completer) 
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The last statement above from Participant 14 emphasises the importance of considering 
differences between people with schizophrenia and what may help them.  
The second type of motivation was gaining personal benefit from the intervention. 
Here, completers in both active and control arms seemed able to recall the details of 
the intervention or being told about the potential benefits better than those who were 
partial completers. Participants put most emphasis on just ‘getting help’, which is 
illustrated in the quotes below: 
“I take all help they can give me, innit [sic]? If they offer I don’t say no. So I did.” 
(Participant 7, Intervention, Partial completer) 
 “I think they said it might help. They were testing it, so there was no guarantee 
but there was no danger. So I thought I will give it a go and see. If it helps, it 
helps. It’s not going to make me worse than I already am.” (Participant 2, 
Control, Partial completer)  
Perceiving trial participation as low risk seemed to be an encouraging factor, which 
suggests that patients considered not only the potential gains but also losses. For 
example, Participant 16 took into account the difficulty of the participation versus 
potentially benefitting from it and not experiencing any harm:  
 “I don’t know… I just… it was just a different thing I suppose. I was like ‘It’s not 
too hard, I can do it.’ and they said it can be good for me and it can’t do any 
harm, can it?” (Participant 16, Intervention, Completer) 
Participant 14 in particular described a combination of factors that led them to take 
part, namely the ease of participation, no change of medication, and making a 
contribution for the benefit of other people:  
“It was easier to say yes to a questionnaire. I don’t want more medication. I don’t 
want to change my medication. But I want to have my say and answering 
questions helps other people. It was fun. I enjoyed it.” (Participant 14, 
Intervention, Completer) 
In addition, Participant 14 wanted to have their voice heard and saw participation in 
the trial as the opportunity to achieve this and help others at the same time.  
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Another aspect that encouraged the decision to take part, as already acknowledged in 
the previous section, was the option of refusing further participation after being 
recruited. This seemed to provide some reassurance to patients who were not sure 
about their level of commitment or about the reality of participating. For Participant 2 
it was having the option of stopping an interview if they got tired:  
 “I’m not sure what I thought back then, like, they ask you something and say 
you can change your mind, so there is no danger. You can always say you are 
finished if you don’t like it. Like if I am tired of answering I will just stop. I don’t 
know if they still give money but you can.” (Participant 2, Control, Partial 
completer) 
Agreeing to take part and signing the consent form was seen as making a promise to 
the researchers. This led to keeping one’s word being provided as a reason to fully 
complete participation, for example: 
“I signed the documents, so I promised to do everything they asked. I keep my 
word.” (Participant 9, Control, Partial completer) 
The prospect of receiving money for completing baseline and follow-up assessments 
had impact on the initial decision to take part. Patients indicated weighing up whether 
it was worth their time by considering the amount of money versus the activities or 
procedures they would be subjected to: 
“I would be lying if I said I didn’t do it for money. I need money, they offer 
money, so I go and do what I need to do. If they were sticking a needle in me 
then maybe I would think twice but this was just talking and ticking answers.” 
(Participant 11, Control, Completer)  
“I don’t know. I just didn’t have a reason to say no. They were giving money so 
I was like ‘Yeah, I’ll do it’. It was just questions, nothing too serious.” 
(Participant 12, Intervention, Completer) 
“This woman came and said they were doing this thing, what you have there 
[points to an iPad], and they asked if I wanted to make £20 and I said ‘Of course, 
who wouldn’t?’ and that was it.” (Participant 19, Intervention, Completer) 
The quotes above show that being asked questions was not seen as invasive, especially 
when compared to receiving injections or changes to existing prescriptions, as 
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exemplified by Participant 11 above. This indicates potential differences in how patients 
make decisions about their participation in trials of pharmacological versus complex 
interventions. In addition, the impact of payment was not limited to the initial decision 
to participate but played a role in the decision-making at every follow-up assessment.  
Money was described as an alternative to ‘doing nothing’ and as a reason to get out of 
bed, especially for those experiencing low motivation and side-effects of medications, 
like Participant 5:  
“But then I think about money and I go. It’s worth it. I can sit at home and do 
nothing and get no money or I can go answer some questions and get cash in 
my pocket. I have days when I don’t want to do nothing, like, the tablets 
sometimes make me so weird, like I could sleep all day and then I wake up and 
I’m like it’s not that different to being in bed. So that makes it harder to do 
anything.” (Participant 5, Control, Completer) 
In the quote below Participant 12 compares research assessments to appointments with 
his or her social worker and, although humorous, points out the motivating nature of 
monetary incentives to see the researcher: 
 “I just thought about getting money and what I would do with it. So it got me 
up and I don’t think I missed it once. It doesn’t always work like this with the 
social worker [laughter] but they don’t pay any money for my time [laughter]. 
Maybe if they started paying people they would come more. It gets you up.” 
(Participant 12, Intervention, Completer) 
This outward recognition of the effect of monetary incentives confirms the findings of 
the previous qualitative study and evidence from other studies investigating the role of 
incentives in research participation (Mee 2009, Brueton et al. 2014). Nonetheless, being 
motivated by monetary incentives and wanting to make a contribution were not 
mutually exclusive. The ability to achieve both was seen as a ‘win-win’ situation, with 
some benefit to both the participant and the researchers.  
 “And I thought it could help and they were paying money, so I was like 
everyone is happy, right? I give something and I get something and they are also 
happy because they need people doing those things, like people who go to NHS 
and use them.” (Participant 15, Intervention, Partial completer) 
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On the whole, money was important to both groups but partial completers did not 
identify and discuss other types of motivators as much as completers did. 
7.6.4 Barriers to study retention  
Those who were partial completers were asked about the reasons for not being able to 
meet with the researcher. Completers were asked to reflect on why they think some 
people could not be retained in studies.  
The character and intensity of a follow-up assessment presented a potential barrier, 
especially for those who did not expect to be asked a lot of questions and to have to 
complete questionnaires. This was not described as directly leading to a missed 
appointment but it seemed to create such risk. One factor, which seemed to help 
overcome this barrier was how nice the researchers were towards participants, as 
expressed by Participant 7 below, highlighting the rapport as the potential redeeming 
factor in the otherwise burdensome and repetitive assessment experience. 
“It was… I didn’t know they were going to ask so many questions but it was okay. 
She [researcher] was nice. I have to take my time with reading. Reading 
questions and I have to think out loud sometimes, so she knew and it took a 
long time.” (Participant 7, Intervention, Partial completer) 
“Sometimes the questions were too many, just too many questions. And it’s the 
same thing all over and you just don’t want to do it anymore. […] Yeah, I don’t 
like that.” (Participant 8, Control, Completer) 
Conversely, for Participant 15, being subjected to more invasive procedures that 
involved taking medication or receiving injections would be a barrier preventing them 
from taking part: 
“And it wasn’t like I was going to lose anything, like they were not going to make 
me pay or like put stuff on me. I’m not doing that. I have a friend who does that 
and they get money and stuff but I’m like get off me and I don’t want people 
doing stuff to me. Like I can talk to people and stuff but don’t prod me with 




The setting in which an intervention was delivered was also important, for example if 
participation required being admitted to a hospital it would present a potential barrier. 
However, if the intervention was embedded into the existing service or care (such as 
DIALOG+ in the EPOS trial), this was more acceptable.  
Participant 15 discussed the difficulties people with schizophrenia experience, such as 
hearing voices and experiencing side effects of medication, and how these can act as 
barriers to regular participation, as opposed to intentional decision not to complete 
part of the trial. The quote below illustrates Participant 15’s account of the challenges 
experienced by people with schizophrenia, especially hearing voices and experiencing 
side effects of medication. This meant that for Participant 15 the choice not to do 
something was often a result of not being able to do it:  
“I guess schizophrenics go… like because of the symptoms we can’t always do 
what we want because we just don’t feel up for it. […] It’s not like we can’t be 
bothered, not like that. It’s more like even if you want to do something you 
really can’t. So even if we want to, if we say yes and then people think ‘Oh, they 
just didn’t want to do it’ or ‘They really didn’t care’ or something like that. It’s 
not like… it’s more to do with the mental health and how we… like daily struggle 
of life and it’s hard for normal people. For us it’s like double as hard because we 
have the voices and the thoughts all the time and the medications and 
everything. And then life with people and family and food and bills and 
everything.” (Participant 15, Intervention, Partial completer)  
Another barrier to retention that was specific to people with psychotic disorders was 
experiencing paranoid thoughts, which came into play especially when researchers 
were visiting participants at home.  
 “I mean I think if someone is paranoid maybe they don’t want someone in their 
house? I don’t know… it’s just a guess. I know some people I see in my group 
and I know they don’t leave the house but they also, they don’t like when 
someone comes knocking because they don’t want to open the door, so they 
pretend they are not there (…) some even when someone calls but they still have 
a phone, so of course it is going to ring. So but those are people who are not 
really well, they’re really sick.” (Participant 17, Control, Completer) 
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This presented a potential challenge, which was related to the severity of psychotic 
symptoms experienced by trial participants and thus would not apply to all patients 
involved.  
7.6.5 “I just do what I’m told”; a passive approach to decision-making 
One of the main themes permeating patients’ accounts was their passive approach to 
making decisions about participation in the EPOS trial, which often seemed to mirror 
the level of involvement in their mental health care and could be linked to negative 
symptoms of schizophrenia. Negative symptoms, avolition (i.e. lack of initiative or 
motivation) in particular, have been argued to threaten the decisional capacity of 
patients with schizophrenia as it affects the ability to initiate and participate in goal-
oriented tasks (Anderson and Mukherjee 2007, Foussias and Remington 2010). Thus, it 
is possible that some of the EPOS trial participants were experiencing these symptoms 
and this contributed to the passive approach to making decisions.  
Overall, the answers showed varying degrees of involvement in decision-making. Based 
on this diversity, two main types of a participant emerged. An ‘active participant’ was 
someone who was curious about the study and their involvement in it and, as a result, 
asked questions to find out more or to clarify the information provided to them. 
Subsequently, an active participant would make an autonomous decision about their 
participation in a study. In contrast, a ‘passive participant’ was an individual who was 
generally obedient in following instructions, depended on directions from others and 
did not question anything. Similar distinctions have been previously made in the 
context of medical care, including shared decision-making or therapeutic alliance 
(Neeraj and McHorney 2000, Street and Millay 2001, Brown et al. 2002), observed 
involvement in care as an inpatient (Latvala et al. 2000), and perceptions of own 
involvement in care (Brody et al. 1989). In the research context, the term ‘participant’ 
replaced ‘research subject’ to suggest a more active and equal role (Corrigan and Tutton 
2006); however, less has been written about the extent to which participants are 
actually involved in research participation decisions. 
The accounts provided by the EPOS participants interviewed in this qualitative study 
show that they all exhibited a passive approach but this took on different forms. The 
passivity was particularly pronounced in the descriptions of participation including 
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statements such as “I just do what I’m told and that’s it” (Participant 1, Intervention, 
Completer) or “I guess it’s like I didn’t know what to expect, so you just do it. You just 
do it in the moment.” (Participant 2, Control, Partial completer). In addition, there was 
a ‘wait and see’ standpoint, where the participants did not fully understand the process 
but obliged to do what was asked of them. This suggested a certain level of dependency 
on someone else for making sure they were safe, most commonly care coordinator or 
researcher.  
“I didn’t know what was going to happen, so I thought I will wait and see. 
Whatever they ask me to do I will have to do. This is how it works. They help 
me.” (Participant 6, Control, Completer) 
Because, see, at first, when they talked to me, I was like ‘Okay, I will do it, why 
not?’ but I didn’t… I wasn’t sure what they were asking me. I just went with it. 
[The researcher] was nice, so why not? But then I had to see her again and I was 
like ‘Is this going to be happening now?’ and she explained how it was going to 
work. They answered questions, it was good.” (Participant 4, Intervention, 
Completer)  
The above quote from Participant 6 in particular makes a direct reference to being 
helped by the same health professional who introduced the patient to the trial. On the 
other hand, Participant 4’s attention is on the researcher who provided an explanation 
both at the start, when the participant seemed to be overwhelmed with information, 
and at the follow-up. Participant 4 is also an example of an individual who initially had 
a passive approach to taking part but then asked questions when seeing the researcher 
again. This implies that it may be easier for trial participants to take on a more active 
role when dealing with a specific task and less abstract information. Good practice 
advises researchers, especially when working with vulnerable populations such as 
psychiatric patients, to check for consent at each assessment point and it seems that it 
also provides a good opportunity to reassess understanding of the study and encourage 
the participant to ask questions they may not have thought of in the beginning, when 
hearing about the study for the first time (Li et al. 2016).  
Associated with the dependency on others was a sense of trust patients had in those 
whose role it was to support them. For example, one patient relied on the care 
coordinator to make their decision about trusting the researchers and agreeing to 
participate in the study: 
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Interviewer: “Did you need to ask any questions about what the information 
meant?” 
Participant 16 (Intervention, Completer): “I don’t remember but I think I was 
just like ‘I trust them because [care coordinator] was there and I trusted her and 
she said it was okay.”  
This reliance on the clinician to make decisions could potentially be indicative of 
paternalism, a phenomenon widely recognised in medical literature in situations where 
health professionals make choices for their patients (Coulter 1999, Rodriguez-Osorio 
and Dominguez-Cherit 2008). However, it has also been recognised that some patients 
may prefer a passive role and do not want to take responsibility for their treatment 
(Coulter 1999). This was difficult to decipher from the interview data. The EPOS trial 
participants interviewed in this study seemed to be comfortable with the care 
coordinator acting as the final decision-maker and/or advisor about their study 
participation.  
Nonetheless, assuming a passive stance was not without consequences for the trial and 
the participants. One of the consequences of not taking a more active approach to one’s 
participation was the lack of understanding of the trial procedures, for example 
expecting a follow-up assessment to be conducted by a health professional, not a 
researcher:  
“She [researcher] came and she asked me things and I didn’t know what it… 
what it was. I didn’t have much to say. I thought she came from the team to do 
an assessment or something but she just said it was going to be one time and 
she gave me £20 in the end, so that was good. So I did some ticking the boxes 
and that’s it.” (Participant 18, Intervention, Partial completer) 
In some cases reliance on others was extended to involving family members in making 
decisions about trial participation. Patients discussed their decision to participate with 
their spouses in the context of receiving payment and the researcher coming to their 
house to complete assessments. However, these conversations happened after 
consenting to take part in the trial.  
“I told [my spouse] they said like we were going to get money for speaking to 
someone and they would come here.” (Participant 5, Control, Completer) 
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Those who did not consult with anyone other than their clinician explained this by the 
low risk involved in taking part in the EPOS trial. However, there was an 
acknowledgement of a difference between a trial evaluating a complex intervention, 
such as DIALOG+ in the EPOS trial, and a study testing a pharmacological treatment. 
In cases where the trial or the intervention was potentially invasive or intensive, 
participants said they would require more time and would appreciate the option of 
consulting with someone else. In contrast, making decisions about participation in 
non-pharmacological trials did not require support from people other than those 
already responsible for their psychiatric care. 
7.6.6 Participants’ needs and preferences 
Participants were asked about their experiences of being contacted by the EPOS 
researchers. The responses revealed a number of common types of preferences and 
needs that the participants had.  
One type of preference was concerned with how individuals wanted to be contacted. 
Telephone contact was the most commonly given answer, however examples of specific 
preferences included receiving a text or a voicemail as this was seen as allowing more 
time to think about the answer.  
Interviewer: “What would be your preferred way [of being contacted] now? 
Phone? Text? Letter?”  
Participant 1 (Intervention, Completer): “Phone. I have voicemail, so when I’m 
sleeping or I can’t hear the ringing they can record and then I 
can go and listen to it later.” 
“She [researcher] would text me. I prefer that. I don’t like phones. I mean if I 
have to, answer but I prefer text. I read and I think and… it’s better.” (Participant 
4, Intervention, Completer) 
“Phone I think it was. Phone. I can answer when I want and when I’m home. I 




The explanations above suggest that patients appreciated having the chance to think 
and reflect on a message before replying to researchers. Although telephone was still 
seen as the most accessible method of contact, for some calls from unknown numbers 
were a source of anxiety. One way of dealing with this barrier was recording the number 
of the researcher on the patient’s mobile in order to quickly identify who was calling 
them.  
“They call but I don’t answer if the number… if number unknown.” (Participant 
6, Control, Completer) 
“I think she [researcher] called. Yes, because I asked her to put the number into 
my phone. I always ask people, so I know who’s calling. I don’t like those 
number that come up on the screen and you don’t know who it is and they tell 
you it’s like an accident or something. Like, now I know it’s scamming but first 
time it happened I was like ‘Did I do something?’, so I kept on the line and then 
it wasn’t making sense, so I don’t answer anymore.” (Participant 13, 
Intervention, Partial completer) 
Compared to partial completers, those who completed all follow-up assessments put 
more emphasis on receiving reminders about appointments when discussing their 
experiences. Having researchers calling them or sending text messages prior to the 
meeting was described as helpful and, in some cases, necessary to ensure a meeting was 
attended: 
“I think they called me to see if I was going to be home. It was good. I sometimes 
forget. I put it in my calendar but then I don’t look at it. So I was ready when 
she came.” (Participant 2, Control, Partial completer) 
“She [researcher] did tell me before, the day before. Just to make sure. So I never 
missed it.” (Participant 4, Intervention, Completer) 
Another important preference referred to where the follow-up assessments took place. 
The responses showed divergent views, with some participants requesting to be seen at 
home (Participants 5 and 7) and others not wanting to have strangers in their home 
(Participant 9). The quotes below illustrate this difference in opinions:  
187 
 
“I wanted him [researcher] to come here. I don’t like to go out and I like when 
she [mother] is around when strangers are around.” (Participant 5, Control, 
Completer) 
“Here [CMHT], I always come here. I know where it is and I don’t like looking 
for new places. I get nervous and stuff. So I prefer here.” (Participant 7, 
Intervention, Partial completer) 
 “I don’t like people here…. I mean in my flat. I come here. If I want to be on my 
own I stay in and I don’t want to come out, see people. I have food in the flat, 
so it’s okay. I can stay, it’s okay.” (Participant 9, Control, Partial completer) 
Participants also reflected on the preferences of other people with schizophrenia they 
knew and identified those who experienced agoraphobia and those who disliked 
unannounced visitors as particularly struggling with having meetings in their homes.  
In addition to the assessment venue, the timing of calls and appointments was also 
identified as important. Preferences ranged from very specific hours when a participant 
could be contacted, to a more flexible approach with a preferred time of the day:  
“I don’t work, so it’s okay. I am free in the day. Just not early and not late but I 
think we met at 12 or something like that.” (Participant 11, Control, Completer) 
“As long as they don’t call very late or very early, it’s okay.” (Participant 19, 
Intervention, Completer) 
A particular need described as important to anxious participants was having a support 
person present during the assessment. As the quote below illustrates this was possible 
to arrange while ensuring confidentiality of the content of the meeting: 
“I remember it being okay. She [researcher] was nice and we sat in my mom’s 
living room and my mom stayed in the kitchen because she wasn’t supposed to 
be listening but I wanted her to be there.” (Participant 16, Intervention, 
Completer) 
However, having a third party present at the assessment was not a common request 
and in practice would require special arrangements given the confidential nature of 




7.6.7 Challenges of gaining trial participants’ perspective and possible 
alternatives; lessons learned 
As described in Section 7.5.2, this study was affected by the delay in obtaining ethics 
approval. This directly influenced the quality and depth of data that participants were 
able to share in interviews. However, the study also provided an opportunity to make 
observations (which were recorded as field notes to supplement interview data) and 
learn about the challenges of conducting retrospective qualitative research.  
The nature of this study with the main focus on a different research study presented a 
challenge to a lot of interviewees. Although effort was made to ensure participants’ 
understanding of the purpose of this qualitative study, this ‘research on research’ meant 
that participants struggled to distinguish between the candidate and the trial team.  
Many patients who were asked about the reasons for missing appointments were either 
unable to recall the reasons or did not elaborate and presented it as a fact that did not 
require explaining, despite the prompts. These issues with exploring some topics in the 
interviews could be attributed to a number of reasons: the time gap between 
recruitment to the EPOS trial and the qualitative interview, memory affected by 
medication, other side effects of medication, and experiencing negative symptoms. 
Some patients were visibly nervous or experiencing side effects of medication. As an 
interviewer the candidate had to observe their non-verbal behaviour and carefully 
judge how much they could be prompted about the same issue before moving on to the 
next question. Previous experience of conducting research with patients with severe 
mental illness that the candidate gained prior to undertaking the doctoral studies 
proved useful when dealing with difficult interviews.  
Another observation, which mirrors the findings of the study, is the motivation to take 
part in the interviews. When invited to the study patients were asking directly if they 
were going to receive money, like in the EPOS trial. Many asked about reimbursement 
during the interview, especially as they were getting impatient towards the end of the 
meeting. This opens up a question about using incentives in an ethical and effective 





7.7.1 Main findings 
This study has identified a number of facilitators and barriers to retention reported by 
former participants in the EPOS trial. Figure 7.2 below presents an overview of those 
factors. A proportion of those were specific to people with schizophrenia. The decision 
to participate involved a consideration of risk and potential benefit of participation. 
The involvement of health professionals in introducing prospective participants to the 
trial and provision of their support was an important factor influencing participants’ 
decisions and experiences related to the trial. Researchers had an important role in 
addressing patients’ needs and preferences, sometimes with clinicians’ support, which 
were related to the symptoms they were experiencing. 
 
 
Figure 7.2 Barriers and facilitators of retention 
7.7.2 Strengths and limitations 
This study contributes to the limited understanding of decision-making about trial 
participation by people with schizophrenia. The interviews were conducted face-to-
face to allow for in-depth exploration of participants’ views and experiences. The 
sample included a mixture of participants who completed all follow-up assessments 
and those who missed at least one. However, the candidate was unable to approach 
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those who dropped out of the EPOS trial, which could have provided further 
understanding into the challenges of retention in clinical trials, especially around the 
factors directly contributing to their decision to withdraw.  
The main limitation of the study stems from its positioning in time, which affected 
participants’ recall of their experiences and the breadth of data they were able to 
provide. This logistical issue highlights the importance of building qualitative 
evaluations into trials from their outset.  
In addition the study involved former participants of a single trial and one that 
experienced high retention rates, therefore the findings may not generalise to other 
trials and other disease areas. These findings are most likely to be applicable to trials 
involving people with psychotic disorders evaluating complex interventions.   
7.7.3 Interpretation and comparison with the literature 
The recognition of the important role of health professionals in recruitment to trials 
corresponds with the literature on facilitating research in mental health services. 
Gatekeeping has been shown to be particularly pronounced in practices dealing with 
vulnerable populations, such as patients with schizophrenia (Anderson and Mukherjee 
2007, Howard et al. 2009, Patterson et al. 2010, Bucci et al. 2015, Hughes-Morley et al. 
2015). As discussed in the previous chapter discussing trial researchers’ perspectives, 
gatekeeping can be explained by the perceived need to protect patients from the 
research burden and to minimise any risk of harm to both the patient and the 
researcher. Previous studies have shown that clinical gatekeepers struggle with 
engaging their patients in research due to competing demands and limited resources 
(Beckett et al. 2011, Borschmann et al. 2014). Some suggestions on how to improve 
clinicians’ involvement have included engagement of senior investigators and 
integrating referrals to research into routine practice, accounting for the additional cost 
of involving ‘hard to reach’ populations, educating health professionals about clinical 
trials, and streamlining regulatory processes (Probstfield and Frye 2011, Borschmann et 
al. 2014).  
Less is known about clinicians’ involvement in retaining participants in longitudinal 
research, especially trials. However, the findings of this qualitative study suggest that 
their role does not end at recruitment and may be particularly important for those 
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individuals who are less involved in making decisions about their mental health care, 
for example trying out a new treatment. This passivity observed in decision-making 
about mental health care was mirrored in the patients’ approach to decisions about trial 
participation, with reliance on care coordinators and researchers to guide them 
through the process. This need for continued support is consistent with the findings 
discussed in the previous chapter, where trial researchers emphasised the importance 
of liaising with care coordinators throughout the duration of the trial and especially 
when participants were at risk of being lost to follow-up. Such risk has been shown to 
be associated with social and emotional withdrawal in patients with schizophrenia, 
making these individuals more likely to withdraw over the course of the trial 
(Thompson et al. 2011). 
However, calling for the need for health professionals’ support with research following 
recruitment should be issued with caution and needs to recognise the existing tension 
between their clinical obligations and the additional pressure created by research 
activity. In a professional culture construed as “not conducive to research” 
(Borschmann et al., 2014, p.1), adding provision of support with trial retention to the 
already heavy load of competing priorities and limited resources, may not be welcome 
without changes to the current interplay between clinical practice and research. 
Integration of clinical practice and research has been one of the tenets of the evidence-
based practice approach to mental health care (Hershenberg et al. 2012, Teachman et 
al. 2012) and beyond (Tsang 2000), with recognition of room for improvement.  
Research has shown that individuals with schizophrenia who participate in clinical 
trials are motivated by various factors, most significantly personal benefit and altruism 
(Roberts et al. 2000, Chong et al. 2009). However, the relative influence of these factors 
is unknown (Grant et al. 2009). Participants in the present study identified both 
personal benefit and altruism as motivating factors, often combined. Their importance 
varied across participants, emphasising the need to appeal to individual circumstances. 
The role of these factors at each follow-up assessment has not been studied and so it is 
not known whether the factors identified as important when entering a study remain 
the same throughout its duration. This study offers some insight into what may act as 
motivation following recruitment, although its retrospective nature does not allow for 
making any firm conclusions. Money seemed to be the most impactful incentive that 
encouraged retention in the EPOS trial. This may however be due to its direct and 
tangible nature and does not exclude altruism as a motivator to remain in a study. 
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Another factor directly affecting participants’ willingness to complete follow-up 
assessments was seeing them as a meaningful activity and an alternative to not doing 
much. This however was also associated with receiving payment for participation.  
Another set of factors directly affecting study retention was the extent to which 
participants’ needs and preferences were met. These were often related to specific 
symptoms or side effects of medication, which dictated the preferred time of the day, 
mode of communication, the need for reminders, and the place of appointments. These 
findings correspond to the previous qualitative study (Chapter 6) showing the 
importance of trial researchers’ flexibility and appreciation of the particular needs of 
participants. This highlights the need for researchers to understand the possible 
presentations of schizophrenia as well as to seek out the preferences of each individual 
and to try to meet them. Adopting such a participant-centred approach to retention is 
in line with the previously discussed (see Chapter 2) Ecological Theory of Research 
Participation, advocating consideration of situation-specific factors affecting 
participation (Marcellus 2004).  
7.8 Conclusion 
This chapter presented and discussed findings from a qualitative study eliciting 
perspectives of former trial participants regarding their decisions and experiences of 
being retained in a trial evaluating a complex intervention. Despite logistical 
challenges, which had negative impact on the breadth of data, the study identified 
themes around the motivations to engage in research, the barriers and facilitators of 
retention, the importance of meeting the participants’ needs and preferences, and the 
level of engagement in participation decision-making. The implications of these 





 Chapter 8 
Final discussion and conclusions 
8.1 Chapter overview 
The purpose of this final chapter is to examine the implications of the findings 
presented in the previous four chapters, to consider the contribution they make to the 
current literature and to propose future directions for trial practice and research on 
participant retention.  
The chapter will begin by returning to the overall aims of the thesis and the objectives 
of the individual chapters. Findings from the four studies will be revisited before 
discussing them in the context of the wider literature. Consideration will be given to 
the methodological strengths and limitations of the thesis, with reflection on the 
pragmatic challenges of conducting the research. The contribution made by research 
presented in this thesis will be discussed before reflecting on the implications of the 
findings for retention practice in RCTs and making recommendations for future trials 
and methodological research.  
8.2 Summary of thesis objectives 
The main aim of this thesis was to improve the current understanding of the retention 
of people with schizophrenia in trials evaluating complex interventions. This included 
identifying the reported attrition rates and examining the factors affecting them. The 
doctoral candidate also explored both the issues created by poor retention and the ways 
in which retention is managed in trial settings from the perspective of both trial 
researchers and patients with schizophrenia.  
In the first empirical part of this thesis (Chapters 4 and 5) the objective was to explore 
the rates of engaging patients with schizophrenia in RCTs and to identify patient and 
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study characteristics that could predict the decision to remain involved or to drop out 
from a trial. As identified in the literature, engaging patients with schizophrenia in both 
long-term psychiatric treatment and clinical research can be problematic (Cramer and 
Rosenheck 1998, Wahlbeck et al. 2001, Nose et al. 2003, Lecomte et al. 2008, Lecomte, 
Leclerc, and Wykes 2012). This phenomenon has been reported mainly in trials 
evaluating pharmacological treatments (Cramer and Rosenheck 1998, Wahlbeck et al. 
2001, Martin et al. 2006, Ghio et al. 2011), with very little literature exploring this issue 
in trials testing non-pharmacological interventions for psychotic disorders (Villeneuve 
et al. 2010). Two quantitative studies were conducted as part of this doctoral research 
to achieve these objectives. In a systematic review and meta-analysis reported in 
Chapter 4, the reported dropout rates from both study and intervention were calculated 
as well as patient- and study-level variables were examined as potential predictors of 
attrition. In Chapter 5, the objective was to further explore the impact of patient 
characteristics on study retention. This analysis drew on individual patient data from a 
sample of relevant trials and allowed for establishing the feasibility of employing the 
IPD-MA method in a systematic way and on a larger scale.  
The second part of the thesis drew on qualitative methodology to explore the 
perspectives of both trial staff and former trial participants on the continued 
involvement throughout the RCT process. The objective of Chapter 6 was to investigate 
the trial practices and strategies concerned with maximising retention of people with 
schizophrenia in follow-up assessments and complex interventions. A number of 
effective retention strategies have been identified in the literature (Robinson et al. 2007, 
Leathem et al. 2009, Zweben et al. 2009, Brueton et al. 2013, Buben 2013, Hartlieb et al. 
2015) but it has not previously been established whether those strategies are effective 
when working with patients with schizophrenia or if any specific actions are required 
to facilitate better retention of this population in RCTs. In Chapter 7 the focus was on 
exploring the perspectives of former trial participants in the context of their experience 
of being involved in the EPOS trial, including making decisions about their continued 
involvement in the and their experience of the trial researchers’ efforts to prevent them 
from dropping out from the trial. While studies exploring trial participant perspectives 
on their involvement in trials have been conducted in other populations, such as 
individuals infected with the Human Immunodeficiency Virus, the elderly population 
with chronic neck pain, or ethnic minority participants (Hussain-Gambles 2004, 
Wendler et al. 2008, Holmberg et al. 2014); psychotic disorders presented a fairly 
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uncharted area and one that has been identified as particularly challenging to promote 
retention in (Brueton et al. 2013).  
8.3 Summary of findings and comparison to the literature 
Chapters 4, 5, 6 and 7 presented and discussed the findings of each individual study 
within the context of the wider literature. This section provides a summary of findings 
organised according to the four research questions the thesis aimed to address and 
compares the overall findings to the wider literature.  
Research Question 1: What is the degree of attrition occurring in trials 
evaluating complex interventions for schizophrenia? 
The background literature reviewed in Chapter 2 discussed the importance of 
developing new treatments for schizophrenia and merging the gap between the rich 
evidence generated for pharmacological treatments and the currently less developed 
evidence-base for complex interventions. The most substantial progress in minimising 
this gap has come from a number of RCTs testing new non-pharmacological 
interventions for schizophrenia. However, the success and quality of these studies 
depends on the effectiveness of two key processes: recruitment and retention of 
participants. While recruitment has received considerable attention in the literature, 
retention is a lesser-explored issue out of the two.  
At the same time, some evidence suggests that retention of patients with schizophrenia 
is particularly difficult and challenges have been observed in both clinical practice and 
research context (Cramer and Rosenheck 1998, Lecomte et al. 2008, Lecomte, Leclerc, 
Wykes, et al. 2012, Brueton et al. 2013). However, this argument has been built largely 
on evidence from trials of antipsychotic medication which have attracted attrition 
ranging from 33% to 48.9% (Wahlbeck et al. 2001, Kemmler et al. 2005). Furthermore, 
a systematic review of studies estimating adherence to treatment programmes for 
people with psychosis offered outside of trial settings revealed that 24.3% individuals 
did not keep appointments as scheduled, compared to 29.74% failing to take drugs as 
prescribed (Nose et al. 2003). This evidence, together with the 14% intervention 
dropout rate found in the current study, non-adherence to psychiatric treatment, either 
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pharmacological or non-pharmacological, offered outside of trial settings can be higher 
than non-adherence to complex interventions provided in a trial context. 
Nonetheless, only one attempt has been previously made to estimate the actual rates 
of attrition in interventions evaluated in RCTs that did not involve taking medication 
and this was limited to psychosocial treatment only (Villeneuve et al. 2010). Given the 
existing body of evidence, it was not clear what the retention rates were in trials 
evaluating all types of complex interventions for schizophrenia, ranging from talking 
therapies to technology-based interventions and new service models. Estimating 
retention rates in such trials was needed in order to decide if low retention was in fact 
a pertinent issue and if it needed to be addressed in practice.  
The most robust way of answering this research question was by conducting a 
systematic review of the existing literature and, as the consecutive step, conducting a 
meta-analysis drawing on the data extracted from trial publications. This study made a 
noteworthy distinction between retention observed at the study and the intervention 
level; the importance of which was further emphasised by trial researchers in the 
subsequent qualitative study discussed in Chapter 6.  
The meta-analysis of proportions showed that the rates of dropout from study are 
higher than from experimental intervention; 20% and 14% respectively. Overall study 
dropout was on the cusp of approaching the level previously defined as causing risk of 
bias and potential threat to validity (Polit and Hungler 1995, Sackett et al. 2000, Schulz 
and Grimes 2002). However, most trials identified in the systematic review achieved 
rates lower than the 20% and thus were not at high risk. In addition dropout from 
intervention was fairly low, with levels corresponding to the ones previously reported 
in psychosocial interventions for schizophrenia by Villeneuve et al. (2010).  
As expected, the attrition rates were lower than those reported in pharmacological 
trials of antipsychotics (Wahlbeck et al. 2001, Martin et al. 2006, Rabinowitz et al. 2009) 
and of those found in outpatient psychiatric services (Nose et al. 2003). Some of the 
possible reasons for the difference in attrition rates between pharmacological and non-
pharmacological trials may be fewer side effects associated with receiving complex 
interventions or embedding this type of treatment within psychiatric services. On the 
other hand, attending therapy sessions often requires additional effort on behalf of 
patients, such as travelling to sessions and being in a group setting, and could 
potentially increase the risk of dropout.  
When compared to treatment dropout rates found in systematic studies of trials of non-
pharmacological interventions for depression, which have ranged from 15.3% to 34.9% 
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(van Ballegooijen et al. 2014, Cooper and Conklin 2015, Stubbs et al. 2016), dropout from 
complex interventions for schizophrenia is similar. Similarly, study attrition is no 
higher than that reported for RCTs of non-pharmacological interventions for 
depression and for borderline personality disorder, reported as 19.9% and 25% 
respectively (Barnicot et al. 2011, Cooper and Conklin 2015).       
Furthermore, when considering dropout from complex interventions evaluated in trials 
with psychiatric treatment provided in the community, it is important to note that it is 
not possible to control and standardise the latter as much as it can be achieved in a trial 
context, nor should this be the intention. As a result, researchers have struggled to 
estimate global attrition rates in outpatient psychiatric services, with reports varying 
from 20 to 60% (Bueno Heredia et al. 2001). When compared to these reports, the 
findings of the systematic review and meta-analysis suggest that retention of patients 
with schizophrenia in experimental non-pharmacological treatment is better than in 
community mental health services. Exploring the reasons for this difference was 
outside of the scope of this thesis.  
Overall, the retention rates reported for trials evaluating complex interventions for 
schizophrenia do not cause immediate concern about the ability to retain participants 
with psychosis in RCTs and the consequential validity and success of such studies; 
however they indicate some room for improvement, especially in ensuring completion 
of follow-up assessments.  
 
Research Question 2: What is the retention of patients with schizophrenia in 
complex intervention RCTs influenced by? 
Following on from calculating the attrition rates in RCTs evaluating non-
pharmacological interventions for schizophrenia, this thesis set out to investigate what 
the differences in the reported rates could be attributed to (i.e. why did some studies 
have problematic attrition rates while others managed to retain majority of 
participants). This question was addressed in all four studies reported in Chapters 4, 5, 
6 and 7 by adopting both quantitative and qualitative methods, thus allowing for an in-
depth investigation of the issue.  
The first analysis presented in Chapter 4 followed on directly from the systematic 
review and meta-analysis of attrition rates, and drew on data reported at study-level for 
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43 trials. A random-effects meta-regression explored the effect of both sample 
characteristics (i.e. age, gender, illness duration) and study features (i.e. location, 
setting, intervention delivery method, duration of the intervention, study duration, 
number of intervention sessions, study quality). The results showed that dropout from 
experimental interventions significantly increased as the number of intervention 
sessions increased. This could be interpreted as a high number of sessions presenting a 
challenge to trial participants, who may be overwhelmed by the commitment they 
made when recruited to the study. Given the typical presentation of schizophrenia 
described in the literature (Roberts 1998, Lecomte et al. 2008, Lecomte, Leclerc, Wykes, 
et al. 2012) and the challenges reported by both trial researcher and participants in 
Chapters 6 and 7, trial participants with this diagnosis may particularly struggle with 
completing treatment if they are expected to attend a high number of appointments. 
Alternatively, being offered many sessions may affect participants’ perception of the 
detrimental effect of missing individual sessions. An additional aspect that should be 
taken into account when interpreting this finding is the intensity of the treatment, i.e. 
the number of sessions provided over a specified amount of time. This was not tested 
in the analysis but could also have influence on completion rates.      
None of the other sample characteristics that could be extracted from the publications 
had a significant effect on the dropout rates at either study- or intervention-level. This 
result was at odds with the previous studies agreeing on two common factors - age and 
gender – predicting adherence to treatment for schizophrenia (Nose et al. 2003, 
Reneses et al. 2009, Villeneuve et al. 2010). However, the reported direction of effect in 
case of age differed depending on the study setting, with older participants more likely 
to drop out of treatment provided within a trial setting (Villeneuve et al. 2010) and 
younger ones out of treatment in a community setting (Nose et al. 2003, Reneses et al. 
2009).  
In addition, the lack of more significant associations may be attributed to the absence 
of clear predictors of attrition or to the inconsistent and sometimes poor reporting of 
information about the study and the sample. An example of the type of data that could 
not be extracted from publications was information about the incentives offered to 
participants for most of the identified trials. Thus, it is possible that incentives are 
among the factors that have an effect on attrition but could not be included in the 
analysis because of inconsistent or poor reporting in trial publications. This obstacle 
identified in the systematic review and meta-analysis provides further support for the 
efforts to improve reporting quality in trial publications, especially those evaluating 
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social and psychological interventions (Dumville et al. 2006, Grant et al. 2013).  
The second study (Chapter 5) addressing this research question was able to draw on 
individual patient level data in examining the effect of participant socio-demographic 
characteristics on study retention in an IPD-MA. For this purpose a meta-regression of 
patient and study characteristics was conducted on a sample of five trials with data 
from 2,006 patients. This analysis tested the association between specific factors and 
dropout. Finding a significant relationship would suggest that studies or participants 
sharing that particular characteristic were more prone to experiencing attrition. In 
practical terms, identifying such characteristics could allow for either making changes 
to the study procedures or tailoring the retention efforts to minimise the chances of 
losing patients at a high risk of dropping out, as long as the strategies would not affect 
or interfere with the study outcome. Such a move from a paternalistic relationship with 
participants towards a participant-centred approach has been recommended in the 
literature (Gross and Fogg 2001, Marcellus 2004). 
This study revisited the issue of inconsistent definitions of retention and attrition. 
While the systematic review distinguished between the study and the intervention 
retention, the IPD-MA was able to extract data on study retention, a lesser-studied 
phenomenon, and to explore the definitions within this level of enquiry. Given the 
multiple follow-up assessments in RCTs, dropout could be reported for any of those 
time points. The most common choices in trial reports, especially those missing a 
CONSORT diagram, are either the final follow-up assessment or the pre-defined point 
of assessment of the primary outcome. However, Hewitt et al. (2010) argued for looking 
into the penultimate follow-up as a reference point for the final follow-up. For the 
purposes of this thesis, the IPD-MA analysed both the penultimate and the final follow-
up completion to see if the same participants were likely to be retained at different 
stages of the trial. The results showed that retention was higher at the final follow-up 
assessment, in line with Hewitt et al.'s (2010) argument. In addition, out of all tested 
variables, the arm allocation almost reached statistical significance, pointing to a higher 
likelihood of those in the experimental intervention to complete the final follow-up 
compared to those in the control arm. Potential explanations include satisfaction with 
allocation to the active arm and thus higher likelihood of completing the final follow-
up, increased efforts of researchers at the final follow-up, and participants in the active 
arm being more engaged in trial activities than those in the control arm resulting 
affecting completion of the final assessment. However, none of these suggested 
interpretations (even the researcher bias given blinding in most trials) explains the 
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presence of the effect only in the final assessment and not the penultimate one.     
 These findings confirm the challenge of predicting retention based on patient 
characteristics previously identified in the systematic review in Chapter 4. The doctoral 
candidate was not able to ascertain whether the lack of significant effects is due to a 
true lack of effect, as the power of the study was limited and not all variables of interest 
could be extracted. At the same time, this lack of clear predictors points to the 
importance of making maximal effort to retain participants despite their socio-
demographic profile or a specific characteristic that is known to put them at risk of 
dropping out. However, in line with Newington and Metcalfe's (2014, p.2) argument, 
“recruitment and retention strategies need to be relevant to the target population and 
the research methodology used, and therefore the optimum strategy is likely to vary.” 
Thus, a balance needs to be struck between making retention strategies relevant to the 
clinical population and tailoring them to individuals. This however is at odds with the 
argument made by and requires more investigation.  
Employing a qualitative approach to address the second research question enabled 
exploration of the possible factors affecting dropout in more depth, including those 
difficult to quantify and report in trial publications. In line with the findings from the 
two quantitative studies, the findings discussed in Chapter 6 showed a lack of 
consensus on the factors predicting dropout. Age and socio-economic status especially 
evoked opposing opinions in terms of their effect on retention in trials, a pattern similar 
to that found in quantitative studies conducted prior to this doctoral research (Davis 
et al. 2002, Nose et al. 2003). The factors identified in this thesis as having a positive 
effect on retention included insight about own illness, understanding of trial 
procedures, and having an interest in the intervention being evaluated. These were 
similar to the previously reported predictors of non-adherence to community 
treatment for schizophrenia, such as poor insight of illness and low social functioning 
reported by Nose et al. (2003). 
Interviews with the former EPOS trial participants in Chapter 7 allowed for an 
exploration of factors that affected their decisions to first enroll and later to attend 
intervention sessions and follow-up assessments. The key facilitators of retention that 
emerged from the data included the desire to help others, benefitting from the 
intervention, receiving money for participation, being supported by a care coordinator 
throughout the process, as well as being offered some flexibility in terms of completing 
research assessments. Moreover, the study also identified a number of factors having 
potentially negative effect on retention, including: interventions involving invasive or 
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inpatient procedures, being expected to use the phone or to receive visitors, and 
experiencing paranoid thoughts.   
Thus, in summary, the second research question can be answered as follows: no single 
participant characteristic can determine the likelihood of being retained or dropping 
out, but the more intervention sessions that are offered to the participants randomised 
to the active arm, the higher the likelihood of premature termination of the 
experimental intervention. There are a number of factors that can influence 
participants’ decisions about their involvement at each stage of the trial, either as 
barriers or facilitators. Some of the barriers are specific to individuals with 
schizophrenia as they are associated with the psychotic symptoms, others are likely to 
be observed in any population. Supporting participants with overcoming barriers they 
experience and remaining involved in trials may require a mixture of general and 
individualised strategies applied by trial professionals.  
Research Question 3: How can patients with schizophrenia be retained in trials?  
Chapters 4 and 5 employed quantitative methods to calculate the rates of retention and 
to investigate what factors were associated with those rates. The objective of this thesis 
was also to explore how these retention rates are achieved in trial practice. Qualitative 
methods were thus chosen to explore trial practices that aim to maximise retention as 
well as to identify the particular challenges of engaging people with schizophrenia in 
RCTs.  
In-depth interviews with trial researchers from across the UK allowed for identifying a 
number of factors influencing retention and the ways in which trial researchers dealt 
with some of these factors. The findings from this study link in with the wider trial 
methodology literature, in particular the Ecological Model of Research Participation 
proposed by Marcellus (2004). The categories of factors identified in the study matched 
these in the ecological model and pointed to the multiple layers within which different 
‘agents’ made key decisions or took actions and where interactions took place, all of 
which affected retention. These categories of factors included: 1) participant factors; 2) 
researcher factors; 3) study factors; and 4) context factors. Depicting the trial as a 
multilevel system allowed for identifying barriers and facilitators occurring at each level 
and associating them with a particular agent, the relationship between them, and the 
specific trial process or procedure.  
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In addition to identifying a system of factors influencing engagement in a trial, the 
findings explored issues common to all RCTs of non-pharmacological interventions and 
those specific to schizophrenia research. In the theme ‘The complexity of involving 
patients with schizophrenia in trial’ (Section 6.5.3, p. 114) trial researchers recognised 
the impact of psychosis symptoms and life circumstances often resulting from those 
symptoms on the participants’ level of engagement in both interventions and research 
assessments. This mirrored the literature on the presentation of psychotic disorders 
introduced in Chapter 2 (Liddle 1987, Holmberg and Kane 1999, Wiersma et al. 2000, 
Saha et al. 2005, Morgan et al. 2014) and emphasised the importance of trial researchers’ 
awareness of the challenges experienced by patients with schizophrenia as well as the 
need for appropriate training of researchers working with this population. The different 
levels of dropout described in the theme ‘Mechanisms of attrition in complex 
intervention trials’ (Section 6.5.4, p. 120) provided further support for exploring this 
issue in the context of treatment adherence and completion of follow-up assessments, 
an approach taken in the systematic review and meta-analysis (Chapter 4). The 
practices and strategies identified in section 6.5.6 illustrated a range of actions at trial 
researchers’ disposal that could be taken to address some of the influential factors 
discussed in section 6.5.5. Figure 6.2 on page 150 has provided an overview of both 
categories, organised by the category of factors (i.e. participant, researcher, study, and 
context). Although researchers were the key link between the participant and the trial, 
they operated within the bounds of ethical conduct, study procedures and resources, 
and the wider organisational and geographical context.  
The findings showed that when it comes to dealing with barriers to retention, the 
systems and procedures put in place need to allow for a balance between maintaining 
ethical, logistical and pragmatic standards and allowing for flexibility in order to enable 
participants to remain involved over the course of a trial. Some practices, such as 
ensuring access to medical records, that could enable tracking participants at risk of 
being lost to follow-up were put in place prior to the trial, while others required ad-hoc 
decisions about the use of resources, for example to travel to a participant or to allow 
patients to come back to an intervention after a break. Adaptability was a catalyst for a 
participant-centred approach, in which meeting the needs and preferences of the 
participant were central to retaining them in a study. The key building block for 
adaptability was a good researcher-participant relationship achieved through rapport 
building, continuity of the researcher, an understanding of participants’ needs and 
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preferences, and study resources enabling researcher flexibility. The findings of the 
qualitative study with trial participants provided further support for the impact of good 
rapport on their experience of the trial and the likelihood of remaining involved. In 
Chapter 7 patients discussed the impact of personality characteristics of the EPOS trial 
researchers on their overall enjoyment and satisfaction with trial participation. Liaison 
between the researcher and the clinician was another type of a relationship important 
for achieving good retention. This finding echoes the wider literature, where involving 
clinicians in research and achieving their support has been described as an important 
factor, especially for recruitment (Bartlett and Canvin 2003, Patterson et al. 2011, 
Fletcher et al. 2012, Joseph et al. 2016). The present study adds weight to the importance 
of the continued liaison between clinicians and researchers beyond the recruitment 
phase.  
The findings of the two qualitative studies combined with the findings of the two 
quantitative studies suggest that no single strategy will guarantee high retention rates 
and emphasised the importance of tailoring approaches to individuals, with awareness 
of the barriers to retention experienced by some people with schizophrenia, such as 
experiencing paranoid thoughts and disliking talking on the phone. In addition, there 
is no ‘profile’ of a stereotypical participant at risk of dropping out, contrary to what has 
been previously suggested in the literature (Davis et al. 2002, Nose et al. 2003, Brueton 
et al. 2014). This could be due to the diversity of the study population, despite them 
sharing a diagnosis falling under the same umbrella of psychotic disorders. Thus, the 
argument for tailoring strategies seems to apply at both study population and 
individual participant level, with consideration of specific and general barriers and 
facilitators to retention (Marcellus 2004, Newington and Metcalfe 2014). 
Research Question 4: What are the experiences of patients with schizophrenia 
in the context of retention in trials?  
Involvement of trial participants in order to investigate their experiences and 
perspectives and to give them a voice as decision-makers was a key consideration and 
also the biggest challenge in the context of this doctoral research. In the last study semi-
structured qualitative interviews were conducted with 20 patients who had taken part 
in the EPOS trial.  
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Findings indicated that patients depended on the support from their clinicians, 
especially in making decisions about their involvement in the EPOS trial, with few also 
involving their family members. The data revealed that most participants had a passive 
approach to both their mental health care and participation in the trial, a finding which 
emphasised the importance of support from clinicians and researchers for those 
enrolling into RCTs.  
The identified motivations for taking part and remaining involved in trials echo the 
evidence discussing the importance of both personal benefit and altruism in research 
participation (Roberts et al. 2000, Chong et al. 2009). Money in particular was discussed 
as a preferred incentive, with helping others and benefitting from the intervention 
identified as secondary motivators. There are a number of things to consider, however, 
when making decisions about the types of incentives for trial participants. Some 
researchers have expressed concerns about using monetary incentives and key among 
those concerns is that such efforts might be coercive or be an undue inducement for 
patients (Grady 2005). Although ethics committees and funders may have a preference 
for a specific reimbursement strategy, the use of incentives remain a grey area (Grant 
et al. 2010) and it is ultimately the patients and researchers who should define what is 
appropriate, and involving individuals with relevant lived experience in making 
decisions about incentives can provide relevant guidance. 
The finding that emerged from both qualitative studies was the importance of having 
one’s needs and preferences understood and met. For participants this made their 
participation easier and less burdensome, and thus prevented them from dropping out. 
The onus of supporting patients with participating in trials is on both the researchers 
and clinicians involved in the process. This finding emphasises the importance of 
liaison between those two professional groups and corresponds to the qualitative study 







8.4 Key strengths and limitations 
This section will examine the methodological, practical and conceptual strengths and 
limitations of the thesis as a whole. These should be considered when interpreting the 
findings of this doctoral research. This is in addition to the critical assessment of 
strengths and limitations included in each chapter discussing findings from the four 
studies.  
8.4.1 Study design 
One of the strengths of this thesis is the use of mixed methods to estimate the rates of 
retention and to explore the patterns and predictors of this phenomenon. The strengths 
and limitations of mixed methods research have been discussed in Chapter 3. This 
approach to research allows for gaining both depth and breadth of understanding by 
exploring the issues from relevant vantage points and by using the most appropriate 
method or technique for the research question under study (Teddlie and Tashakkori 
2009). In case of this thesis, it was important to first estimate the magnitude of the 
attrition in non-pharmacological trials for schizophrenia in a numerical manner before 
identifying factors influencing this phenomenon and the possible ways of moderating 
them in a combination of numerical and qualitative approaches.  
Strengths of the quantitative work presented in Chapters 3 and 4 included the 
systematic literature search in the former and the use of individual patient data in the 
latter. Systematic literature reviews with meta-analyses represent one of the most 
rigorous analyses of current evidence (Elamin and Montori 2012). Traditionally, such 
analyses focus on outcome data from RCTs to answer questions about the effectiveness 
of treatments. This study took a novel angle on this method by studying the non-
clinical outcome of involvement in trials. The IPD-MA comprised another novel 
element of the thesis as this type of analysis is only gaining popularity and has not been 
applied much in the mental health context. This was the first study to examine the 
relationship between study and participant factors on the retention at both 
intervention- and study-level. In addition, the use of two time points in the IPD-MA 
enabled the comparison between retention at the penultimate follow-up assessment 
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and the final one. This adds to the understanding of the patterns of retention in non-
pharmacological trials for schizophrenia.  
In addition to the use of systematic and novel quantitative methodologies, this thesis 
employed a qualitative approach to explore the perspectives of both trial researchers 
and patients on retention. A number of measures were taken to ensure the reliability 
and validity of the qualitative analyses. Attention was paid to representing participants 
who completed all research assessments and those whose involvement was more 
erratic. In the study involving trial researchers, care was taken to represent different 
roles within a traditional trial team and to interview staff from different research 
institutions. 
8.4.2 Interdisciplinary approach 
This doctoral study was funded by the Life Sciences Initiative with the aim of tackling 
a research question from multidisciplinary viewpoints (Life Sciences Initiative 2014). 
Consequently, in addition to methodological and data sources triangulation, this thesis 
also involved triangulation of disciplinary perspectives (Denzin 1978, Patton 1999). 
Combining multiple theories and epistemological perspectives in examining and 
interpreting data allowed for gaining a better understanding of retention as a 
phenomenon. This was enabled by the multidisciplinary makeup of the candidate’s 
supervisory team and colleagues at the Unit for Social and Community Psychiatry 
combining social psychiatry, psychology and human geography perspectives.  
Both the methods and the emerging findings were presented throughout the duration 
of the research process to a multidisciplinary team of researchers at the Unit for Social 
and Community Psychiatry and at relevant seminars and conferences. This yielded 
valuable feedback and advice on the research plan and analysis; for example, 
conducting a subgroup analysis in the meta-analysis following the systematic review.  
One way in which the interdisciplinary approach of this thesis could have been 
strengthened would be by involving people with relevant lived experience in the study 
design and interpretation of findings. While it is important to acknowledge this as a 
weakness, this doctoral study did not have access to sufficient resources to engage in 
meaningful public and patient involvement activities. The involvement of patients with 
schizophrenia, especially those with experience of participating in research, could have 
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helped with planning the study, designing materials and analysing the findings. Any 
future research endeavours in this subject would benefit from patient involvement.  
8.4.3 Scope of the systematic review 
The systematic review needed to be defined by a specific research question and 
resources available. Given the number of trial publications that could be identified in a 
systematic literature search, it was important to minimise the heterogeneity of the 
results. One way of achieving this was to include trials of a specific size. Consequently, 
a decision was made to include only trials with a sample size of at least 100 participants. 
In addition, it was thought that trials of interventions involving a family member or a 
support person would involve a different decision-making process about patient’s 
involvement in an RCT and such studies were therefore excluded. This limited the 
scope of the review and reduced its generalisability to trials with a similar profile. As a 
consequence, the findings may not translate to trials excluded from the systematic 
review, for example RCTs of family interventions for people with schizophrenia.  
8.4.4 Quantitative analyses 
All quantitative analyses drew on data from existing studies and pooled them in meta-
analyses. As a consequence, the scope of the analyses was limited by the quality and 
type of the data available in publications or supplied directly by study authors. For 
example, information about non-adherence to interventions required for a meta-
analysis in Chapter 4 was reported in 34 out of 49 papers identified in the systematic 
literature search.  
In addition, the IPD-MA from Chapter 5 relied on the datasets available to the 
candidate, resulting in a convenience sample. While conducting a full IPD-MA of trials 
identified in a systematic literature search would have improved the power of the 
analysis and the generalisability of the findings, the process would have required 
resources in excess of what was available in this doctoral study.  
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8.4.5 Recall bias and data quality 
The main limitation of the qualitative study with trial participants discussed in Chapter 
6 is linked to its dependence on the EPOS trial and the associated requirement to gain 
a separate ethics approval to recruit its former participants. The delay in receiving the 
approval inevitably affected the quality of data collected in interviews with patients. 
The majority of interviewees struggled to recall details about their participation and 
the candidate had to ensure, as much as possible, they were reporting their actual 
experiences rather than discussing their decisions about participation hypothetically.  
8.4.6 Reporter bias 
It is possible that the qualitative data collected from trial researchers were subject to 
reporter bias, where the interviewees may have been inclined to share practices that 
were more acceptable and to conceal those which would cause controversy. All 
participants were reminded about the confidentiality of the data and were encouraged 
to be honest. Given that some potentially controversial issues were discussed, such as 
coercing patients to participate or excluding homeless individuals, this bias is likely to 
be minimal. 
8.4.7 Diversity of participants 
The geographical location of participants involved in both qualitative studies may have 
played a role in the limited diversity of their accounts and the generalisability of the 
findings. Almost all trial researchers and therapists who took part in the study reported 
in Chapter 6 were employed at academic institutions based in urban settings in the UK. 
There was little representation from researchers working in rural and remote areas, 
which could be expected to deal with different issues affecting retention and to employ 
different strategies. Similarly, all patients interviewed in the study discussed in Chapter 
7 were recruited through a single study conducted in East London. Although this area 
is known for its ethnic diversity reflected in the sample characteristics, the experiences 
of patients from this area may be specific to this context.  
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8.4.8 Conceptualising retention 
A key conceptual consideration was the definition of the phenomenon under study. 
The inconsistency in the definitions used to describe the continuous involvement of 
participants in a study or completion of key research activities has been highlighted in 
the literature (Kane et al. 2007) and further confirmed in this thesis. An additional 
complexity has been introduced in this thesis by the recognition of the multiple levels 
at which retention can occur: study and intervention. This was an important distinction 
considered in this thesis, although it was not possible to investigate both levels across 
all studies; for example, the IPD-MA discussed in Chapter 5 was able to investigate only 
post-randomisation retention during follow-up due to the lack of data on retention at 
the intervention level. 
As discussed in Section 2.4.5, there are two main models of retention: one focused on 
the research process (process model) and one built around the factors affecting 
retention (ecological model). This thesis adopted mainly the ecological model, which 
enabled identification of the potential sources of attrition and the factors affecting 
engagement in research. The advantages of applying this model include approaching 
trial retention as a system comprising multiple levels (participant, research, study, and 
environment) and exploring the interactions between those levels. As a result, the 
source of problems with retention can be identified and this can guide developing 
strategies to address challenges identified at the specific level of the model. However, 
this approach does not take into account the different phases of a research process and 
their impact on participants’ decisions about their participation. For example, different 
factors may influence decisions to drop out after being randomised compared to when 
a participant has completed their first follow-up assessment. 
Adopting the process model would have required a different approach to the methods 
applied in this thesis. The systematic review and meta-analysis (Chapter 4) could have 
explored the changes in retention rates over time, making comparisons between 
different time points. This was addressed in the IPD-MA (Chapter 5), which explored 
the differences in retention rates between the final and the penultimate follow-up 
assessments. The two qualitative studies (Chapters 6 and 7) were designed to explore 
the factors affecting retention and the strategies used to minimise dropout. Introducing 
the process-based model would have involved exploring how trial staff adapt their 
retention practices depending on the stage of the study and how trial participants make 
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their decisions throughout the duration of a trial. While this was explored to an extent 
in the study involving trial staff (Chapter 6), for example by identifying the points in 
the research process where retention was considered, the main focus of the analysis 
was on the categories of factors affecting retention. In addition, investigating the 
impact of the different stages of the research processes on decision-making with former 
trial participants (Chapter 7) could have presented a number of challenges given the 
issues with recall observed during the study.   
8.5 Contribution to the existing literature 
To the candidate’s knowledge this thesis was the first study to systematically look into 
the retention rates in non-pharmacological schizophrenia RCTs using mixed-methods. 
Previous attempts to study retention of patients with schizophrenia have been limited 
to pharmacological trials (Wahlbeck et al. 2001, Martin et al. 2006, Rabinowitz et al. 
2009), a specific sub-type of non-pharmacological trials (Villeneuve et al. 2010) or 
employed a single method to investigate the dropout rates or their predictors (Nose et 
al. 2003, Thompson et al. 2011).  
The results obtained in the systematic review and meta-analysis (Chapter 3) 
demonstrate the attrition rates reported in RCTs evaluating complex interventions for 
schizophrenia, both overall and for specific types of interventions and single studies. 
This evidence has been published and can be used by trialists to guide sample size 
planning in similar studies. 
The lack of support for specific prognostic factors, especially those based on participant 
socio-demographic characteristics, negates the previous evidence proposing profiles of 
participants who are more likely to drop out of trials (Nose et al. 2003, Reneses et al. 
2009, Villeneuve et al. 2010). The lack of clear predictors of retention or attrition 
suggests the importance of adopting a participant-centred approach, combining 
scientific rigour with knowledge of the specific study population (i.e. symptomatology, 
commonly experienced challenges in a trial context) and the needs and preferences of 
each individual (Gross and Fogg 2001, Marcellus 2004, Gul and Ali 2010).  
The methodological challenges encountered in the process of conducting this doctoral 
research and discussed in this thesis provide further support to the calls for improved 
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and more consistent reporting of information about participant flow in RCTs using the 
available tools developed specifically for this purpose (Altman 1996, Moher et al. 2001, 
Dumville et al. 2006, Perera et al. 2007, Turner et al. 2012, Hooper et al. 2013, 
Montgomery et al. 2013).  
Prior to this thesis there was an absence of evidence about good practice in retaining 
patients with schizophrenia. This study incorporates the perspectives of trial 
researchers, therapists and participants to gain insight into trial management practice 
and decision-making of patients. Gaining multiple viewpoints was instrumental for 
creating a fuller picture of retention practices as previous literature has shown the 
differences in reports regarding participation decisions provided by patients and by 
researchers (Featherstone and Donovan 2002).   
Although this thesis did not empirically evaluate the effectiveness of different practices, 
it provides evidence about the possible strategies to maximise retention in non-
pharmacological RCTs involving patients with schizophrenia and other populations 
and highlights the importance of future research in this area together with the existing 
gaps and potential challenges.  
8.6 Implications 
The findings presented in this thesis point to a number of implications for trial design, 
trial management practice, and provide evidence for further research. The following 
sections will discuss key implications from the thesis overall and offer 
recommendations for these areas. Priorities for research questions and the methods 
best suited to answer those are presented in Box 8.1. 
8.6.1 Use of relevant evidence to estimate realistic sample sizes 
Evidence about the dropout rates reported in previous studies involving the same 
population is pivotal in estimations of the required sample size (Noordzij et al. 2010), 
especially as the calculations have been found to be based on arbitrary assumptions 
(Rutterford et al. 2015). Oversampling has been used to account for the expected 
attrition (Ribisl et al. 1996); however this strategy can lead to increased costs and raises 
212 
 
ethical concerns in terms of involving unnecessarily large numbers of patients. To 
increase the accuracy of the calculations trialists should use evidence from relevant trial 
publications and available systematic reviews. The systematic review and meta-analysis 
presented in Chapter 4 has provided such evidence relevant to trials of non-
pharmacological interventions for schizophrenia. This thesis showed that trialists 
working in this context can realistically aim to achieve dropout rates lower than 20% at 
both the intervention and study level. Participants with schizophrenia should not be 
associated with a high risk of dropping out of studies or non-pharmacological 
treatments. This finding could help with achieving more accurate estimations and 
planning resources adequately in future trials.  
8.6.2 Considering the intensity of new interventions 
The findings of the meta-analysis discussed in Chapter 4 suggest that completion of 
experimental interventions can be put at risk by a high number of sessions participants 
are expected to attend in order to complete a course of treatment. Although the analysis 
did not estimate the point at which the number of sessions can become problematic, it 
is an implication to be considered by investigators designing new interventions.  
When conceiving new non-pharmacological treatments, trialists should take into 
account the required number of sessions and the intensity of interventions. The 
number of sessions required to show a desired effect will be dependent on the type of 
intervention to be offered; however trialists are advised to consider the risk of dropout 
in designing new complex interventions and to plan accordingly. If a high number of 
sessions is required for the success of experimental treatment, a trial may require 
specific retention strategies to prevent or at least minimise the expected dropout from 
intervention.  
8.6.3 Adopting a flexible and participant-centred approach to retention 
This thesis has demonstrated the importance of considering retention at the planning 
stage of a trial. There is a need for establishing procedures, which will allow for 
flexibility and adaptability to maximise the retention of participants while complying 
with ethical standards. The qualitative study discussed in Chapter 6 has provided some 
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examples of the areas needing flexibility from researchers, such as where follow-up 
assessments take place and whether patients are allowed to return to an interrupted 
course of treatment.  
Linked to the importance of flexibility and adaptability is adopting an approach that 
puts the needs and preferences of each participant at the heart of trial researchers’ 
efforts to maximise retention. Such a participant-centred approach, advocated in 
previous studies (Gross and Fogg 2001, Marcellus 2004), should be built on the 
foundation of a good understanding of the disease or health condition that can be 
achieved with appropriate training for researchers and experience of working with the 
population under study. Researchers need to be educated about the diversity of patients 
with schizophrenia as well as a typical presentation of the disorder. This can enable 
them to make appropriate arrangements in order to support participants in an ethical 
and considerate manner with the aim of maximising their retention in trials.  
8.6.4 Use of retention strategies 
The thesis has identified retention strategies used in RCTs involving patients with 
schizophrenia. This evidence suggests that most RCTs use multiple retention 
enhancing practices, and this is in line with the recommendations in the literature 
(Davis et al. 2002, Robinson et al. 2007, Polit and Gillespie 2010). The choice of strategies 
should be dictated by the sample population and the activities participants are expected 
to partake in, although this thesis did not find support for tailoring the approach based 
on specific socio-demographic characteristics. Adjusting retention practices should 
occur on a case-by-case basis and take into account the needs and preferences of each 
participant as much as possible. Different types of motivation should also be considered 
when planning and applying incentives to encourage patients to remain in the study, 
since this thesis found variability in what participants considered important. Although 
using personalised enticement may not be possible given ethical and moral constraints, 
incentives should appeal to a range of individuals with different reasons to take part in 
a trial.  
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8.6.5 Strengthening liaison with care coordinators 
The findings of this thesis provide further support for the importance of care-
coordinators in engaging patients in research reported in previous research (Bartlett 
and Canvin 2003, Mason et al. 2007, Patterson et al. 2011). Both qualitative studies have 
shown that establishing good rapport between researchers and clinical gatekeepers is 
important for ensuring an ethical and sensitive approach to each participant, as 
clinicians can facilitate the introduction the study, provide researchers with 
information about the patient’s needs and preferences, help with the efforts to retain 
individuals in a study, and provide support with participation decision-making for their 
patients. The two groups of professionals should liaise to identify the needs and 
preferences of each participant, come up with best ways of supporting them with trial 
activities, and problem-solve if issues with participation arise. However, relying on 
clinical staff should be carefully considered as this has implications for their clinical 
capacity. Changes to the interplay between mental health practice and research are 
needed to enable the involvement of clinicians in research (Tsang 2000, Hershenberg 
et al. 2012, Teachman et al. 2012). This would have direct implications for the 
engagement of patients in research, facilitating participant retention and improving 
quality and reliability of studies, which is central to evidence-based medicine.    
8.6.6 Need for evaluations of retention strategies  
This study has provided evidence about the retention strategies currently utilised in 
RCTs of complex interventions for schizophrenia, and offers potential ideas for similar 
future studies. However, testing the effectiveness of these strategies was outside of the 
scope of this doctoral research and this type of evidence is needed to improve retention 
practices. One of the most methodologically sound methods, although not without its 
logistical, ethical and scientific challenges (Fletcher et al. 2012), used to develop and/or 
test specific recruitment and retention interventions is embedding them within a full 
trial conducted in routine settings (Graffy et al. 2010, Treweek et al. 2013, Bower et al. 
2014, Rick et al. 2014, Madurasinghe et al. 2016). Although the existing literature is 
limited mainly to embedded recruitment trials, adopting this design to test 
interventions aimed to improve retention offers a new and exciting area. Examples of 
such studies, especially testing recruitment interventions, are available in the literature 
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(for instance Brueton et al. 2014, Rick et al. 2014) and can serve as models for future 
research on retention together with evidence from the existing studies on the strategies 
used in practice, including the current thesis.  
8.6.7 Improvements to reporting of trial information 
This doctoral study highlighted reporting information relevant to participant flow 
throughout a trial as a weakness of the current evidence base. The quality of this 
information bears implications for the possible research investigating retention as it 
relies on the primary data recorded within individual trials.  
Future studies should comply with the current standards of reporting attrition rates 
outlined in the CONSORT (Altman 1996, Moher et al. 2001, Plint et al. 2006, 
Montgomery et al. 2013), including making a distinction between dropout from follow-
up and treatment non-attendance for complex interventions. In addition, information 
about factors that may have affected retention rates should be offered, considering the 
key levels at which influences occur, namely participant, researcher, study, and context.  
Standardising the data recorded at the trial level could be problematic; however such 
efforts have been suggested for outcome measures reported across clinical trials (Clarke 
2007). Key steps would involve deciding on the core baseline variables and reporting 
them consistently across studies. Improved reporting of this information would enable 
accurate interpretation of the reported attrition rates, could facilitate systematic 




Box 8.1 Priorities for future practice and research on retention 
 
8.7 Concluding statement 
In conclusion, this thesis improved the understanding of current practice regarding 
retaining participants in trials of non-pharmacological interventions for schizophrenia, 
including strategies used to enhance retention. This was achieved by establishing the 
degree of attrition in non-pharmacological RCTs involving patients with schizophrenia, 
identifying factors influencing the continued engagement in an intervention and study 
Priority 1: Evaluation of effective retention strategies in specific populations.  
Method: Quantify the effects of specific retention strategies and ascertain the 
applicability to the real world by conducting sufficiently powered trials embedded 
in host RCTs. 
 
Priority 2: Further research exploring participant-centred trial practices to aid 
retention.  
Method: Qualitative and/or quantitative exploration of the current and potential 
participant-centred approaches to maximising retention in trials, for example a 
narrative synthesis of literature, a survey of trial practices, or a qualitative study 
involving various stakeholders.  
 
Priority 3: Improvements to the quality of reporting recruitment and retention 
information in trial publications. 
Method: Adequate reporting is the responsibility of researchers undertaking trials 
and appropriate tools are available for the purpose of reporting participant flow and 
design of interventions. Introducing this as a requirement across all peer-reviewed 
journals could improve the current quality of information related to recruitment 
and retention of trial participants.     
 
Priority 4: Improving liaison between researchers and care coordinators.  
Method: Training research and clinical staff in ethical and effective retention 
strategies, with particular focus on the two groups working together to maximise 
participant retention while monitoring risk.   
217 
 
follow-up assessments, and exploring the ways in which trial professionals maximise 
retention.  
The thesis showed that attrition is a phenomenon that should be anticipated and 
prevented with the use of appropriate practices and strategies. The study found that 
the extent to which dropout can be minimised will depend on a number of factors 
specific to the participant, researcher, study and wider organisational and geographical 
context. A diagnosis of schizophrenia should not be automatically associated with a 
high dropout from treatment or study as it is realistic to lose less than 20% in RCTs of 
complex interventions for schizophrenia.  
Although the quantitative analyses did not find support for patient socio-demographic 
characteristics being associated with retention in this population; the qualitative 
component of this thesis identified a number of patient- and researcher-reported 
barriers and facilitators to retention. These factors consist of those specific to 
schizophrenia as well as those previously reported in other clinical trial populations. 
Moreover, the study highlighted the importance of using multiple strategies and 
applying participant-centred approach to retention efforts. 
The practices used by trial professionals identified in this thesis show the potential for 
enhancing retention of patients with schizophrenia in trials through addressing specific 
barriers and emphasising the factors encouraging continuous engagement.  
Further research could employ methods such as nested trials to test the effectiveness 
of specific retention strategies in the population of patients with schizophrenia and 
should aim to involve individuals with relevant lived experience in all aspects of the 
research. More accurate and systematic reporting of the observed loss of participants 
throughout the duration of trials would enable future research on retention and raise 
awareness about the issue of attrition. 
Development of effective retention strategies should be informed by the factors 
affecting participants’ decision-making and the reasons for attrition observed in 
practice. This study suggests that these influential aspects are likely to be both general 
and condition specific.  
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Appendix 11 Participant preference form – interviews with the 
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Appendix 13 Interview guide for interviews with the EPOS trial 

























Appendix 14 Interview guide for interviews with the EPOS trial 
participants - Version B: Participants who did not complete 
all assessments  
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